SECURITIES & EXCHANGE COMMISSION EDGAR FILING
Celcuity Inc.
Form: 10-K
Date Filed: 2018-03-15
Corporate Issuer CIK: 1603454
© Copyright 2019, Issuer Direct Corporation. All Right Reserved. Distribution of this document is strictly prohibited, subject to the terms of use.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-K
(Mark One)
x
For the fiscal year ended December 31, 2017
ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
or
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
¨
For the transition period from _______________ to _______________
Commission File Number: 001-38207
Celcuity Inc.
(Exact name of registrant as specified in its charter)
Delaware
(State or other jurisdiction of
Incorporation or organization)
16305 36th Avenue North, Suite 450
Minneapolis, MN
(Address of principal executive offices)
82-2863566
(I.R.S. Employer
Identification No.)
55446
(Zip Code)
Registrant’s telephone number, including area code: (763) 392-0767
Title of Each Class
Common Stock, $0.001 par value per share
Name of Each Exchange on which Registered
The Nasdaq Capital Market
Securities registered pursuant to Section 12(b) of the Act:
Securities registered pursuant to Section 12(g) of the Act:
None
Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.
¨ Yes x No
Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. ¨ Yes x No
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for
the past 90 days. x Yes ¨ No
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate website, if any, every Interactive Data File required to be
submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the
registrant was required to submit and post such files). x Yes ¨ No
Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K (§229.405 of this chapter) is not contained herein, and will not be
contained, to the best of registrant’s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any
amendment to this Form 10-K. ¨
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or emerging
growth company. See definition of “large accelerated filer,” “accelerated filer,”, “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of
the Exchange Act.:
Large accelerated filer ¨
Non-accelerated filer ¨
(Do not check if a smaller reporting company)
Accelerated filer ¨
Smaller reporting company x
Emerging growth company x
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or
revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act x
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).
¨ Yes x No
The aggregate market value of the voting and non-voting common equity held by non-affiliates of the Registrant as of September 19, 2017 was approximately
$54,831,578, based on a price per share of $9.50. The Registrant was privately held on June 30, 2017 (the last business day of the Registrant’s most recently
completed second fiscal quarter), and as such, the Registrant has elected to use September 19, 2017 as the calculation date, which was the effective date of the
registration statement for the Registrant’s initial public offering. The price per share listed above is equal to the initial public offering price of the Registrant’s
common stock and the value of the Registrant’s voting and non-voting common equity listed above assumes conversion of the Company’s outstanding
convertible promissory notes immediately following the Registrant’s initial public offering, which closed on September 22, 2017.
EDGAR Stream is a copyright of Issuer Direct Corporation, all rights reserved.
As of February 28, 2018, there were 10,106,464 shares of the Registrant’s common stock outstanding.
DOCUMENTS INCORPORATED IN PART BY REFERENCE
Portions of the Registrant’s definitive proxy statement relating to its 2018 Annual Meeting of Stockholders is incorporated by reference into Part III of this Annual
Report on Form 10-K.
EDGAR Stream is a copyright of Issuer Direct Corporation, all rights reserved.
2017 Annual Report on Form 10-K
Table of Contents
PART I
Item 1.
Item 1A.
Item 1B.
Item 2.
Item 3.
Item 4.
PART II
Item 5.
Item 6.
Item 7.
Item 7A.
Item 8.
Item 9.
Item 9A.
Item 9B.
PART III
Item 10.
Item 11.
Item 12.
Item 13.
Item 14.
PART IV
Item 15.
Item 16.
Business
Risk Factors
Unresolved Staff Comments
Properties
Legal Proceedings
Mine Safety Disclosures
Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities
Selected Financial Data
Management’s Discussion and Analysis of Financial Condition and Results of Operations
Quantitative and Qualitative Disclosures About Market Risk
Financial Statements and Supplementary Data
Changes in and Disagreements with Accountants on Accounting and Financial Disclosure
Controls and Procedures
Other Information
Directors, Executive Officers and Corporate Governance
Executive Compensation
Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters
Certain Relationships and Related Transactions, and Director Independence
Principal Accounting Fees and Services
Exhibits, Financial Statement Schedules
Form 10-K Summary
Signatures
2
Page
5
30
46
46
46
46
46
47
49
55
56
71
71
71
71
73
73
73
73
74
74
75
EDGAR Stream is a copyright of Issuer Direct Corporation, all rights reserved.
Special Note Regarding Forward-Looking Statements
This Annual Report on Form 10-K contains forward-looking statements regarding us, our business prospects and our results of operations that are subject to
certain risks and uncertainties posed by many factors and events that could cause our actual business, prospects and results of operations to differ materially
from those that may be anticipated by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to,
those described in Part I, Item 1A. “Risk Factors” and elsewhere in this report. Readers are cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date of this report. We expressly disclaim any intent or obligation to update or revise any forward-looking statements,
whether as a result of new information, future events or otherwise. Readers are urged to carefully review and consider the various disclosures made by us in this
report and in our other reports filed with the Securities and Exchange Commission that advise interested parties of the risks and factors that may affect our
business.
All statements, other than statements of historical facts, contained in this Annual Report on Form 10-K, including statements regarding our business,
operations and financial performance and condition, as well as our plans, objectives and expectations for our business, operations and financial performance and
condition, are forward-looking statements. In some cases, you can identify forward-looking statements by the following words: “anticipate,” “believe,” “continue,”
“could,” “estimate,” “expect,” “intend,” “may,” “might,” “target,” “ongoing,” “plan,” “potential,” “predict,” “project,” “should,” “will,” “would,” or the negative of these
terms or other comparable terminology, although not all forward-looking statements contain these words. Forward-looking statements involve known and
unknown risks, uncertainties and other factors that may cause our results, levels of activity, performance or achievements to be materially different from the
information expressed or implied by the forward-looking statements in this Annual Report on Form 10-K. Forward-looking statements may include, among other
things, statements relating to:
·
·
·
·
·
·
·
·
·
·
·
·
·
our plans to develop and commercialize our CELx platform and CELx tests for patients with cancer and our expectations regarding the various cancer
sub-types our CELx tests will identify;
any perceived advantage of our CELx platform and CELx tests as compared to traditional molecular or other diagnostic tests, including without limitation,
the ability of our platform and tests to help physicians treat their patients’ cancers or to identify new patient populations not diagnosable with currently
available diagnostic tests;
our expected first-mover advantage in providing products to culture living tumor cells on a commercial scale, or the sustainability of our competitive
advantages;
the size and growth potential of the markets for our CELx platform, and our ability to serve those markets;
the rate and degree of market acceptance, both in the United States and internationally, and clinical utility of our diagnostic platform and tests;
our ability to partner with and generate revenue from pharmaceutical partners and physicians, and the market opportunity for HER2 therapies and other
CELx programs for our pharmaceutical partners as a result of our CELx platform;
the success of competing tests that are or may become available;
the ability of our CELx platform and tests to impact clinical trials by our pharmaceutical partners, such as streamlining approval from the U.S. Food and
Drug Administration, or FDA of targeted therapeutics;
the success, cost and timing of our CELx platform development activities and planned clinical trials, as well as our reliance on collaboration with third
parties to conduct our clinical trials;
our commercialization, marketing and manufacturing capabilities and strategy;
expectations regarding federal, state, and foreign regulatory requirements and developments, such as potential FDA regulation of our CELx platform and
CELx tests, our operations, as well as our laboratory;
our plans with respect to pricing in the United States and internationally, and our ability to obtain reimbursement for CELx tests, including expectations as
to our ability or the amount of time it will take to achieve successful reimbursement from third-party payors, such as commercial insurance companies
and health maintenance organizations, and government insurance programs, such as Medicare and Medicaid;
our ability to obtain funding for our operations, including funding necessary to complete further development and commercialization of our CELx platform
and CELx tests;
3
EDGAR Stream is a copyright of Issuer Direct Corporation, all rights reserved.
·
·
·
·
·
·
·
·
·
our expectations with respect to our facility needs;
our estimates regarding expenses, future revenue, capital requirements and needs for additional financing;
future agreements with third parties about the commercialization of our CELx diagnostic platform and tests;
our expectations regarding our ability to obtain and maintain intellectual property protection for CELx platform and approach;
our ability to attract and retain key scientific or management personnel;
our expectations regarding the period during which we qualify as an emerging growth company defined under the Jumpstart Our Business Startups Act
of 2012, or the JOBS Act;
the requirements of being a public company;
our expectations regarding having our stock listed on The Nasdaq Capital Market; and
our anticipated use of the net proceeds from our initial public offering.
You should read the matters described in Part I, Item 1A. “Risk Factors” and the other cautionary statements made in this Annual Report on Form 10-K. We
cannot assure you that the forward-looking statements in this report will prove to be accurate and therefore you are encouraged not to place undue reliance on
forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking
statements we make. You are urged to carefully review and consider the various disclosures made by us in this report and in other filings with the SEC that
advise of the risks and factors that may affect our business. Other than as required by law, we undertake no obligation to update or revise these forward-looking
statements, even though our situation may change in the future. Our forward-looking statements do not reflect the potential impact of any future acquisitions,
mergers, dispositions, joint ventures or investments that we may make.
4
EDGAR Stream is a copyright of Issuer Direct Corporation, all rights reserved.
ITEM 1. Business
Overview
PART I
Unless otherwise provided in this Annual Report on Form 10-K, references to the “Company,” “we,” “us,” and “our” and similar references refer to Celcuity
Inc., a Delaware corporation.
We are a cellular analysis company that is discovering new cancer sub-types and commercializing diagnostic tests designed to significantly improve the
clinical outcomes of cancer patients treated with targeted therapies. Our proprietary CELx diagnostic platform is the only commercially ready technology we are
aware of that uses a patient’s living tumor cells to identify the specific abnormal cellular process driving a patient’s cancer and the targeted therapy that best
treats it. We believe our CELx platform provides two important improvements over traditional molecular diagnostics. First, molecular diagnostics can only provide
a snapshot of the genetic mutations present in a patient’s tumor because they analyze dead cells. Using dead cells prevents molecular diagnostics from
analyzing in real-time the dynamic cellular activities, known as cell signaling, that regulate cell proliferation or survival. Cancer can develop when certain cell
signaling activity becomes abnormal. Since genetic mutations are often only weakly correlated to the cell signaling activity driving a patient’s cancer, a molecular
diagnostic is prone to providing an incomplete diagnosis. CELx tests overcome this limitation by measuring real-time cell signaling activity in a patient’s living
tumor cells. When a CELx test detects abnormal signaling activity, a more accurate diagnosis of the patient’s cancer driver is obtained. Second, molecular
diagnostics can only estimate the probability of a patient’s potential drug response based on a statistical analysis of the drug’s clinical trial results. Instead of this
indirect estimate of drug response, CELx tests directly measure the effectiveness of a targeted therapy in a patient’s living tumor cells. This enables physicians
to confirm that the therapeutic matching the patient’s cancer driver is functional in the patient’s tumor cells before prescribing it, which significantly increases the
likelihood of a positive clinical outcome. We have one U.S. patent, five pending U.S. patent applications, one pending PCT patent application, as well as
numerous corresponding non-U.S. patent applications covering our diagnostic approach using cell signaling analysis in living patient cells to guide treatment of
patients with targeted therapies.
Our first analytically validated and commercially ready test using our CELx platform, is our CELx HER2 Signaling Function Test, or CELx HSF Test. Our
CELx HSF Test diagnoses two new sub-types of HER2-negative breast cancer that traditional molecular diagnostics cannot detect. Our internal studies show
that approximately 20% of HER2-negative breast cancer patients have abnormal HER2 signaling activity similar to levels found in HER2+ breast cancer cells. As
a result, these HER2-negative patients have undiagnosed HER2-driven breast cancer and would be likely to respond to the same anti-HER2 targeted therapies
only HER2+ patients receive today. Our CELx HSF Test is targeting HER2-negative breast cancer patients receiving drug treatment. As a companion diagnostic,
or CDx, our CELx HSF Test could potentially drive additional clinical usage of HER2 therapies to treat the patients our test identifies with abnormal HER2
signaling. We believe this creates financial motivation for pharmaceutical companies to partner with us. We also believe that having an analytically validated and
commercially ready diagnostic platform is attractive to potential pharmaceutical company partners as it will enable them to use our diagnostic tests immediately
after receiving the regulatory approvals required to sell their drug therapies to the newly identified patient populations identified by our CDx.
Once our CELx HSF Test was analytically validated and became commercially ready, we sought opportunities to collaborate with pharmaceutical companies
that owned HER2 drugs. Our efforts resulted in a collaboration with Genentech, Inc., or Genentech and the National Surgical Adjuvant Breast and Bowel Project
Foundation, or NSABP, to field a prospective clinical trial to evaluate the efficacy of Genentech’s HER2 targeted therapies in patients with these newly identified
cancer sub-types. We expect interim results from this trial in late 2018 and final results six to nine months later. We believe a successful outcome of this
collaboration will demonstrate the suitability of our CELx HSF Test as a CDx for HER2 therapies and support our activities to attract other pharmaceutical
company partnerships.
5
EDGAR Stream is a copyright of Issuer Direct Corporation, all rights reserved.
In addition to the two new breast cancer sub-types our CELx HSF Test diagnoses, we discovered 14 new potential cancer sub-types in breast, lung, colon,
ovarian, kidney, bladder and hematological cancers. Approved or investigational drugs are currently available to treat each of these new potential cancer sub-
types. CELx tests for these additional cancer sub-types are in various stages of development, and we expect them to become commercially ready on a
staggered basis over the next few years. The development process for these additional CELx tests will mirror the process used to develop our CELx HSF test.
This process includes completion of internal animal, verification, training set, and validation studies. As new CELx tests become commercially ready, we expect
to initiate collaborations with pharmaceutical companies to help them obtain new drug indications for the new cancer sub-types our tests identify. In addition, we
will continue our research to identify additional new cancer sub-types and to develop the corresponding CELx tests to diagnose them.
The need for more complete cancer diagnoses is significant. The complexity and dynamic nature of cancer makes it difficult to determine the underlying
cellular activity driving the disease. Molecular tests are used to identify genetic mutations and select targeted therapies, but the overall impact of those tests on
patient outcomes has fallen far short of expectations, primarily due to two factors. First, molecular tests provide a static and limited genetic profile of a patient’s
tumor, and, therefore, cannot measure dynamic disease activity. These tests rely on statistical correlations to diagnose patients, and when a genetic mutation is
only weakly correlated to oncogenic-related cellular dysfunction, a high number of false positive diagnoses will result. With patient response rates to therapies
targeting a genetic mutation typically less than 50%, and in some cases, only 10% to 20%, there is significant need for an alternative approach. Second, many
cancers lack a genetic biomarker to guide treatment. For those patients, the cellular dysfunction responsible for their cancer goes undiagnosed, which means
they are less likely to receive a potentially beneficial targeted therapy. Thus, current molecular tests have demonstrated only a limited ability to diagnose the
specific cellular dysfunction that is driving most patients’ cancer.
Our CELx platform addresses the need for better cancer diagnostic tests using two complementary technologies that represent a significant departure from
molecular-based analyses. Unlike molecular tests that use fixed or lysed (dead) cells and can only measure the static composition of a cell, our CELx platform
measures real-time signaling activity in a patient’s live tumor cells. This enables us to: (1) identify the cellular signaling dysfunction driving a patient’s cancer; and
(2) confirm whether the matching targeted therapy is functional in the patient’s cells. Our CELx tests are performed in our laboratory in Minneapolis, Minnesota
that is certified under the Clinical Laboratory Improvement Amendments of 1988, or CLIA, and accredited by the College of American Pathologies, or CAP.
Our platform, comprised of our internally developed cell microenvironment and cell signaling quantification technologies, allows for more accurate diagnoses
and the discovery of new cancer sub-types:
·
·
Cell microenvironment. Culturing living tumor cells poses three primary challenges. First, there is typically only a small amount of patient tumor tissue
available. Second, the tumor cells often die once they are removed from the tumor tissue. Third, tumor cells that do survive are difficult to maintain.
Moreover, when conventional cell culture approaches are used it can often take more than two months to prepare a test sample and the success rate is
typically less than 50%. Due to these challenges, the pharmaceutical industry principally relies on widely available immortalized or genetically modified
cancer cell lines, which are easily maintained and proliferate indefinitely at predictable rates. While these properties are useful for drug discovery
purposes, that usefulness has minimized incentives to transfer patient tumor cell culturing technologies to the clinical setting. Our proprietary cell
microenvironment technologies were designed to overcome these challenges and provide a testable cell sample from a patient tumor specimen as small
as 20 milligrams in 10 to 14 days for more than 90% of the patient tumor specimens we receive.
Dynamic cell signaling quantification. We analyze the signaling pathway activity of live patient tumor cells using a biosensor that converts the
dynamic cellular response to pathway activators or pathway inhibitors to a measurable electrical signal in real-time. To determine the activity of a specific
signaling pathway, an activating agent specific to a pathway receptor is used to turn on the pathway and a corresponding inhibitory agent specific to the
pathway receptor is used to turn signaling off. Thus, our tests allow us to identify both the signaling pathway abnormalities driving a patient’s cancer and
to confirm whether a matching targeted therapy may prove beneficial.
We believe our CELx platform will fundamentally change the standard-of-care many cancer patients receive. Patients with the newly identified cancer sub-
types we have discovered have oncogenic pathways that are signaling abnormally, and, we believe, may respond positively to a matching targeted therapy. By
identifying patients with a new cancer sub-type, each CELx test will create, in effect, a proprietary patient population that molecular diagnostics cannot identify.
6
EDGAR Stream is a copyright of Issuer Direct Corporation, all rights reserved.
Our initial commercial strategy is to partner with pharmaceutical companies to provide companion diagnostics for the pharmaceutical partners’ existing or
investigational targeted therapies. We expect such partnerships to involve collaboration on clinical trials, regulatory submissions, and commercialization
activities. We will initiate activities to pursue partnerships as our CELx tests become commercially ready and can be matched with a potential partner’s targeted
therapies. Our commercial-related efforts to date have focused on seeking partnerships for our CELx HSF test, which became commercially ready as a
laboratory developed test after it was analytically validated in 2016. We expect to seek pharmaceutical partnerships for a variety of different targeted therapies in
other solid tumor types as we are conducting our initial clinical trial with Genentech and the NSABP.
We believe our CELx CDx tests will expand the matching drug’s market size because they can facilitate approval of new drug indications that a
pharmaceutical company would not otherwise be able to obtain.
We expect that successful pharmaceutical company partnerships will generate significant revenue from the sale of tests to identify patients eligible for clinical
trials, from milestone payments, and, potentially, from royalties on the incremental drug revenues our tests enable. A key requirement for success of these
partnerships will be clinical trial results that demonstrate the advantages of using a CELx test as a companion diagnostic. Once a new drug indication is received
that requires use of our CDx to identify eligible patients, we will offer our tests directly to treating physicians and coordinate go-to-market strategies with our
partner. This coordination of commercialization strategies will allow us to significantly leverage the sales, marketing and reimbursement resources of our
pharmaceutical partner, unlike traditional molecular diagnostic companies.
Our Value Proposition
We believe we offer a clear and compelling value proposition to the key healthcare stakeholders:
·
·
·
Patients & Providers—Improved patient outcomes. Our CELx tests provide a more accurate diagnosis of a patient’s cancer driver and an
assessment of a matching targeted therapy’s effectiveness in blocking the cellular dysfunction. This will enable physicians to match more precisely the
targeted therapy they use to treat their patients. We believe this will increase the percentage of patients responding to the drug, improving overall patient
outcomes significantly.
Pharma—Increased revenue & optimized clinical trials. CELx tests can significantly increase the revenue potential for many existing targeted
therapies by identifying entirely new pools of patients potentially responsive to their therapy. For some targeted therapies, we estimate a CELx test could
double the number of patients approved to receive treatment, thus driving billions of dollars in incremental sales. Also, by providing more precise
selection of patients, our CELx tests can increase the odds a clinical trial meets its trial endpoint, greatly enhancing the likelihood the drug will obtain
FDA approval for a new indication. In addition, according to an ARK Invest publication dated August 2016, companion diagnostics that increase the
response rates of a drug can reduce Phase 3 clinical trial size as much as ten-fold and costs as much as 60%.
Payors—Lower costs per responsive patient. By providing more precise cancer diagnoses and driving higher drug response rates, we will
significantly reduce the money spent on drugs that do not benefit patients. Many targeted therapies cost more than $50,000 per treatment and only
benefit a small fraction of patients receiving them. Calculating drug costs on a cost-per-responsive patient, and not just cost-per-treated patient, highlights
the true cost of targeted therapies and the expense associated with low drug response rates. For instance, a $50,000 targeted therapy with a 30%
response rate costs $167,000 per responsive patient; however, that same drug would only cost $83,000 per responsive patient if the response rate was
60%.
Our Competitive Strengths
We have a number of key strengths that enhance our ability to achieve our mission and build a successful company:
·
·
First mover. We are the first company that we are aware of to launch diagnostic tests that measure the signaling pathway activity in a patient’s live
tumor cells, which we believe gives us a significant first mover advantage.
High barriers to entry. Our issued and pending patents, as well as our proprietary information and trade secrets, give us a strong intellectual property
position that we believe creates a significant barrier to entry for potential competitors.
7
EDGAR Stream is a copyright of Issuer Direct Corporation, all rights reserved.
·
·
·
Broad range of applications for our platform. We can develop tests for a wide range of signaling pathways and a wide range of cancer types. This
allows us to build a deep new product pipeline that creates multiple paths to build a large and profitable business.
Diverse revenue streams including pharma partnerships. We anticipate generating significant revenue from CDx pharmaceutical partners, including
revenue from the sale of tests to identify patients eligible for clinical trials, milestone payments, and potentially, from royalties on the incremental drug
revenues our tests enable. Our most significant revenue opportunity comes from ongoing sales of CELx tests to physicians during the commercialization
stage of the CDx.
Strong senior leadership team. Our founders and senior leaders have a proven track record of success building, operating and selling several
successful companies. We have deep and highly relevant and complementary diagnostic, scientific, product development, and commercialization
experience that has enabled us to establish market leadership positions for the companies we previously led.
Our Platform Advantages
Our unique and proprietary CELx functional cellular analysis technology represents a major shift from the diagnostic industry’s reliance on molecular profiling
to characterize a patient’s cancer sub-type. Our goal is to leverage our technology to build a durable competitive advantage that enables us to improve outcomes
for a significant percentage of cancer patients.
Our CELx platform advantages include:
·
·
·
·
·
Powerful cancer sub-type discovery tool. We have already discovered 16 new potential cancer sub-types that are not currently diagnosed and
treated with a matching targeted therapy. These sub-types are characterized by the dysfunctional signaling pathway activity our CELx tests identify. By
identifying new cancer sub-types, we are creating new patient populations to which pharmaceutical companies can offer new and existing drug
therapies.
Direct patient-specific assessment of disease status. Even though the response rates for many targeted therapeutics are low, for those patients
who do respond, their outcomes can be improved significantly. The problem is matching the patient to the right drug. Our platform overcomes this
problem by directly identifying whether an oncogenic signaling pathway is abnormally active in a patient’s cells. This provides the most complete
assessment available today of the intracellular activity driving a patient’s cancer. Existing genomic tests typically can only provide a determination
whether cancer is present and an assessment of molecular mutations that may or may not be associated with the patient’s cancer driver.
Direct measurement of matching drug effectiveness. An important advantage of the CELx platform is its ability to quantify the amount of signaling
dysfunction that a matching targeted therapy can inhibit in an individual patient’s cancer cells. This allows us to evaluate whether there are inherent drug
resistance mechanisms that would prevent the therapy from functioning in the patient’s tumor cells. Molecular tests cannot provide this evaluation.
Improved response rates. We believe a patient population will have a higher response rate to a matching targeted therapy when it is diagnosed with a
CELx test than with a molecular biomarker. By first identifying whether dysfunctional signaling is present and then confirming that a matching targeted
therapy can inhibit the dysfunction, a CELx test eliminates the two primary variables that confound patient response to targeted therapy signaling: the
presence or absence of the disease and the drug not functioning as intended. A molecular test provides insight on neither of these variables in most
cases.
Identify drug responsive proprietary patient cohorts. There are large numbers of cancer patients who lack a genetic biomarker to guide treatment.
For these patients, the cellular dysfunction driving the cancer goes undiagnosed, thus excluding such patients from receiving a potentially beneficial
targeted therapy. We believe our CELx tests will enable us to identify new proprietary patient populations not currently diagnosable with molecular tests
and increase the number of patients likely to respond to a matching targeted therapy. Moreover, we will be the only partner a pharmaceutical company
can work with to develop a CDx for a new indication of a targeted therapy addressing these new patient populations. By contrast, most molecular
diagnostic tests are undifferentiated and have little proprietary value, which gives pharmaceutical companies a wide range of companies to select from
when choosing a molecular-based CDx partner.
8
EDGAR Stream is a copyright of Issuer Direct Corporation, all rights reserved.
·
Streamlined FDA approval of targeted therapeutics. CELx tests will enable our pharmaceutical partners to enroll patients in their clinical trial with
the same cellular dysfunction their targeted therapy is designed to inhibit. We believe this will improve patient response rates, increasing the likelihood
the trial meets its endpoint target and thus the likelihood the drug receives FDA approval. Improved patient response rates would also help reduce the
size, cost, and length of our partner’s clinical trials.
Our Industry
According to the Centers for Disease Control and Prevention, or CDC, cancer was the second-leading cause of death in the United States in 2015,
responsible for nearly one of every four deaths. There are many types of cancer treatment options, including surgery, radiation therapy, chemotherapy,
immunotherapy, hormone therapy, stem cell transplant, and targeted therapy. Targeted therapies are drugs or other substances that block the growth and
spread of cancer by interfering with specific molecular targets involved in the progression of cancer. Targeted therapies differ from standard chemotherapy
drugs in that they are often cytostatic (block tumor cell proliferation) rather than cytotoxic (kill tumor cells). According to the National Cancer Institute, there are
currently more than 80 approved targeted oncology therapies, some of which cost more than $100,000 per treatment course.
Diagnostic tests to detect single biomarkers are now widely used by pathologists to determine the molecular sub-type of a cancer. When a molecular
biomarker test is used to support the choice of therapy to prescribe, it is often referred to as a “companion diagnostic.” Increasing numbers of targeted
therapeutics are prescribed based on the results from a companion diagnostic test to detect the presence of a molecular biomarker. Only patients testing positive
for the biomarker are eligible to receive the associated therapy.
Companion diagnostics are becoming increasingly important to the pharmaceutical industry. The use of companion diagnostics to better match patients to
effective treatments positively impacts clinical outcomes and lowers expenditures on drugs that do not benefit patients. Stratifying the eligible patient population
to include only likely responders is particularly important when the percentage of likely responders is only a fraction of the total cancer population. In these
circumstances, narrowing the eligible patient population is often necessary to meet the clinical endpoint targets required to receive FDA drug approval.
Our Market Opportunities
CDx Development Opportunities
We believe there at least 50 different potential opportunities for our company to collaborate on CDx programs with pharmaceutical companies. Our ability to
develop partnering relationships with these pharmaceutical companies will be predicated on a number of factors, including the size of the patient population our
CELx test identifies, the remaining patent life of the matching targeted therapy, as well as the success or failure of clinical trials we have conducted with other
pharmaceutical companies. Completing clinical trials requires, among other things, successful enrollment of patients, meeting trial endpoint goals, and
completing the trial in a timely manner. The time to complete a clinical trial can vary widely depending on a number of factors, many of which will be specific to
any particular clinical trial.
We believe the revenue opportunity per CDx program will be consistent with other development programs pharmaceutical companies support. In addition,
the revenue for an individual CDx program would represent only a small fraction of the potential value the new drug indication our CDx could create for our
pharmaceutical company partner. For some drugs, our tests could double the number of patients eligible for a targeted therapy. Our CELx HSF Test identified
20% of HER2-negative patients with abnormal HER2 signaling who may benefit from treatment with HER2 drugs. Fully deployed, this test could double the
annual number of eligible patients to receive HER2 targeted therapies in the U.S. alone.
9
EDGAR Stream is a copyright of Issuer Direct Corporation, all rights reserved.
CELx Testing Opportunities
We expect to generate recurring CDx testing revenues once a CELx CDx-linked drug therapy is approved for patient use. On average, we believe that the
lifetime value of providing the CDx test will significantly exceed the revenue generated from the CDx development program. We expect to offer each CELx test
to patients at prices ranging from $4,000–$7,000, depending on the number of pathways evaluated. No tests directly comparable to the CELx tests are available
today to offer reference points for pricing purposes. Pricing for several proprietary complex genomic tests, however, fall within this range and we believe this
provides guidance on the amount insurance companies are willing to pay for highly informative tests that guide patient care.
CELx Technology Background
The Role of Cellular Signaling Pathways in Cancer
Cancer is a class of exceedingly complex and diverse diseases characterized by the development of abnormal cells that divide uncontrollably and can
infiltrate and destroy normal body tissue and disrupt normal organ function. In normal cells, a series of biochemical activities, known as signal transduction,
transmit biochemical signals through an interconnected network of signaling pathways to control cell proliferation and survival. Cancer arises when alterations
occur in one or more of these signaling pathways and normal cell processes are disrupted, resulting in uncontrolled cell proliferation. These alterations are driven
by a variety of cellular aberrations, including genetic mutations and dysfunctional signaling pathway mechanisms. Identifying the alteration driving an individual’s
cancer is complicated by the immense complexity of these signal transduction processes and the practically unquantifiable number of pathway variables.
As recently as 20 years ago, most cancers were classified and subsequently treated solely on the basis of the anatomical location of the tumor in the body.
Chemotherapies that kill rapidly dividing cells were widely used, but they had only limited efficacy for many patients and caused a wide range of dangerous side
effects due to lack of discrimination for tumor tissue. As tools to identify molecular mutations became available, scientists began to uncover correlations between
certain molecular mutations, cancer tissue type, and a patient’s prognosis. This fostered the development of molecularly targeted therapeutics that were
designed to disrupt the specific cellular function of the drug target, typically abnormal signaling pathway activity, associated the molecular mutation. These
targeted therapies greatly improved outcomes for some cancer patients and are a testament to the efficacy of targeted therapies when effectively prescribed.
According to information published by the Journal of Clinical Oncology in July 2015, targeted therapies are oftentimes 10 to 20 times more expensive than
chemotherapies.
In conjunction with the advent of targeted therapies, new molecular diagnostics were developed to help physicians refine the classification of a patient’s
cancer into sub-types based on the presence of a specific molecular anomalies, such as genetic mutations or over-expressed proteins. Such mutations or over-
expressed proteins are commonly referred to as “biomarkers” when they are used to diagnose a disease and evaluate treatment options. For instance, breast
cancer diagnostic tests are performed to determine whether two protein biomarkers, human epidermal growth factor receptor 2 (HER2) or estrogen receptors
(ER), are overexpressed in the cancer cells. The results of these tests are used to classify the patient’s cancer molecular sub-type and to guide selection of a
corresponding targeted drug therapy.
The launch and on-going development of many new targeted therapies and the increasing use of companion molecular diagnostics to guide selection of the
most appropriate therapy for each patient ushered in the era of so-called “precision medicine” in oncology. Advances in genomic and proteomic techniques and
drug discovery enabled researchers to identify new drug targets, new molecular diagnostics, and drugs that would specifically bind to the target.
While the increased usage of targeted therapies has improved patient outcomes, there is increasing recognition that the promise of molecularly guided
diagnoses and targeted treatment has fallen far short of expectations. This is generally due to the heterogeneous nature of these diseases from patient to patient
and the challenge of identifying the specific cellular dysfunction driving a cancer patient’s tumor growth. No matter how sophisticated or detailed, a point-in-time
molecular profile can only provide a snapshot of a tumor. As a result, the genetic mutations many current tests identify are often only weakly correlated to the
abnormal signaling driving a patient’s cancer. This is because protein and gene profiling provide an incomplete assessment of the biochemical activity promoting
cancer tumor growth. In fact, when dysfunctional, the activity of signaling pathway networks are, we believe, not possible to assess using current genetic
analyses, despite the impressive investments in mapping the human genome and advancements in techniques to identify molecular mutations.
10
EDGAR Stream is a copyright of Issuer Direct Corporation, all rights reserved.
The combination of the heterogeneous nature of cancer and the weak correlation of abnormal signaling to many genetic mutations helps explain why the
response rates for patients treated with many targeted therapies are often less than 50%, and in some cases as low as 10% to 20%. For a patient to respond to
a targeted therapy designed to disrupt disease-related signaling activity, two factors must be present: (1) the patient’s diseased cells must have the same
signaling pathway dysfunction the drug is designed to inhibit, and (2) the drug affects its targeted pathway as intended. Current state-of-the-art genomic tests
use fixed (dead) cells, which limits them to evaluating the presence or concentration of a genetic mutation or protein. These tests cannot evaluate either
dynamic signaling activity or whether a drug can affect that activity. When a patient’s genomic biomarker status does not represent underlying signaling pathway
dysfunction, this can lead to selection of the wrong targeted therapy to treat the patient. Of particular interest to us are those patients with dysfunctional signaling
who lack a corresponding biomarker; they are not currently eligible to receive any targeted therapy that treats their dysfunctional signaling.
To measure dynamic cellular activity, living patient tumor cells are required. Until our advancements, efforts to use living patient tumor cells have been
limited by the lack of reliable methods to extract and culture cancer cells from patient tumors. These previously limited efforts reflect the emphasis amongst
cancer researchers on creating stable cell lines for use to model cell function or to studies screen millions of test compounds in drug discovery programs.
Pharmaceutical companies driving the commercial development of cell technologies work primarily with immortalized cells or cell lines genetically modified to
express a target or mutation of interest. These cell lines consist of established cell cultures that proliferate indefinitely and very uniformly. They are used primarily
because they provide a highly uniform response when tested with millions of small molecules in the search for potential new drugs, and because techniques to
culture these cells are well known, their properties well understood, and other experimental results using them are available for comparison purposes.
Conversely, live patient tumor cells are difficult to obtain, are only available in small quantities, and according to a 2014 article published by Science, the
percentage of tumors that yield proliferative cells with conventional culturing methods has until now been well below 50%, which required months of culturing to
obtain sufficient testable quantities of cells. For these reasons, researchers prefer paraffin-fixed tissue or cell lines over living tumor cells when studying disease
processes or screening drug candidates. This lack of compelling rationale for pharmaceutical companies and academic institutions to work with live tumor cells
for research purposes left the field of live tumor cell research in a relatively immature state.
Our CELx Platform
We have made significant investments in research and development to build the first commercially-ready cancer diagnostic platform that we are aware of
that measures the signaling pathway activity in a patient’s living tumor cells. To measure dynamic cellular activity, we internally developed two distinct but
complementary technologies, which now comprise our CELx platform:
·
·
our proprietary cell microenvironment; and
our method to quantify dynamic patient cell signaling dysfunction.
We utilize our CELx platform to create CELx tests that measure specific signaling pathway activity in various tumor types.
Cell microenvironment. Previous research has shown that cancer cells extracted from a patient’s tumor share the molecular features of the primary cancers
from which they were derived and could provide an ex vivo (outside the patient) model of a patient’s tumor. The technology around tumor cell extraction from
individual patients and culturing techniques, however, has largely remained undeveloped. For instance, no competing diagnostic tests use live patient tumor
cells to measure dynamic cell signaling activity and studies on the topic have historically highlighted the challenges of deriving a viable patient tumor cell sample
from an individual patient tumor specimen.
We have developed a cell microenvironment to extract and expand viable tumor cells from fresh human tumor tissue, which meets the three critical clinical
parameters a patient-derived tumor cell sample would need to satisfy in order to meet the regulatory and clinical requirements for a diagnostic test measuring
signaling activity:
·
The patient cell sample tested must reflect the starting tumor’s composition. If samples do not reflect the original tumor’s composition, test
results derived from that sample may not be representative of the patient’s tumor. Competing techniques largely rely upon use of irradiated non-tumor
cells to foster cell proliferation, transformative “engineering” techniques or other un-natural manipulations of the cells to keep them alive. Because these
competing approaches significantly increase the risk that the resulting patient cell test sample may not mirror the patient’s original tumor, we developed
processes that only utilize tumor cells derived directly from the patient’s tumor specimen.
11
EDGAR Stream is a copyright of Issuer Direct Corporation, all rights reserved.
·
·
The sample must be available for testing in less than 21 days. Clinicians generally require test results in cases of complex diseases such as
cancer within two to three weeks so they can begin treatment of their patient as soon as the initial symptoms are evaluated or a preliminary diagnosis is
made. Competing techniques require two to six months to culture sufficient tumor cells for a test sample, making them unsuitable for use with a clinical
diagnostic. To meet this time requirement, we developed processes that allow tumor cell proliferation outside the patient.
At least 90% of the tumor specimens obtained from a patient must yield testable samples.
specimen when they are highly likely to receive a test result. The challenges of increasing the cell sample yield from tumor tissue are well known and
competing techniques are only able to obtain testable quantities of cells from less than 50% of patient tumor specimens. To meet this requirement, we
developed processes that enhance cell survival when tumor cells are removed from live tissue.
Clinicians will only order tests that require a patient
We believe our pioneering efforts have substantially advanced the technology of primary tumor cell culture technology. We have one issued U.S. patent, five
pending U.S. patent applications, nine pending non-U.S. patent applications and one pending international PCT patent application, as well as significant
proprietary know-how and trade secrets for the various cell sample preparation methods we have developed.
Dynamic patient cell signaling quantification. The second component of our CELx platform involves methods to quantify specific dynamic signal
transduction events in patient derived tumor cells. The complexity of signal transduction processes is immense and the permutations of the pathway variables
are practically unquantifiable. Current analytical methods to assess these variables use dead (fixed or lysed) cells. Point-in-time measurements are limited to
assessment of the compositional status (e.g. mutation), concentration level (e.g. protein amount), or activation status (e.g. phosphorylation) of a finite number of
signaling pathway components. A key insight underlying our technology was our observation that, no matter how sophisticated or detailed, a point-in-time
molecular profile would only provide a snapshot. These methods could not provide a complete, dynamic assessment of the signaling activity driving a patient’s
cancer. These point-in-time molecular analyses would, in many cases, only provide a weak correlation to the presence of the signaling pathway dysfunction
driving a patient’s cancer. Instead, we concluded that a complete diagnosis of cancer and an assessment of a patient’s response to treating their disease
requires measurement of the underlying activity of signaling pathways in live patient tumor cells.
To measure live real-time dynamic cell signaling activity, we utilize an impedance biosensor instrument. An impedance biosensor is an analytical platform
that converts changes in cellular activity to a measurable electrical signal. We use the instrument to monitor dynamic changes in cell adhesion and morphology
initiated by signal pathway activation or inhibition in live patient tumor cells. The instrument is comprised of a 96-well microplate with thin gold electrodes
covering the bottom of each well. Wells employed with a selective extracellular matrix attach viable cells in a specific manner to the electrodes. The presence of
viable cells on top of the electrodes affects the local ionic environment at the electrode/cell interface, leading to an increase in electrode impedance. To obtain a
measurement, a small alternating current is applied across the electrode. When cells are added to the microplate wells and attach to the electrodes, they act as
insulators increasing the impedance in each well.
As cells cover the electrodes, the current is impeded in a manner related to the number of cells and their adhesion properties. In addition, since cell signaling
changes modulate a cell’s adhesion properties, the impedance biosensor detects and quantifies these changes. When cells are stimulated and change their
function, the accompanying changes in cell adhesion thus alter the impedance that is measured.
To determine the activity of a specific signaling pathway, an activating agent specific to a pathway receptor is used to turn on the pathway and a
corresponding inhibitory agent specific to the pathway receptor is used to turn signaling off. When signaling pathways are stimulated in this manner, adhesion
molecules are effected and cause a change in the impedance measured in a well. By relying on the principle of detecting signaling pathway activity, we believe
we can develop tests for a range of disease types and targeted therapies that affect various cellular pathways.
12
EDGAR Stream is a copyright of Issuer Direct Corporation, all rights reserved.
Data is recorded in real-time when a patient’s tumor cells are responding to activating or inhibitory agents and analyzed with the impedance biosensor. The
output value is reported as the change in the electrical impedance measured. The change in impedance values is quantified over time and used to determine a
Signaling Function Score.
New Product Development
We are leveraging our CELx technology to discover new cancer sub-types that a genomic test cannot detect. These new sub-types are characterized by the
hyperactive signaling pathway our test identifies. These sub-types cannot be detected by genomic tests because they lack a corresponding molecular biomarker
to identify it. We will translate our discoveries into diagnostic tests that incorporate the following primary steps:
(1) Extraction of proliferative tumor cells from patient biopsy. This step provides the patient tumor cells that we use to perform the test.
(2) Activation of signaling pathway activity. This step determines whether the signaling pathway we are assessing is dysfunctional or not.
(3) Inhibition of signaling pathway activity. This step determines whether the matching targeted therapy is functional in the patient’s tumor cells. If the
drug can block a significant amount of the signaling dysfunction, this demonstrates lack of an inherent resistance mechanism in the patient’s tumor cells
that would prevent the drug from functioning when prescribed to the patient.
We confirmed that we can discover new cancer sub-types in 2015 with the discovery of two new breast cancer sub-types—HER2-/ER+ and HER2-/ER-
breast cancer with abnormal HER2 signaling. We are now leveraging the expertise we gained while validating the resulting CELx HSF Test for breast cancer to
guide our discovery of additional cancer sub-types.
We are currently conducting research to identify additional cancer sub-types in five solid tumor types. Our research studies to date have identified 14
potentially new breast, lung, ovarian, kidney, and bladder cancer sub-types that involve dysfunctional oncogenic signaling pathways. Multiple dysfunctional
pathways were active in each of these tumor types. These studies confirm that the CELx platform can be a cancer sub-type discovery engine and that we can
create a multi-pathway test to identify the specific driver in a patient’s tumor. We expect to eventually expand the tumor types we evaluate to include colon, head
and neck, leukemia, esophageal, and gastric cancers.
We will seek to identify individual signaling pathways that may be driving at least 5% to 10% of the total cancers in each tissue area. Once we have
characterized the prevalence of the different sub-types of signaling dysfunction in each tumor type and validated the tests for the different pathways, our plan will
be to launch a corresponding CELx test. Eventually, each CELx test will analyze multiple pathways in a patient’s tumor to identify the specific pathway
dysfunction driving a patient’s cancer. Testing multiple pathways will thus provide a systems view of the patient’s cancer using dynamic functional analysis. We
believe this will result in more accurate diagnosis of a patient compared to molecular diagnostics that are using next generation sequencing to assess the status
of multiple static biomarkers.
Clinical Trial Approach
A major component of our development and commercial activities is providing clinical data from interventional clinical trials using our CELx tests. Our clinical
trial strategy is predicated on proving the correlation between our CELx Signaling Function Score and a patient’s clinical results. Once our first trial demonstrates
that our CELx HER2 Test identifies patients responsive to HER2 targeted therapies, we expect pharmaceutical companies to partner with us to fund trials to
evaluate new potential indications for their drugs with patients identified by one of our CELx tests. The trials will be designed to confirm that patients with
abnormal pathway signaling obtain a superior clinical response to a therapy targeting that pathway than to the standard-of-care therapy they currently receive.
Each clinical trial would be structured as a prospective interventional study. The objective would be to confirm the relationship between the CELx Signaling
Function Score generated by the CELx test and the study endpoint. Different primary endpoints will be used depending on the stage and type of cancer. For late-
stage solid tumor trials, Time-to-Progression, or TTP, or Progression-Free Survival, or PFS, would likely be used, mirroring the endpoints used in the tested
drug’s pivotal trial. For early stage solid tumor trials, pathological complete response, or pCR, would likely be used. The trials will either be single-arm or
randomized two-arm.
13
EDGAR Stream is a copyright of Issuer Direct Corporation, all rights reserved.
We also expect to evaluate multiple CELx tests in the same trial when we have identified two or more cancer sub-types in the same tumor type (e.g., breast,
ovarian, lung). Screened subjects would be assigned to a therapy arm that corresponds to the pathway found to be abnormal.
To obtain statistically significant results, a randomized two-arm trial is projected to require enrollment of approximately 120 to 150 patients for each drug
evaluated, or between 60 to 75 patients in each arm. A single-arm trial would require 25 to 50 patients. We estimate each trial will require 18 to 27 months from
the initiation of enrollment to completion of the follow-up period and that interim analysis will be performed in most trials with interim data available after 10 to 15
months.
For trials involving patients not currently eligible for a cancer drug that targets a certain pathway, we would first obtain a tissue specimen from each subject
and perform the CELx test to identify subjects who have abnormal signaling. These patients would then be randomly assigned to either an arm that receives the
current standard-of-care therapy or one that includes the current standard-of-care therapy plus the targeted therapy. All patients would be monitored until their
disease progresses.
First Test—CELx HER2 Signaling Function Test
HER2+ breast cancer. Roughly 15% to 20% of breast cancer patients are diagnosed with HER2+ breast cancer when their tumor cells are found to have
overexpressed or amplified levels of HER2. These patients are treated with anti-HER2 targeted therapies in combination with chemotherapies. Results from a
number of clinical trial results for HER2 drugs reveal that only about 40% of HER2-positive patients respond to them. In addition, findings from several clinical
trials have shown that a sub-set of HER2-negative patients benefit from therapies that target HER2. These results highlight the relatively weak correlation
between HER2 receptor or gene amplification status and drug response.
Signaling activity status vs. HER2 receptor status. Based on this analysis, we concluded that measurement of HER2 signaling activity, rather than absolute
HER2 levels, may more accurately diagnose HER2-driven breast cancer. This led to our successful studies in 2014 when we discovered abnormal HER2
signaling in HER2-negative breast cancer patient tissue. We concluded that this patient population provided an excellent opportunity to validate our hypothesis
that signaling activity is more correlative to disease activity than receptor status. Measuring HER2-status not sufficient to diagnose all HER2 cancers. Despite
the widely recognized role that a dysfunctional HER2-related signaling network plays in promoting breast cancer, only tests measuring a single reactant, HER2
protein, are performed in the clinic to diagnose it; we believe no diagnostic tests are available today that measure HER2 signaling activity within a patient’s breast
tumor epithelial cells. This focus on measuring HER2 expression-levels reflects the widely-held view that measuring a patient’s HER2 status is sufficient to
diagnose HER2-driven breast cancers. When only HER2 expression is measured, though, patients classified as HER2-negative but whose tumor cells have
abnormal HER2 signaling are diagnosed as not having HER2-driven breast cancer, when, in fact, they do.
Diagnosing HER2 disease in HER2-negative patients with CELx HER2 Signaling Function Test. Since current genomic methods cannot identify the HER2-
negative breast cancer patients who have the HER2-driven cancer, a new method was required. Such a method would need to analyze the HER2-signaling
pathways (MAPK and PI3K) associated with HER2 cancers in a patient’s tumor cells. This is what our CELx HER2 Test is designed to do. Our test identifies
patients whose HER2 status as determined by conventional techniques does not represent the correct diagnosis of their breast cancer at a functional level.
Improving outcomes, HER2 drug response rates, and lower cost per responding patient. Identifying these HER2-negative/HER2-signaling abnormal
patients, and treating them with HER2 therapies, offers the potential to improve their clinical outcomes significantly. It is also likely that patients with abnormal
HER2 signaling will respond at higher rates than HER2-positive patients. We believe that patients with abnormal HER signaling (e.g., those the CELx HSF Test
diagnoses) are very likely to respond because they have the specific disease mechanism the HER2 therapies are designed to treat. This would result in a
reduction in the cost of HER2 drugs per responsive patient for those the CELx HSF Test identifies compared to those identified with HER2 protein or gene status
tests.
14
EDGAR Stream is a copyright of Issuer Direct Corporation, all rights reserved.
Clinical Studies
Prevalence Studies: 20% of HER2-Negative Patients Have Abnormal HER2-Signaling
To derive an initial estimate of the prevalence of abnormal HER2 signaling within the HER2-negative breast cancer population, we conducted a cell line
survey, a training set study and a validation study using primary tumor cells. Live cell response to specific HER2 agonists (NRG1b and EGF) and antagonist
(pertuzumab) was measured.
Key findings include:
·
Cell Line Survey Study (N=19)
·
·
·
4 of 9 HER2+ cell lines had HER2 signaling activity above 250 signaling units—these results helped establish an initial cut-off value;
Confirmed that normal HER2 signaling can occur in cells with overexpressed amounts of HER2; and
Confirmed that abnormal HER2 signaling can occur in cells with normal HER2 receptor levels.
·
Training Set Study (N=50).
·
·
7 of 34 HER2-negative breast cancer patients (20.5%; 95% CI = 10%–37%) had tumor cells with HER2 signaling activity that was characterized as
abnormally high and consistent with the HER2 signaling found in the upper 50% of the HER2+ cell lines; and
The 16 healthy breast specimens had a significantly lower average and standard deviation HER2 Signaling Scores than the HER2- and HER2+ breast
cancer specimens.
·
Validation Study (N=114)
·
·
27 of 114 patients (23.7%; 95% CI = 17%–32%) had tumor cells with HER2 signaling activity that was characterized as abnormally high and consistent
with the HER2 signaling found in the upper 50% of the HER2+ cell lines.
The graph below presents the data from the Cell Line, Training Set and Validation Prevalence Studies in a Box-Whiskers plot format.
o
The dotted line at 250 represents the cut-off value for the CELx HSF Test. The cut-off value of 250 is equivalent to the median CELx Signaling Score
recorded from the sample of HER2+ cell lines.
o HER2-negative breast cancer patients with CELx Signaling Scores at or above 250 have abnormal HER2 signaling.
o
The circled portions of the plots for the HER2- Training Set and HER2 Validation Set results represent the specimens with Abnormal HER2-driven
signaling.
15
EDGAR Stream is a copyright of Issuer Direct Corporation, all rights reserved.
Xenograft Study: Abnormal HER2 Signaling Correlates to Drug Response Better than HER2 Status
We conducted a study in collaboration with the University of Minnesota using xenograft mouse models of human breast tumors to evaluate the relationship
of HER2-driven signaling and response to lapatinib, a reversible dual-HER2 kinase inhibitor. Key findings:
·
·
·
The HER2 signal inhibitor shrank a HER2-negative tumor with abnormal HER2 signaling;
The HER2 signal inhibitor did not affect the HER2+ tumor with normal HER2 signaling; and
Findings contradict HER2 receptor-based conclusions:
·
·
Lapatinib inhibition more correlative to HER2 signaling than HER2 receptor expression; and
HER2 signaling status independent of HER2 receptor expression.
These findings support the hypothesis that HER2-negative breast cancer patients with abnormal HER2-driven signaling may benefit from treatment with
anti-HER2 drugs.
A summary of results:
Xenograft Study Results
Parameter
HER2 Receptor Expression
(IHC)
HER2 Signaling Status
(CELx)
Lapatinib Inhibition
(Xenograft)
Cell Line
HCC1954
HER2+
(3+)
BT483
HER2-
(0)
Normal
Abnormal
13%
(p = 0.34)
49%
(p = 0.01)
Study of Two HER2 Antibody Therapies, Trastuzumab and Pertuzumab, in HER2- and HER2+ Cells
We conducted this study to compare the effectiveness of two anti-HER2 antibodies in blocking HER2-driven signaling in HER2+ and HER2- cells. Tumor
cells from 5 HER2- primary tumors and 4 HER2+ cell lines were obtained. Real-time live cell response to NRG1, a specific HER2/HER3 agonist, with or without
pertuzumab, trastuzumab, or the combination of the two, was measured and quantified. All cell samples tested had comparable, and abnormal, levels of NRG1
activated HER2-driven signaling. Key findings:
16
EDGAR Stream is a copyright of Issuer Direct Corporation, all rights reserved.
·
·
·
In each sample, the two mAb’s inhibited a higher percentage of signaling in combination than either mAb alone; no interference effects between the two
mAb’s were detected;
Pertuzumab and trastuzumab alone were each more effective in the HER2- cell samples than in the HER2+ ones; and
Two HER2 mAb’s used to treat HER2+ breast cancer patients are as effective in blocking abnormal HER2-driven function ex vivo in HER2- primary cells
as they are in HER2+ cell lines.
Average % NRG1 Inhibition
HER2 mAb
Pertuzumab
Trastuzumab
T+P
HER2+
Cell Lines
62%
19%
87%
HER2-(HER2S+)
Primaries
73%
44%
81%
Study of Four HER2 Signal Inhibitors in HER2- and HER2+ Cells with Abnormal HER2 Signaling
Tumor cells from seven HER2-negative tumor specimens with abnormal HER2-driven signaling (HER2 S +) and the nine HER2-positive cell lines were
obtained. Real time live cell response to NRG1, a specific HER2/HER3 agonist, with or without a HER2 targeted drug (pertuzumab, lapatinib, neratinib, afatinib)
was measured and quantified. From these responses, the percentage inhibition of the HER2-driven signaling initiated by NRG1 by the HER2 drugs was
determined. Key findings:
·
·
·
Each of the HER2 drugs inhibited an average of at least 69% of the HER2-driven signaling activated by NRG1 stimulation in the HER2-negative primary
cell samples;
The highest level of inhibition was found with the two irreversible covalent dual RTKi’s, afatinib and neratinib; and
All of the HER2 drugs inhibited a greater percentage of HER2-driven signaling in the HER2-negative primary tumor cells than in the HER2-positive cell
lines.
Average % NRG1 Inhibition
HER2 Drugs
Pertuzumab
Lapatinib
Afatinib
Neratinib
Mechanism of Action
HER2 dimerization inhibitor
Reversible Dual RTKi
Irreversible Covalent Dual RTKi
Irreversible Covalent Dual RTKi
Cell Lines
(HER2+)
Primaries
(HER2-/HER2S+)
46%
15%
47%
95%
78%
69%
93%
100%
Analytical Validation Study
We conducted analytical validation studies in accordance with applicable FDA guidance and Clinical and Laboratory Standards Institute, or CLSI, standards
to characterize the performance of the CELx HSF Test. CLSI standards define the test protocols that the FDA and CLIA require laboratories to use to
characterize the performance of their diagnostic tests. The study results confirm that the CELx HSF Test has high analytical sensitivity and specificity. A
summary of the results is provided below:
17
EDGAR Stream is a copyright of Issuer Direct Corporation, all rights reserved.
CELx HSF Test Analytical Study Results
Performance Characteristics
Results
Analytical Precision (Qualitative)
Analytical Sensitivity (95% CI)
Analytical Specificity (95% CI)
Detection Limits
Limit of Blank
Limit of Detection
Cut-Off Characterization
Carry Over
95.8%–100% (88/88)
95.8%–100% (88/88)
0.0020 cell attachment units
0.0099 cell attachment units
250 signaling units
0%
Clinical Trial (in process): CELx test FDA Approved for Use in Clinical Trials
On May 8, 2017, we entered into a non-exclusive Clinical Trial Agreement with NSABP to conduct a 54-patient single-arm interventional trial. Pursuant to
the agreement, NSABP serves as the Sponsor and Principal Investigator of the trial and is responsible for, among other things, setting up clinical sites, enrolling
patients, and managing clinical data. NSABP has contracted separately with Genentech to provide drugs for the study at no cost. We are performing the CELx
HSF Test to select patients for the trial and are providing the funding for the trial’s patient-related costs. Completing this trial will require, among other things,
successful enrollment of patients, meeting trial endpoint goals, and completing the trial in a timely manner. Based on our estimates of patient enrollment rates,
we expect to obtain interim results in late 2018 and final results six to nine months later.
NSABP is one of the country’s premier clinical research cooperatives. Its members include many of the country’s leading medical centers and their
investigators are amongst the most-respected in the breast cancer field. Genentech is one of the largest biopharmaceutical companies in the world and was the
first company to launch a HER2 targeted therapy; their anti-HER2 targeted therapies have roughly 95% market share.
We submitted an Investigational Device Exemption, or IDE, application to the FDA to obtain approval to use our CELx HSF Test in a clinical trial setting. The
IDE submission included validation test protocols and study reports, manufacturing process summaries, and relevant publications. The FDA approved our IDE in
early 2017.
The goal is to demonstrate that patients who have an abnormal signaling pathway, as identified by our CELx test, respond to treatment with a matching
targeted therapy. A synopsis of the trial protocol is provided below.
18
EDGAR Stream is a copyright of Issuer Direct Corporation, all rights reserved.
Clinical Trial Synopsis
To evaluate the efficacy of neoadjuvant HER2 drug treatment in early stage HER2-/HER2 S+
breast cancer patients
Multi-center in collaboration with NSABP and Genentech
54 HER2- early stage breast cancer (26 ER+/28ER-)
Pathological complete response (ypT0/Tis ypN0)
N=54 (HER2S+)
AC-T + Trastuzumab + Pertuzumab
Objective
Sites/Sponsor
Subjects
Endpoint
Investigational
(Single) Arm
Pursuant to our agreement with NSABP, the cost of the study is $2.65 million, subject to adjustment based on reimbursement for travel and similar
expenses. Of this amount, we paid $300,000 upon entry into the agreement and $50,000 or one quarterly payment in 2017 and we will pay: (i) an aggregate of
approximately $1.8 million as certain patient milestones are met, (ii) five quarterly payments of $50,000 in 2018 and ending in 2019, and (iii) a final payment of
$250,000 upon completion of the study.
Our agreement with NSABP may be terminated by one or either party upon certain events, such as: (i) the FDA withdrawing its authorization and approval to
perform the study, (ii) NSABP determining that the human and/or toxicology test results support termination of the study, (iii) either us or NSABP determining that
an adverse reaction or side-effect of drugs administered in the study or a modification of the study’s protocol raises safety issues to support termination of the
study, (iv) either party remaining in material breach of the agreement for a period of 30 days following notice of such breach, (v) us not performing the CELx HSF
Tests or providing study kits, (vi) us failing to pay amounts owed to NSABP, and/or (vii) Genentech terminating its agreement with NSABP to supply drugs for
the study or the drugs for the study no longer being manufactured or being available.
Commercialization Strategy
Our commercial activities will target three complementary groups at various phases of the development of our CELx tests.
·
Pharmaceutical companies. For each CELx test we develop to diagnose a new cancer sub-type, we will identify the matching targeted therapies,
either currently approved or in the investigational phase, and the manufacturer of those therapies. We will initiate discussions and seek to reach
development agreements with each of these pharmaceutical companies when we have verified the prevalence of the cancer sub-type and completed
successful animal studies.
· Medical and surgical oncologists. We will initially target key opinion leaders, or KOLs, in each cancer type once we have completed the analytical
validation of a CELx test. This will allow us to build awareness and credibility for the CELx test as we are generating clinical validation data. When a new
drug indication is received that requires use of a CELx CDx to identify eligible patients, we will coordinate the pharmaceutical company’s go-to-market
activities with our own. This coordination will allow us to significantly leverage the pharmaceutical company’s sales, marketing, and reimbursement,
unlike traditional molecular diagnostic companies.
·
Payors. We will initiate pilot activities with payors for late stage patients during the clinical validation phase of a CELx test’s development. We will
expand our payor efforts to include health economics analysis once we have clinical trial data available. When a new drug indication is received that
requires use of a CELx CDx to identify eligible patients, we expect to coordinate the pharmaceutical company’s reimbursement activities with our own.
19
EDGAR Stream is a copyright of Issuer Direct Corporation, all rights reserved.
Our CELx tests are laboratory developed tests and subject to regulation under CLIA. We completed the analytical validation of our first CELx test and
received CLIA certification in 2016, at which time our CELx HSF Test was ready to sell commercially on a stand-alone basis to treating physicians. We expect to
generate revenues from CELx tests performed in conjunction with the clinical trials a pharmaceutical company will field during the clinical phase of our partners’
drug approval process. We also expect that the agreements we enter into with the pharmaceutical companies partnering with us on these trials will include
milestone payments at initiation and completion of trials and perhaps at various other negotiated points during the trials. We expect to generate revenue from the
sale of CELx tests ordered by physicians either as stand-alone diagnostics or, upon the approval of our pharmaceutical company’s matching drug, as a CDx. A
key requirement for success of these partnerships will be clinical trial results that demonstrate the advantages of using a CELx test as a companion diagnostic.
We intend to position our unique and highly differentiated tests as practice changing advancements in patient care. To inform key stakeholders of the value
of our solution in order to drive adoption and reimbursement, we expect to employ the following diverse commercialization strategies over time:
·
·
·
·
·
·
leverage our pharmaceutical partnership and their go-to-market initiatives for the drug our CDx is partnered with;
collaborate with oncology thought and KOLs and leading institutions on clinical research, publications, and product development;
build an experienced, oncology-focused sales force in the United States and international distribution channels that are supported by dedicated company
personnel;
integrate into the everyday practice of clinicians through our medical affairs and client services efforts;
publish important medical and scientific data in peer-reviewed journals and present at major industry conferences, conduct clinical trials; and
work with patient advocacy groups, leading cancer philanthropic organizations, and medical societies to drive awareness of CELx tests and the
importance of incorporating functional cellular analysis into cancer treatment.
Through these efforts, we will seek to promote our CELx test’s unique capabilities throughout the oncology community—from patients, to the physicians
treating them, to the third-party payors for these treatments and to biopharmaceutical companies developing new treatments—all with the goal of facilitating
better-informed treatment decisions for the greatest number of patients.
Once results from our current clinical trial are available, we expect to launch our first test, the CELx HSF Test in two phases. During the first phase, we
intend to target KOLs in the oncology field to build awareness of our CELx platform. These KOLs are primarily comprised of oncologists and surgeons practicing
at major academic health systems who participate in clinical research and cancer research scientists. They often are early adopters of new technologies,
particularly those involving new insights into disease mechanisms. We expect to gradually ramp up our efforts to the remainder of the medical oncologists once
we have established our reputation within the KOL community.
Once a CELx test is launched to the broader market, we expect physicians, typically a medical or surgical oncologist, will order our tests either as stand-
alone diagnostics or, upon the approval of a pharmaceutical company’s matching drug, as a CDx. The physician will prescribe a CELx test and coordinate
provision of a patient specimen from a biopsy or surgical procedure. The fresh tissue would then be shipped overnight directly to our laboratory where we would
use our proprietary methods to extract diseased cell samples from the patient’s tissue and perform the CELx tests ordered. Test results would typically be
available in 10 to 14 days after receipt of the patient specimen. For each patient sample analyzed, a Signaling Function Score would be calculated quantitatively
and converted into a final qualitative result: abnormal or normal. For patients found to have an abnormal signaling function, clinicians would use the results of the
CELx test as a guide to select a targeted drug that inhibits the abnormal signaling activity identified.
United States
For our first tests, we will target the estimated 4,300 medical oncologists working in hospitals and cancer centers in the United States. We expect to hire
domestic sales professionals with typically over 10 years of experience in clinical oncology sales working at leading biopharmaceutical or specialty reference
laboratory companies.
In general, we intend to focus our initial sales efforts on building relationships with KOLs and researchers at leading academic research institutions to
demonstrate the scientific credibility of our CELx tests. We also plan to build relationships in community oncology practice settings through leading physician
networks and community hospitals and community based cancer centers. We will also attend national and regional clinical meetings focused on cancer treatment
for our anti-cancer tests.
20
EDGAR Stream is a copyright of Issuer Direct Corporation, all rights reserved.
We believe the unique and important nature of the results our CELx tests provide, and their positioning as a CDx, will drive many medical oncologists to
independently seek out our tests once they become aware of them. We believe this may allow us to achieve our market penetration goals with a sales force and
marketing expenses significantly less costly than has been experienced by molecular diagnostic companies.
International
We believe we can serve the international market from our laboratory in Minnesota. We expect to establish an international presence using local distributors
that sell to physicians and coordinate shipment of specimens to the United States. To serve international markets, we would expect to add dedicated regional
managers located outside the United States to oversee our relationships at the local level.
Pricing and Reimbursement
The principal groups that we expect to pay us in the future for our CELx tests include:
·
·
·
·
·
commercial third-party payors;
government payors, including Medicare and state Medicaid plans;
biopharmaceutical customers;
hospitals, cancer centers, and other institutions; and
patients.
Adequate reimbursement will be an important factor in achieving broad clinical adoption of our CELx tests. At the same time, we believe broad clinical
adoption will help drive favorable reimbursement decisions. To achieve broad reimbursement coverage with commercial third-party payors and government
payors, including Medicare and Medicaid, we plan to demonstrate the economic and clinical value of our CELx tests to payors by employing a multi-pronged
strategy:
·
Set a high bar for analytical validation. We expect to present data on the reproducibility and precision of CELx tests at conferences and will seek to
publish the results in peer-reviewed journals.
· Meet the evidence standards necessary to be consistent with leading clinical guidelines. We believe inclusion in leading clinical practice
guidelines plays a critical role in payers’ coverage decisions. We plan to conduct clinical validation and clinical utility studies that are consistent with the
requirements of the widely recognized National Comprehensive Cancer Network clinical practice guidelines.
·
·
·
·
·
Execute an internal managed care policy and claims adjudication function as part of our core business operations. We plan to make obtaining
adequate and widespread reimbursement a critical component of our business operations. We expect to hire a team of in-house claims processing and
reimbursement specialists who will work with patients and payers to navigate the claims process and obtain maximum reimbursement.
Cultivate a network of KOLs. KOLs are able to influence clinical practice by publishing research and determining whether new tests should be
integrated into practice guidelines. We expect to collaborate with KOLs early in the development process to ensure our clinical studies are designed and
executed in a way that clearly demonstrates the benefits of our tests to physicians and payers.C.
Compile a growing library of peer-reviewed studies that demonstrate the test is effective. We will seek to publish peer-reviewed articles and
review papers to help support our efforts to obtain widespread adoption and reimbursement of our CELx tests. In each disease area we pursue, we
intend to conduct studies in order to develop similar supporting literature.
Reduce expenditures. We intend to build economic models to measure the financial benefits of using our CELx test in guiding patient treatment and
minimizing the use of drugs that will not likely have a positive impact. We plan to use the data we gather through the use of these models as we meet
with commercial third-party payors and government payors.
Commercial third-party payors and government payors are increasingly making significant efforts to contain healthcare costs. A major cost
reduction opportunity is to reduce expenditures for drug courses that provide no patient benefit. Our technology will enable physicians to prescribe
therapies that have significantly higher response rates than has been the case with targeted therapies to date. Since this will lower the drug cost per
responsive patient, we believe widespread use of our CELx tests is consistent with payors goals of delivering health care more cost effectively.
21
EDGAR Stream is a copyright of Issuer Direct Corporation, all rights reserved.
Our Competition
At present, we are not aware of any other companies that offer diagnostic tests that use a patient’s live tumor cells to identify the signaling pathway driving a
patient’s cancer. There are several companies focused on developing genomic or proteomic analyses of a patient’s diseased cells. Initial efforts identified protein
targets or genetic mutations, oftentimes referred to as “biomarkers,” that are associated with a disease process to enable development of drugs more closely
tailored to specific patient populations.
As tools for human genome analysis have become less expensive, a number of companies have also recently launched more complex genomic test panels
and gene expression signatures tests. These tests rely on a static measurement of molecular properties and mathematical analysis to identify statistically
significant correlations between the selected molecular properties and a clinical condition or outcome of populations of patients with the “same” disease.
These genetic tests often have limited predictive success because they only identify some, but not all of, the molecular and cellular conditions required for a
drug therapy to function in a patient. They may identify the presence of the genes associated with a disease but they cannot determine how the gene products
function in the context of a particular individual.
Providers of genomic or proteomic tests includes diagnostic kit manufacturers, hospitals and independent laboratories. We do not plan to develop tests
where a molecular biomarker can identify drug responsive patients, so our current tests will not compete directly against the tests provided by these other
companies. The table below provides a summary of the points of differentiation between our signaling function analysis approach and the molecular approaches
used by our potential competitors.
22
EDGAR Stream is a copyright of Issuer Direct Corporation, all rights reserved.
Current Molecular Methods vs. Celcuity’s Functional Cellular Analysis Platform
Type of Cell Sample Used:
Dead tumor cells
(fixed, lysed)
Live tumor cells
Type of Analysis Performed
Single point-in-time mutation(s) status or protein
amount, or activation status
Quantify signaling pathway activity over 24-hour period
Relationship to disease driver
Correlative
Direct Cause
Disease driver evaluated
No. Only a single or small set of components of the cell
are evaluated
Yes. The activity of the entire signaling pathway is
assessed
Drug function evaluated
No. Cannot assess drug function with dead cells
Yes. Drug’s effect on signaling pathway activity in
patient’s cells quantified
Companies
Foundation Medicine, Caris Life Sciences,
NeoGenomics, LabCorp, Quest, Nanostring, Paradigm,
Biocept, Exosome Diagnostics, Guardant Health,
Roche Diagnostics, Qiagen, Myriad, Genomic Health
Celcuity
We are not aware of any available tests directly comparable to the CELx tests. We expect to offer each CELx test to patients at list prices ranging from
$4,000 to $7,000, depending on the number of pathways evaluated. List prices for several proprietary complex genomic tests fall within this range and we believe
this provides guidance as to the pricing of highly informative tests that guide cancer patient care.
Intellectual Property
We believe one of our core competitive advantages is the strength of our intellectual property portfolio. We developed our CELx technology internally. We are
seeking both U.S. and non-U.S. patents to protect our inventions. Our patent portfolio currently includes the following:
23
EDGAR Stream is a copyright of Issuer Direct Corporation, all rights reserved.
Subject Matter
Patent/Application #
Status
Methods of treating a cancer patient using
cell signaling analysis
US 9,404,915
U.S. granted; Europe and Japan
pending
Priority
Date
Expiration
6/12/2012
2033
Methods of treating a cancer patient using
cell signaling analysis
Methods of determining the functional status
of a cellular pathway
US 15/192,280
U.S. pending
6/12/2012
2033
US 15/179,119
U.S. pending
12/12/2013
2034
Methods of diagnosing a cancer patient
using cell signaling analysis
US 15/533,897
U.S., Australia, Canada, China,
Europe, Japan, South Korea and
New Zealand pending
12/12/2014
2035
Methods of creating a patient cell
microenvironment
Methods of treating a cancer patient using
cell signaling analysis
Methods of treating a cancer patient using
cell signaling analysis
PCT/US2016/057923
PCT pending
10/20/2015
2036
US 62/473,936
U.S. pending
3/20/2017
2038
US 62/587,572
U.S. pending
10/17/2017
2038
We understand we must develop and maintain protection on the proprietary aspects of our technologies in order to remain competitive. We rely on a
combination of patents, copyrights, trademarks, trade secret and other intellectual property laws and confidentiality, material transfer agreements, invention
assignment agreements and other contracts to protect our intellectual property rights.
We plan to develop names for new products and apply for trademarks and as appropriate secure trademark protection for them, including domain name
registration, in relevant jurisdictions. We also have developed a number of proprietary methods, materials, processes, and techniques related to the preparation
of patient samples and performance of the CELx test that we believe are most effectively protected as trade secrets rather than as patented subject matter.
Research and Development
We have made significant investments in research and development for our CELx platform. Our annual research and development expenses were
approximately $3.1 million and $5.0 million for the years ended December 31, 2016 and 2017, respectively.
Principal Suppliers
We purchase commercially available reagents and instruments from a variety of suppliers. Our principal reagent suppliers include Bio-Techne Corporation,
Selleck Chemicals, Sigma-Aldrich, and VWR International. Our principal instrument suppliers include Acea Biosciences, Integra Biosciences, Invitrogen, and
Thermo Fisher Scientific. These items are purchased on a purchase order basis pursuant to the applicable supplier’s standard terms and conditions. The items
purchased from these suppliers are standard products sold widely to the biotechnology industry. All items purchased are typically available within several days
after an order is placed.
24
EDGAR Stream is a copyright of Issuer Direct Corporation, all rights reserved.
Government Regulation
CLIA and CMS
The Centers for Medicare & Medicaid Services, or CMS, an agency within the U.S. Department of Health and Human Services, regulates all clinical
laboratory testing (except research) performed on humans in the U.S. through CLIA. All clinical laboratories that perform clinical lab services on human
specimens for the purpose of providing information on the diagnosis, prevention or treatment of disease must receive CLIA certification. This covers
approximately 175,000 laboratories as of 2017. Laboratories must obtain CLIA certification and demonstrate compliance with CLIA requirements as confirmed by
an inspection by CMS. We received our CLIA certification in 2016. We also had our laboratory certified by the College of American Pathologies, or CAP, in
2016, an organization recognized by CMS as a third-party reviewer of clinical laboratories. Several states, including, among others, New York and California,
require licensure of out-of-state labs that receive specimens from the state and compliance with the state’s individual laboratory regulations.
If our laboratory is out of compliance with CLIA requirements, we may be subject to sanctions such as suspension, limitation or revocation of our CLIA
certificate, as well as directed plan of correction, state on-site monitoring, civil money penalties, civil injunctive suit or criminal penalties. We must maintain CLIA
compliance and certification to be eligible to bill for services provided to Medicare and Medicaid beneficiaries. If we were to be found out of compliance with CLIA
program requirements and subjected to sanction, our business could be harmed. Failure to comply with state licensure laws, if applicable, could subject us to
additional sanctions imposed by state licensing authorities.
FDA
FDA approval or clearance is not currently required for CELx tests offered as a stand-alone laboratory developed test. If we are partnered with a drug
company to launch a CELx test as a CDx for a new drug indication, we would be required to obtain a Pre-Market Approval, or PMA, in conjunction with the
pharmaceutical company seeking a New Drug Approval for the matching therapy. Historically, the FDA has exercised enforcement discretion with respect to
tests performed solely in a central laboratory, like the CELx tests, often referred to as Laboratory Developed Tests, or LDTs. The FDA has not required
laboratories that furnish only LDTs to comply with the agency’s requirements for medical devices (e.g., establishment registration, device listing, quality systems
regulations, pre-market clearance or pre-market approval, and post-market controls).
Although the FDA proposed regulations that would apply to LDTs, FDA recently decided that, at present, those regulations are not moving forward towards
approval and implementation. In mid-2014, the FDA published a Draft Guidance Document describing a proposed approach for a regulatory framework for LDTs
that would have resulted in most of the high-value LDT tests marketed today eventually being required to obtain 510(k) clearances or Pre-Market Approvals. If
implemented, this regulatory framework would require most hospital clinical labs to abandon a number of tests it performs or to pursue regulatory clearances or
approvals to perform them. These proposals met significant resistance from Congress, the hospital industry, and independent clinical laboratories. The FDA
indicated in late 2016 that it does not intend to finalize the 2014 Draft Guidance Document at this time. However, FDA continues to discuss potential regulatory
approaches to LDTs.
HIPAA and HITECH
Under the administrative simplification provisions of HIPAA, as amended by the HITECH Act, the U.S. Department of Health and Human Services, or HHS,
issued regulations that establish uniform standards governing the conduct of certain electronic healthcare transactions and protecting the privacy and security of
protected health information used or disclosed by healthcare providers and other covered entities. HIPAA includes the following primary sets of regulations:
privacy regulations, security regulations, and standards for electronic transactions, which establish standards for certain healthcare transactions. The privacy and
security regulations were extensively amended in 2013 to incorporate new requirements from the HITECH Act.
25
EDGAR Stream is a copyright of Issuer Direct Corporation, all rights reserved.
The privacy regulations cover the use and disclosure of protected health information by healthcare providers and other covered entities. They also set forth
certain rights that an individual has with respect to his or her protected health information, including, but not limited to, the right to access or amend certain
records containing protected health information, or to request restrictions on the use or disclosure of protected health information. The security regulations
establish requirements for safeguarding the confidentiality, integrity, and availability of protected health information that is electronically transmitted or
electronically stored. The HITECH Act, among other things, makes many of HIPAA’s privacy and security standards applicable to business associates of covered
entities, and established certain protected health information security breach notification requirements. A covered entity must notify affected individual(s) and the
HHS when there is a breach of unsecured protected health information. HIPAA also governs patient access to laboratory test reports. Effective October 6, 2014,
individuals (or their personal representatives, as applicable), have the right to access test reports directly from clinical laboratories and to direct that copies of
those test reports be transmitted to persons or entities designated by the individual.
These laws impose significant fines and other penalties for improper use or disclosure of protected health information. Additionally, to the extent that we
submit electronic healthcare claims and payment transactions that do not comply with the electronic data transmission standards established under HIPAA and
the HITECH Act, payments to us may be delayed or denied.
In addition to the federal privacy regulations, there are a number of state laws regarding the privacy and security of health information and personal data that
are applicable to our operations. The HIPAA privacy and security regulations establish a uniform federal “floor” that covered entities and business associates
must meet and do not supersede state laws that are more stringent or provide individuals with greater rights with respect to the privacy or security of, and access
to, their records containing protected health information. The compliance requirements of these various state laws, including additional breach reporting
requirements, and the penalties for violation vary widely and new privacy and security laws in this area are evolving. We believe that we have taken the steps
required for us to comply with health information privacy and security statutes and regulations in all jurisdictions, both state and federal. However, we may not be
able to maintain compliance in all jurisdictions where we do business. Failure to maintain compliance, or changes in state or federal laws regarding privacy or
security, could result in civil and/or criminal penalties and could have a material adverse effect on our business.
Federal, State and Foreign Fraud and Abuse Laws
In the United States, there are various fraud and abuse laws with which we must comply and we are potentially subject to regulation by various federal, state
and local authorities, including CMS, other divisions of the HHS (e.g., the Office of Inspector General), the U.S. Department of Justice, and individual U.S.
Attorney offices within the Department of Justice, and state and local governments. We also may be subject to foreign fraud and abuse laws in connection with
our international business activities.
In the United States, the federal Anti-Kickback Statute prohibits, among other things, knowingly and willfully offering, paying, soliciting or receiving
remuneration to induce, or in return for patient referrals for, or purchasing, leasing, ordering, recommending or arranging for the purchase, lease or order of, any
healthcare item or service reimbursable under a governmental payor program. Courts have stated that a financial arrangement may violate the Anti-Kickback
Statute if any one purpose of the arrangement is to encourage patient referrals or other federal healthcare program business, regardless of whether there are
other legitimate purposes for the arrangement. The definition of “remuneration” has been broadly interpreted to include anything of value, including gifts,
discounts, credit arrangements, payments of cash, consulting fees, waivers of co-payments, ownership interests, and providing anything at less than its fair
market value. Recognizing that the Anti-Kickback Statute is broad and may technically prohibit many innocuous or beneficial arrangements within the healthcare
industry, the HHS issued a series of regulatory “safe harbors.” These safe harbor regulations set forth certain provisions, which, if met, will assure healthcare
providers and other parties that they will not be prosecuted under the federal Anti-Kickback Statute. Although full compliance with these provisions protects
against prosecution under the federal Anti-Kickback Statute, the failure of a transaction or arrangement to fit within a specific safe harbor does not necessarily
mean that the transaction or arrangement is illegal or that prosecution under the federal Anti-Kickback Statute will be pursued. Many states also have anti-
kickback statutes, some of which may apply to items or services reimbursed by any third-party payor, including commercial insurers.
26
EDGAR Stream is a copyright of Issuer Direct Corporation, all rights reserved.
In addition, federal false claims laws, including the federal civil False Claims Act, prohibit, among other things, any person or entity from knowingly
presenting, or causing to be presented, a false claim for payment to, or approval by, the federal government or knowingly making, using, or causing to be made
or used a false record or statement material to a false or fraudulent claim to the federal government. As a result of a modification made by the Fraud Enforcement
and Recovery Act of 2009, a claim includes “any request or demand” for money or property presented to the U.S. government. Recently, several pharmaceutical
and other healthcare companies have been prosecuted under these laws for allegedly providing free product to customers with the expectation that the
customers would bill federal programs for the product. Other companies have been prosecuted for causing false claims to be submitted because of the
companies’ marketing of the product for unapproved, and thus generally non-reimbursable, uses. The civil monetary penalties statute imposes penalties against
any person or entity who, among other things, is determined to have presented or caused to be presented a claim to a federal health program that the person
knows or should know is for an item or service that was not provided as claimed or is false or fraudulent.
HIPAA created additional federal criminal statutes that prohibit knowingly and willfully executing, or attempting to execute, a scheme to defraud or to obtain,
by means of false or fraudulent pretenses, representations or promises, any money or property owned by, or under the control or custody of, any healthcare
benefit program, including private third-party payors and knowingly and willfully falsifying, concealing or covering up by trick, scheme or device, a material fact or
making any materially false, fictitious or fraudulent statement in connection with the delivery of or payment for healthcare benefits, items or services.
In addition, various states have enacted false claim laws analogous to the federal False Claims Act, although many of these state laws apply where a claim is
submitted to any third-party payor and not merely a governmental payor program. If our operations are found to be in violation of any of the federal or state
healthcare laws described above or any other governmental regulations that apply to us, we may be subject to significant penalties, including without limitation,
civil, criminal and/or administrative penalties, damages, fines, disgorgement, exclusion from participation in government programs, such as Medicare and
Medicaid, injunctions, private “qui tam” actions brought by individual whistleblowers in the name of the government, or refusal to allow us to enter into
government contracts, contractual damages, reputational harm, administrative burdens, diminished profits and future earnings, and the curtailment or
restructuring of our operations, any of which could adversely affect our ability to operate our business and our results of operations.
In Europe, various countries have adopted anti-bribery laws providing for severe consequences, in the form of criminal penalties and/or significant fines, for
individuals and/or companies committing a bribery offence. Violations of these anti-bribery laws, or allegations of such violations, could have a negative impact
on our business, results of operations and reputation. For instance, in the United Kingdom, under the Bribery Act 2010, which went into effect in July 2011, a
bribery occurs when a person offers, gives or promises to give a financial or other advantage to induce or reward another individual to improperly perform certain
functions or activities, including any function of a public nature. Bribery of foreign public officials also falls within the scope of the Bribery Act 2010. Under the
new regime, an individual found in violation of the Bribery Act 2010 faces imprisonment of up to 10 years. In addition, the individual can be subject to an
unlimited fine, as can commercial organizations for failure to prevent bribery.
Federal and State Physician Self-Referral Prohibitions
Under a federal law directed at “self-referral,” commonly known as the “Stark Law,” there are prohibitions, with certain exceptions, on referrals for certain
designated health services, including laboratory services, that are covered by the Medicare and Medicaid programs by physicians who personally, or through a
family member, have an investment or ownership interest in, or a compensation arrangement with, an entity performing the tests. The prohibition also extends to
payment for any testing referred in violation of the Stark Law. A person who engages in a scheme to circumvent the Stark Law’s referral prohibition may be fined
up to $100,000 for each such arrangement or scheme. In addition, any person who presents or causes to be presented a claim to the Medicare or Medicaid
programs in violation of the Stark Law is subject to civil monetary penalties of up to $15,000 per bill submission, an assessment of up to three times the amount
claimed and possible exclusion from participation in federal governmental payor programs. Bills submitted in violation of the Stark Law may not be paid by
Medicare or Medicaid, and any person collecting any amounts with respect to any such prohibited bill is obligated to refund such amounts. Many states have
comparable laws that are not limited to Medicare and Medicaid referrals.
27
EDGAR Stream is a copyright of Issuer Direct Corporation, all rights reserved.
Other Regulatory Requirements
Our operations do not currently use hazardous materials, but we do generate regulated medical waste in the normal course of performing our CELx tests.
This subjects us to a variety of federal, state and local environmental and safety laws and regulations. Some of the regulations under the current regulatory
structure provide for strict liability, holding a party potentially liable without regard to fault or negligence. We could be held liable for damages and fines as a
result of our, or others’, business operations should contamination of the environment or individual exposure to hazardous substances occur. We cannot predict
how changes in laws or development of new regulations will affect our business operations or the cost of compliance.
New Legislation and Regulations
From time to time, legislation is drafted, introduced and passed in Congress that could significantly change the statutory provisions governing the testing,
approval, manufacturing and marketing of products that are or will be regulated by the FDA or CMS. In addition to new legislation, CMS and FDA regulations and
policies are often revised or interpreted by the agencies in ways that may significantly affect our business and our products. It is impossible to predict whether
further legislative changes will be enacted or FDA or CMS regulations, guidance, policies or interpretations will be changed, or what the impact of such changes,
if any, may be. The 2016 presidential election and change in administration make it even more difficult to predict if and how federal regulations may change
and/or federal agencies might alter their positions.
Pharmaceutical Coverage, Pricing and Reimbursement
Significant uncertainty exists as to the coverage and reimbursement status of any products for which we sell. Sales of any of our products will depend, in
part, on the extent to which the costs of the products will be covered by third-party payors, including government health programs such as Medicare and
Medicaid, commercial health insurers, managed care organizations or pharmaceutical companies. The process for determining whether a third-party payor will
provide coverage for a test sometimes is separate from the process for setting the price of a drug product or for establishing the reimbursement rate that a payor
will pay for the drug product. Third-party payors may limit coverage to specific testing products on an approved list, which might not include all of the tests
available for a particular indication.
In order to obtain coverage and reimbursement for any product, we may need to conduct expensive pharmacoeconomic studies in order to demonstrate the
medical necessity and cost-effectiveness of the test. Whether or not we conduct such studies, our products may not be considered medically necessary or cost-
effective. A third-party payor’s decision to provide coverage for a test does not imply that an adequate reimbursement rate will be approved. Further, one payor’s
determination to provide coverage for a product does not assure that other payors will also provide coverage, and adequate reimbursement, for the product.
Third-party reimbursement may not be sufficient to enable us to maintain price levels high enough to realize an appropriate return on our investment in product
development.
The containment of healthcare costs has become a priority of federal, state and foreign governments, and the prices of tests and drugs have been a focus in
this effort. Third-party payors are increasingly challenging the prices charged for medical products and services, examining the medical necessity and reviewing
the cost-effectiveness of testing products, drug products and medical services and questioning safety and efficacy. If these third-party payors do not consider our
products to be cost-effective compared to other available tests, they may not cover our products or, if they do, the level of payment may not be sufficient to allow
us to sell our products at a profit. The U.S. government, state legislatures and foreign governments have shown significant interest in implementing cost-
containment programs to limit the growth of government-paid healthcare costs, including price controls and restrictions on reimbursement. Adoption of such
controls and measures, and tightening of restrictive policies in jurisdictions with existing controls and measures, could limit payments for testing products or
drugs that require use of our testing products and could adversely affect our net revenue and results.
Pricing and reimbursement schemes vary widely from country to country. Some countries may require the completion of additional studies that compare the
cost-effectiveness of a particular test to currently available tests. The downward pressure on healthcare costs in general, particularly prescription drugs and
testing products, has become intense. As a result, increasingly high barriers are being erected to the entry of new products. In addition, in some countries, cross-
border imports from low-priced markets exert competitive pressure that may reduce pricing within a country. Any country that has price controls or
reimbursement limitations for testing products may not allow favorable reimbursement and pricing arrangements for any of our products.
28
EDGAR Stream is a copyright of Issuer Direct Corporation, all rights reserved.
Coverage policies, third-party reimbursement rates and test pricing regulation may change at any time. In particular, in the United States, the Affordable
Care Act contains provisions that have the potential to substantially change healthcare delivery and financing, including impacting the profitability of testing and
drugs. For example, the Affordable Care Act revised the methodology by which rebates owed by manufacturers for covered outpatient drugs are calculated
under the Medicaid Drug Rebate Program, extended the Medicaid Drug Rebate Program to utilization of covered drugs dispensed to individuals enrolled in
Medicaid managed care organizations and subjected manufacturers to new annual fees for certain branded prescription drugs. As the price of our test may be
included in the reimbursement rates for certain drugs, this could significantly impact our pricing. Even if favorable coverage and reimbursement status is attained
for one or more products, less favorable coverage policies and reimbursement rates may be implemented in the future. However, the proposed repeal of the
Affordable Care Act and the uncertainty surrounding a potential replacement law make it even more difficult to predict the future for reimbursement and pricing of
drugs and tests in the United States.
Corporate History
We were organized as a Minnesota limited liability company in 2011 and commenced operations in 2012. On September 15, 2017, we converted from a
Minnesota limited liability company into a Delaware corporation and changed our name from Celcuity LLC to Celcuity Inc.
Employees and Labor Relations
As of December 31, 2017, we had 22 employees, each of which were full-time employees. None of our employees are currently covered by collective
bargaining agreements and we believe that our relations with our employees are good.
29
EDGAR Stream is a copyright of Issuer Direct Corporation, all rights reserved.
ITEM 1A. Risk Factors
Risk factors which could cause actual results to differ from our expectations and which could negatively impact our financial condition and results of
operations are discussed below and elsewhere in this report. Additional risks and uncertainties not presently known to us or that are currently not believed to be
significant to our business may also affect our actual results and could harm our business, financial condition and results of operations. If any of the risks or
uncertainties described below or any additional risks and uncertainties actually occur, our business, results of operations and financial condition could be
materially and adversely affected.
Risks Relating to Our Business
We have a limited operating history upon which you can evaluate us. We may never generate revenue or profit.
We are an early-stage biotechnology company that commenced activities in January 2012. We only have a limited operating history upon which you can
evaluate us. Our business plan has not been tested. Since inception, we have had no revenue and have incurred significant operating losses. We have financed
our operations primarily through private placements of common equity and convertible notes prior to our initial public offering, as well as proceeds from our initial
public offering of common stock. To generate revenue and become and remain profitable, we must continue to develop and commercialize the CELx platform. To
do so, we need to successfully complete our clinical trial collaboration with Genentech and the NSABP for our CELx HSF Test, continue to develop other CELx
tests for other cancer sub-types and cultivate partnerships with pharmaceutical companies. We must also build operational and financial infrastructure to support
commercial operations, train and manage employees, and market and sell our CELx tests (as a CDx and/or as a stand-alone test).
We may never succeed in any or all of these activities and, even if we do, we may never generate revenue that is sufficient to achieve profitability. We
expect to continue to incur significant expenses and operating losses for the foreseeable future, and the net losses we incur may fluctuate significantly from
quarter to quarter. Our failure to become and remain profitable would decrease the value of the company and could impair our ability to raise capital, maintain or
expand our research and development efforts, expand our business, or continue our operations.
Our initial success is heavily dependent on the success of our CELx HSF Test.
Our business strategy is focused on attracting pharmaceutical company partnerships that provide revenue from the sale of CELx tests during clinical trials,
from milestone payments during clinical trials, from sales of our CELx tests as companion diagnostics or stand-alone tests thereafter, and, potentially, from
royalties on the incremental drug revenues our tests enable. Our ability to obtain such partnerships and generate such revenue depends in part on the ability of
our CELx HSF Test to demonstrate the potential incremental opportunity available for pharmaceutical companies. We do not expect to receive interim results for
our first prospective clinical trial for the CELx HSF Test until late 2018 and final results six to nine months later. Success of the HSF Test trial will depend on
many factors, such as successful enrollment of patients, meeting trial endpoint goals, and completing the trial in a timely manner. Our ability to complete the trial
could be delayed or prevented for several reasons that are out of our control, such as the FDA withdrawing its authorization and approval to perform the study,
the NSABP determining that the human and/or toxicology test results do not support continuing the trial, or participants having adverse reactions or side-effects
to the drugs administered in the study. If we are unable to demonstrate that the HSF Test is suitable as a CDx for the targeted therapy, we will likely not be able
to generate future revenue from our CELx HSF Test and may not be able to attract other pharmaceutical companies to partner with us for the development and
commercialization of other CELx tests. Further, potential pharmaceutical company partners may delay negotiating development agreements until results of the
CELx HSF Test trial are available. Even if the ultimate outcome of our CELx HSF Test trial is positive, any delays could materially and adversely affect our
business.
30
EDGAR Stream is a copyright of Issuer Direct Corporation, all rights reserved.
We may not be successful in finding pharmaceutical company partners for continuing development of additional CELx tests.
We intend to develop strategic partnerships with pharmaceutical companies for developing additional CELx tests. Many of the potential partners are global,
multi-billion-dollar pharmaceutical companies with sophisticated research and development organizations and multiple priorities. We may not be successful in our
efforts to establish such a strategic partnership or other alternative arrangements for our CELx tests because, among other things, our research and
development pipeline may be insufficient, such tests may be deemed to be at too early of a stage of development for collaborative effort, or third parties may not
view such tests as having the requisite potential to demonstrate efficacy. In addition, we may be restricted under collaboration agreements from entering into
future agreements with other partners. Even if we are able to find suitable partners, we may not be successful in negotiating development agreements with such
partners that provide revenue from the sale of our CELx tests to identify patients eligible for required clinical trials, milestone payments, and/or royalties on the
incremental drug revenues that our tests enable. If we are unable to reach agreements with suitable strategic partners on a timely basis, on acceptable terms or
at all, we may have to curtail the development of additional CELx tests, our expected revenue opportunities may be significantly smaller than expected and our
business may fail.
While our CELx HSF Test is commercially ready, we have not attempted to market it to physicians or their patients as a stand-alone test and have no
ability to determine this test or any of our other tests are currently commercially viable.
While our CELx HSF test has been analytically validated, is conducted in our CLIA certified and CAP accredited laboratory, and is currently ready for
commercial use as a laboratory developed test, we have not attempted to market it to physicians or their patients. Furthermore, we have commenced only limited
communications with KOLs to build awareness and credibility of our CELx diagnostic platform and CELx HSF Test. Accordingly, we have no ability to determine
whether our CELx HSF Test, or any other future CELx test, will be commercially viable as a stand-alone test. We may never be successful in generating
revenue from our CELx HSF Test or other CELx tests as stand-alone tests, and if we are unable to build pharmaceutical partnerships that enable us to market
this and other tests as companion diagnostic tests, we may never generate any revenue and our business may fail.
Developing our CELx tests involves a lengthy and complex process that may not be successful.
Our CELx tests may take several years to develop from the time they are discovered to the time they are available for patient use, if ever. In order to
develop additional CELx tests into commercially ready products, we need to successfully complete a variety of activities, including, among other, conducting
substantial research and development, conducting extensive analytical testing, and maintaining our CLIA certified and CAP accredited laboratory. In addition, our
business strategy is focused heavily on our CELx tests being sold as companion diagnostics. This will require obtaining and maintaining partnerships with
pharmaceutical companies and successfully completing clinical studies that demonstrate the suitability of the applicable CELx test as a CDx for their targeted
therapies.
These activities will require us to expend significant resources. Based on comparable companies in this industry, few research and development projects
result in commercially viable products, and success in early clinical studies often is not replicated in later studies. At any point, we may abandon development of
a product candidate for several reasons, such as a clinical validation study failing to demonstrate the prospectively defined endpoints of the study. We may also
be required to expend considerable resources repeating clinical studies, which would adversely affect the timing for generating potential revenue from a new
product and our ability to invest in other products in our pipeline.
Clinical trials are expensive and complex with uncertain outcomes, which may prevent or delay commercialization of our CELx tests.
For our CELx tests to become a CDx for a matching targeted therapy, we must conduct clinical trials to demonstrate that patients who have an abnormal
signaling pathway, as identified by our CELx tests, respond to treatment with a matching targeted therapy. Clinical testing is expensive, difficult to design and
implement, and can take many years to complete, and its outcome is inherently uncertain. As a company, we have no experience in conducting or participating
in clinical trials. We cannot be certain that any future clinical trials will conclusively demonstrate that any CELx test is effective as a CDx. If our trials do not yield
positive results, we may be unable to maintain the pharmaceutical company partnerships we build or find additional partners, we may not be able to successfully
commercialize our CELx tests or generate any revenue, our business may fail, and you may lose part or all of your investment.
31
EDGAR Stream is a copyright of Issuer Direct Corporation, all rights reserved.
We cannot be certain that our existing clinical trial or future clinical trials, if any, will begin or be completed on time, if at all. We may experience numerous
unforeseen events during, or as a result of, clinical trials that could delay or prevent our ability to commercialize our CELx tests, such as:
·
·
·
·
·
·
delays in reaching, or failure to reach, agreement on acceptable clinical trial contracts or clinical trial protocols with planned trial sites and/or strategic
partners;
delay or failure in reaching agreement with the FDA or a comparable foreign regulatory authority on a trial design, in obtaining authorization from such
authorities to commence the trial, and/or in complying with conditions or other requirements imposed by such regulatory authorities with respect to the
trial;
delay or failure in recruiting and enrolling suitable subjects to participate in one or more clinical trials, or with such participants completing a trial or
returning for follow-up during or after the trial;
clinical sites, investigators or other third-parties deviating from the trial protocol, failing to conduct the trial in accordance with regulatory and contractual
requirements, and/or dropping out of a trial;
regulatory imposition of a clinical hold for any of our clinical trials, where a clinical hold in a trial in one indication would result in a clinical hold for clinical
trials in other indications; and
changes in governmental regulations or administrative actions.
Significant nonclinical or clinical trial delays could prevent us from maintaining and/or developing new pharmaceutical company partnerships. Delays could
also shorten any periods during which we may have the exclusive right to commercialize our CELx tests or allow our competitors to bring products to market
before we do. As such, any delays could impair our ability to successfully commercialize our CELx tests and may materially and adversely affect our business,
financial condition, results of operations and prospects.
Even if our CELx tests achieve positive clinical trial results, they may fail to achieve the degree of market acceptance by physicians, patients, third-
party payors and others in the medical community necessary for commercial success.
If any of our potential CELx tests, including the CELx HSF Test, achieve positive clinical trial results, they may nonetheless fail to gain sufficient market
acceptance by physicians, patients, third-party payors and others in the medical community necessary for commercial success. For example, conventional
genomic- or proteomic-based analyses are commonly used today to diagnose cancer and prescribe cancer medications, and physicians may continue to rely on
these diagnostic tests instead of adopting the use of a CELx test. The degree of market acceptance of our CELx tests, will depend on a number of factors,
including:
·
·
·
·
·
·
·
their efficacy and other potential advantages compared to alternative diagnostic tests;
our ability to offer them for sale at competitive prices;
their convenience and ease of administration compared to alternative diagnostics;
the willingness of the target patient population to try new diagnostics and of physicians to initiate such diagnostics;
the strength of marketing and distribution support;
the availability of third-party coverage and adequate reimbursement for our diagnostic tests; and
our ability to partner with pharmaceutical companies to develop CDx programs for the new cancer sub-types we discover.
If our CELx tests do not achieve an adequate level of acceptance, we may never generate significant product revenues and we may not become profitable.
32
EDGAR Stream is a copyright of Issuer Direct Corporation, all rights reserved.
Our business, operational and financial goals may not be attainable if the market opportunities for our CELx tests or our pharmaceutical company
partners are smaller than we expect. Our internal research and estimates on market opportunities have not been verified by independent sources,
and we have not independently verified market and industry data from third-parties that we have relied on.
The total market opportunities that we believe exist are based on a variety of assumptions and estimates, including the number of potential CDx programs we
will be able to successfully pursue, the amount of potential milestone payments that we could receive in CDx programs, the number of patients we will test in
clinical trials, the price we will be able to charge for our tests and the total annual number of cancer patients with undiagnosed abnormal cell signaling. In
addition, we have relied on third-party publications, research, surveys and studies for information related to determining market opportunities, including without
limitation, information on the number of cancer patients and those receiving various forms of treatment, the cost of drug therapy, the amount of revenue
generated from various types of drug therapy, the objective response rates of drug therapies, the number of deaths caused by cancer and the expected growth
in cancer drug therapy and diagnostic markets. Our internal research and estimates on market opportunities have not been verified by independent sources, and
we have not independently verified market and industry data from third-parties that we have relied on. Any or all of our assumptions and/or estimates may prove
to be incorrect for several reasons, such as inaccurate reports or information that we have relied on, potential patients or providers not being amenable to using
our CELx platform for diagnostic testing or such patients becoming difficult to identify and access, limited reimbursement for companion diagnostics, pricing
pressure due to availability of alternative diagnostic tests, or an inability of the CELx tests’ companion drugs to obtain the necessary regulatory approvals for new
indications. If any or all of our assumptions and estimates prove inaccurate, we and our CDx pharmaceutical partners may not attain our business, operational
and financial goals.
The expected selling price range of our CELx test is an estimate. We have not yet sold any such tests and the actual price we are able to charge may
be substantially lower than our expected price range.
We have estimated the selling price range of our CELx test based on the pricing of other diagnostic tests currently available and assumptions regarding the
efficacy and market acceptance of our tests. We have not yet sold our CELx tests and cannot be certain of the actual price we may be able to charge. The
availability and price of our competitors’ products could limit the demand and the price we are able to charge. We may not achieve our business plan if
acceptance is inhibited by price competition, if pharmaceutical companies refuse to pay our expected prices for CELx tests in clinical trials, if physicians are
reluctant to switch from other diagnostic tests to our CELx tests or if physicians switch to other new products or choose to reserve our CELx tests for use in
limited circumstances. Furthermore, reductions in the reimbursement rate of third-party payors have occurred and may occur in the future. Each of these factors
could cause our selling price to be substantially lower than expected, and we may fail to obtain revenue or become profitable.
The insurance coverage and reimbursement status of new diagnostic products is uncertain. Failure to obtain or maintain adequate coverage and
reimbursement for CELx tests could limit our ability to market those CELx tests and decrease our ability to generate revenue.
The availability and extent of reimbursement by governmental and private payors is essential for most patients to be able to afford expensive diagnostic tests
and treatments. Sales of any of our potential CELx tests will depend substantially, both in the United States and internationally, on the extent to which the costs
of our CELx tests will be paid by health maintenance, managed care, and similar healthcare management organizations, or reimbursed by government health
administration authorities, private health coverage insurers and other third-party payors. Reimbursement by a payor may depend on a number of factors,
including a payor’s determination that the CELx tests are:
·
·
·
·
·
neither experimental nor investigational;
appropriate for the specific patient;
cost-effective;
supported by peer-reviewed publications; and
included in clinical practice guidelines.
If reimbursement is not available, or is available only to a limited amount, we may not be able to successfully commercialize our CELx tests at expected
levels, or potentially at all. Even if coverage is provided, the approved reimbursement amount may not be high enough to allow us to establish or maintain
pricing sufficient to realize a sufficient return on our research and development investment.
There is significant uncertainty related to the insurance coverage and reimbursement of newly approved diagnostic products. In the United States, the
principal decisions about reimbursement for new diagnostic products and services are typically made by CMS. CMS decides whether and to what extent a new
product or service will be covered and reimbursed under Medicare. Private payors tend to follow CMS to a substantial degree. As such, a significant portion of
our potential revenue depends on CMS approving coverage and reimbursement of our CELx tests.
33
EDGAR Stream is a copyright of Issuer Direct Corporation, all rights reserved.
Outside the United States, international operations are generally subject to extensive governmental price controls and other market regulations, and we
believe the increasing emphasis on cost-containment initiatives in Europe, Canada and other countries has and will continue to put pressure on the pricing and
usage of diagnostic tests such as our potential CELx tests. In many countries, particularly the countries of the European Union, the prices of medical products
are subject to varying price control mechanisms as part of national health systems. In these countries, pricing negotiations with governmental authorities can
take considerable time. To obtain reimbursement or pricing approval in some countries, we may be required to demonstrate the cost-effectiveness of our CELx
tests relative to other available diagnostic tests. The prices of products under such systems may be substantially lower than in the United States. Other countries
allow companies to fix their own prices for products, but monitor and control company profits. Additional foreign price controls or other changes in pricing
regulation could restrict the amount that we are able to charge for our CELx tests. Accordingly, in markets outside the United States, the reimbursement for our
potential CELx tests may be reduced compared with the United States and may be insufficient to generate commercially reasonable revenue and profit.
Moreover, increasing efforts by governmental and third-party payors, in the United States and internationally, to cap or reduce healthcare costs may cause
such organizations to limit both coverage and level of reimbursement for new products approved and, as a result, they may not cover or provide adequate
payment for our potential CELx tests. The downward pressure on healthcare costs in general, particularly prescription drugs and surgical procedures and other
treatments, has become very intense. We expect to experience pricing pressures in connection with the sale of any CELx tests due to the trend toward
managed healthcare, the increasing influence of health maintenance organizations and additional legislative changes.
We may encounter difficulties in commercializing and marketing our products.
In order to commercialize any CELx test, we must build marketing, sales, managerial and other non-technical capabilities or make arrangements with third
parties to perform these services, and we may not be successful in doing so. For each CELx test we develop, we intend to pursue development agreements with
the pharmaceutical companies that provide matching targeted therapies. Once we have completed the analytical validation of a CELx test, we plan to target key
opinion leaders (KOLs) to build product awareness. Once we have clinical validation data available, we expect to expand our sales and marketing efforts to
target the broader market, and coordinate our go-to-market activities with those of our partner pharmaceutical companies. These activities will be expensive and
time consuming and will require significant attention of our executive officers to manage. Furthermore, there is no guarantee that any new drug indications will
require our CELx tests as a CDx or that any pharmaceutical company will effectively coordinate sales and marketing activities with us. Any failure or delay in
these activities would adversely impact the commercialization our CELx platform, and our business, financial condition, results of operations and prospects may
be materially and adversely affected.
We may encounter difficulties in managing growth, which could disrupt our operations.
To manage our anticipated future growth, we must continue to implement and improve our managerial, operational and financial systems, expand our
facilities and continue to recruit and train additional qualified personnel. Due to our limited financial resources, we may not be able to effectively manage the
expansion of our operations or recruit and train additional qualified personnel. The expansion of our operations may lead to significant costs and may divert our
management and business development resources. Any inability to manage growth could delay the execution of our business plans or disrupt our operations.
We face significant competition from other diagnostic companies and our operating results will suffer if we fail to compete effectively.
The diagnostic testing related industry is intensely competitive. We have competitors both in the United States and abroad, including universities and other
research institutions and providers of diagnostics that focus on developing genomic or proteomic analyses of a patient’s diseased cells or theranostic tests to
predict specific patient responses to a drug therapy. Many of our competitors have substantially greater financial, technical and other resources, such as larger
research and development staff and well-established marketing and sales forces. Our competitors may succeed in developing, acquiring or licensing, on an
exclusive basis, products or services that are more effective or less costly than the CELx tests that we are currently developing or that we may develop. In
addition, established medical technology, biotechnology and/or pharmaceutical companies may invest heavily to accelerate discovery and development of
diagnostic tests that could make our CELx tests less competitive.
34
EDGAR Stream is a copyright of Issuer Direct Corporation, all rights reserved.
Our ability to compete successfully will depend largely on our ability to:
·
·
·
·
·
·
·
discover and develop CELx tests for cancer sub-types that are superior to other products in the market;
demonstrate compelling advantages in the efficacy and convenience of our CELx tests on a cost competitive basis;
attract qualified scientific, product development and commercial personnel;
obtain and maintain patent and other proprietary protection as necessary for our CELx platform;
obtain required U.S. and international regulatory approvals;
successfully collaborate with research institutions and pharmaceutical companies in the discovery, development and commercialization of our current
and future CELx tests; and
successfully expand our operations and build a sales force to support commercialization.
We may not be able to compete effectively if we are unable accomplish one or more of these objectives.
If our sole laboratory facility becomes inoperable, we will be unable to perform our tests and our business will be harmed.
We do not have redundant laboratory facilities. We perform all of our diagnostic services in our laboratory located in Minneapolis, Minnesota. Our facility and
the equipment we use to perform our tests would be costly to replace and could require substantial lead time to repair or replace. The facility may be harmed or
rendered inoperable by physical damage from fire, floods, tornadoes, power loss, telecommunications failures, break-ins and similar events, which may render it
difficult or impossible for us to perform our tests for some period of time. The inability to perform our tests may result in the loss of customers or harm our
reputation, and we may be unable to regain those customers in the future. Although we possess insurance for damage to our property and the disruption of our
business, this insurance may not be sufficient to cover all of our potential losses and may not continue to be available to us on acceptable terms, or at all.
In order to rely on a third party to perform our tests, we could only use another facility with established state licensure and CLIA accreditation under the
scope of which our potential CELx tests could be performed following validation and other required procedures. We cannot assure you that we would be able to
find another CLIA-certified facility willing to adopt CELx tests and comply with the required procedures, or that this laboratory would be willing to perform the tests
for us on commercially reasonable terms.
We must hire and retain a qualified sales force.
Our ability to grow revenue for our CELx tests is dependent upon our ability to build an effective sales team. We do not currently have a dedicated sales
force, and building one will be an expensive and time-consuming process. We face intense competition for qualified sales personnel and our inability to hire or
retain an adequate number of sales representatives could limit our ability to maintain or expand our business and increase sales. Even if we are able to increase
our sales force, our new sales personnel may not provide sufficient high quality service and attention to effectively market and sell our CELx platform. If we are
unable to develop our marketing and sales networks or if our sales personnel do not perform as expected, we may be unable to maintain or grow our existing
business and our business, financial condition, results of operations and prospects may be materially and adversely affected.
We will be dependent on our ability to attract and retain key personnel.
Our operations will be materially dependent upon the services of our officers and key employees, including Brian F. Sullivan, our Chief Executive Officer, and
Dr. Lance G. Laing, our Chief Science Officer. Successful implementation of our business plan will also require the services of other consultants and additional
personnel. We cannot assure you that we will be able to attract and retain such persons as employees, independent contractors, consultants or otherwise. If we
are not able to attract individuals with the skills required for our business, or if we lose the services of either Mr. Sullivan or Dr. Laing, we may be unable
successfully to implement our business plan.
35
EDGAR Stream is a copyright of Issuer Direct Corporation, all rights reserved.
Our inability to raise additional capital on acceptable terms in the future may limit our ability to develop and commercialize our CELx platform.
We may require additional capital to finance capital expenditures and operating expenses over the next several years as we launch our CELx platform and
expand our infrastructure, commercial operations and research and development activities. We may seek to raise additional capital through equity offerings, debt
financings, collaborations or licensing arrangements. Additional funding may not be available to us on acceptable terms, or at all. If we raise funds by issuing
equity securities, dilution to our stockholders could result. Any equity securities issued may also provide for rights, preferences or privileges senior to those of
holders of our existing securities. The incurrence of additional indebtedness or the issuance of certain equity securities could result in increased fixed payment
obligations and could also include restrictive covenants, such as limitations on our ability to incur additional debt or issue additional equity, limitations on our
ability to acquire or license intellectual property rights, and other operating restrictions that could adversely affect our ability to conduct our business. In the event
that we enter into collaborations or licensing arrangements to raise capital, we may be required to accept unfavorable terms. If we are not able to secure
additional funding when needed, we may have to delay, reduce the scope of or eliminate one or more research and development programs or selling and
marketing initiatives. In addition, we may have to work with a partner on one or more of our products or market development programs, which could lower the
economic value of those programs to our company.
Risks Related to Our Reliance on Third Parties
We will rely on collaboration with third parties to conduct our clinical trials, including the current trial involving the CELx HSF Test, and those third
parties may not perform satisfactorily.
We will rely on third parties to conduct clinical trials for our CELx tests. For our CELx HSF Test, we are collaborating with Genentech and the NSABP to
conduct a 54-patient single-arm interventional trial that is expected to obtain interim results in late 2018 and final results six to nine months later. We are funding
the patient-related costs for this trial and Genentech is supplying the drugs. We will rely on NSABP to conduct our clinical trial of the CELx HSF Test, including
setting up clinical sites, enrolling patients, and managing clinical data.
We expect to field additional clinical trials to evaluate new potential indications for drugs with patients identified by one of our new CELx tests. NSABP, other
contract research organizations that we hire and/or pharmaceutical companies we partner with might not successfully carry out their contractual duties, meet
expected deadlines, or conduct our planned clinical trials in accordance with regulatory requirements or our stated protocols. Any of them may also terminate
their relationship with us for a variety of reasons. Furthermore, these third parties may also have relationships with other entities, some of which may be our
competitors. If we need to enter into alternative arrangements, we may not be able to complete our clinical trials and may not be able to, or may be delayed in
our efforts to, successfully commercialize our potential CELx tests.
The pharmaceutical companies that we partner with may not be successful in receiving regulatory approval for drug indications or may not
commercialize their companion therapies for our expected CDx programs.
While we intend to provide our pharmaceutical company partners with new patient populations for such partners’ existing or investigational targeted
therapies, there can be no assurances that such partners will be able to obtain regulatory approval for new indications to treat these patient populations or
otherwise be successful in commercializing these new therapies. The pharmaceutical companies we partner with:
· may not meet clinical trial endpoint targets in evaluating efficacy of a targeted therapy in the patient population;
· may encounter regulatory or production difficulties that could constrain the supply of the companion therapies;
· may have difficulties gaining acceptance of the use of the companion therapies in the clinical community;
· may not pursue commercialization of any companion therapies;
· may elect not to continue or renew commercialization programs based on changes in their strategic focus or available funding, or external factors, such
as an acquisition, that divert resources or create competing priorities;
· may not commit sufficient resources to the marketing and distribution of such companion therapies; or
· may terminate their relationship with us.
36
EDGAR Stream is a copyright of Issuer Direct Corporation, all rights reserved.
Any of these factors could adversely affect our commercialization strategy, business, results of operations and financial condition.
Our instrument or reagent suppliers may fail to meet our quality requirements for the items we purchase or fail to provide a continuous supply of the
items we utilize to perform our CELx tests.
We utilize highly specialized reagents and instruments to perform our CELx tests. We may be unable to find suitable replacement reagents and instruments
on a timely basis, if at all. Interruption in the supply of these items or degradation in their quality could delay analytical and clinical studies, and/or render us
unable to deliver CELx tests. This would interrupt sales and adversely affect our business, results of operations and financial condition.
Performance issues or price increases by our shipping carriers could adversely affect our business, results of operations and financial condition,
and harm our reputation and ability to provide our CELx tests on a timely basis.
Expedited, reliable shipping is essential to our operations. Should our shipping carrier encounter delivery performance issues such as loss, damage or
destruction of a sample, such occurrences may damage our reputation and lead to decreased demand for our services and increased cost and expense to our
business. In addition, any significant increase in shipping rates could adversely affect our operating margins and results of operations. Similarly, strikes, severe
weather, natural disasters or other service interruptions by delivery services we use would adversely affect our ability to receive and process patient samples on
a timely basis. There are only a few providers of overnight nationwide transport services, and there can be no assurance that we will be able to maintain
arrangements with providers on acceptable terms, if at all.
Risks Related to Government Regulation
Our CELx tests represent a novel approach to companion diagnostics, which could result in heightened regulatory scrutiny, delays in clinical
development, or delays in our ability to commercialize any products.
Our unique and proprietary CELx technology is the first cancer diagnostic platform we are aware of that can detect the underlying signaling dysfunction
driving a patient’s cancer. Because this is a novel approach to companion diagnostics, there can be no assurance as to the length of a clinical trial period, the
number of patients the FDA or another applicable regulatory authority will require to be enrolled in the trials in order to establish the safety and efficacy of our
CELx tests and the companion drugs, or that the data generated in these trials will be acceptable to the FDA or another applicable regulatory authority to
support marketing approval of new indications for the companion drugs. This could delay or prohibit our clinical trials and/or commercialization of our CELx tests.
If the FDA were to begin regulating our tests, we could incur substantial costs and delays associated with trying to obtain premarket clearance or
approval.
Most LDTs, are not currently subject to FDA regulation, although reagents, instruments, software or components provided by third parties and used to
perform LDTs may be subject to regulation. We believe that the CELx tests are LDT’s, which is a term that describes tests that are designed and performed
within a single laboratory. As a result, we believe the CELx tests are not currently subject to regulation by the FDA in accordance with the FDA’s current policy of
exercising enforcement discretion regarding LDTs.
Historically, the FDA has not required laboratories that furnish only LDTs to comply with the agency’s requirements for medical devices (e.g., establishment
registration, device listing, quality systems regulations, premarket clearance or premarket approval, and post-market controls). In mid-2014, the FDA published a
Draft Guidance document describing a proposed approach for a regulatory framework for LDTs, but in late 2016, the FDA indicated it no longer intended to
finalize the LDT Guidance Document at that time. It is not clear when or if the FDA will seek to alter the current LDT regulatory framework in the future. We
cannot provide any assurance that FDA regulation, including premarket review, will not be required in the future for our tests, whether through additional
guidance issued by the FDA, new enforcement policies adopted by the FDA or new legislation enacted by Congress. We cannot predict with certainty the timing
or content of future legislation enacted or guidance issued regarding LDTs, or how it will affect our business.
37
EDGAR Stream is a copyright of Issuer Direct Corporation, all rights reserved.
If premarket review is required by the FDA at a future date or if we decide to voluntarily pursue FDA premarket review of our CELx tests, there can be no
assurance that our CELx tests or any tests we may develop in the future will be cleared or approved by the FDA on a timely basis, if at all, nor can there be
assurance that labeling claims will be consistent with our current claims or adequate to support continued adoption of and reimbursement for our CELx tests. If
our CELx tests are allowed to remain on the market but there is uncertainty in the marketplace about our tests, if they are labeled investigational by the FDA, or
if labeling claims the FDA allows us to make are more limited than we expect, reimbursement may be adversely affected and we may not be able to sell our
CELx tests. Compliance with FDA regulations would increase the cost of conducting our business, and subject us to heightened regulation and scrutiny by the
FDA and penalties for failure to comply with these requirements.
If we fail to obtain required federal and state laboratory licenses, we could lose the ability to perform our tests.
Clinical laboratory tests, including our CELx tests, are regulated under CLIA. CLIA is a federal law that regulates clinical laboratories that perform testing on
specimens derived from humans for the purpose of providing information for the diagnosis, prevention or treatment of disease. CLIA regulations mandate
specific standards for laboratories in the areas of personnel qualifications, administration, and participation in proficiency testing, patient test management and
quality assurance. CLIA certification is also required in order for us to be eligible to bill state and federal healthcare programs, as well as many private third-party
payers, for any tests we launch. We will also be required to maintain state licenses in certain states to conduct testing in our laboratories. While we currently
have CLIA Certification for our Minnesota laboratory, failure to maintain this certification would adversely affect our ability to launch our CELx tests.
We generate medical waste and could face substantial liability if we violate laws with respect to the handling of medical waste.
We generate regulated medical waste in the normal course of performing our CELx tests. This subjects us to a variety of federal, state and local
environmental and safety laws and regulations. Some of the regulations under the current regulatory structure provide for strict liability, holding a party potentially
liable without regard to fault or negligence. We could be held liable for damages and fines as a result of our, or others’, business operations should contamination
of the environment or individual exposure to hazardous substances occur related to our business. We cannot predict how changes in laws or development of
new regulations will affect our business operations or the cost of compliance.
Failure to comply with the HIPAA security and privacy regulations may increase our operational costs.
A portion of the data that we obtain and handle for or on behalf of our clients is considered protected health information, or PHI, subject to the Health
Insurance Portability and Accountability Act of 1996, or HIPAA. Under HIPAA and our contractual agreements with our HIPAA-covered entity health plan
customers, we are considered a “business associate” to those customers, and are required to maintain the privacy and security of PHI in accordance with HIPAA
and the terms of our business associate agreements with our clients, including by implementing HIPAA-required administrative, technical and physical
safeguards. We are also required to maintain similar business associate agreements with our subcontractors that have access to PHI of our customers in
rendering services to us or on our behalf. We will incur significant costs to establish and maintain these safeguards and, if additional safeguards are required to
comply with HIPAA regulations or our clients’ requirements, our costs could increase further, which would negatively affect our operating results. Furthermore,
we cannot guarantee that such safeguards have been and will continue to be adequate under applicable laws. If we have failed, or fail in the future, to maintain
adequate safeguards, or we or our agents or subcontractors use or disclose PHI in a manner prohibited or not permitted by HIPAA, our subcontractor business
associate agreements, or our business associate agreements with our customers, or if the privacy or security of PHI that we obtain and handle is otherwise
compromised, we could be subject to significant liabilities and consequences.
38
EDGAR Stream is a copyright of Issuer Direct Corporation, all rights reserved.
We will also need to expend a considerable amount of resources complying with other federal, state and foreign laws and regulations. If we are
unable to comply or have not complied with such laws, we could face substantial penalties or other adverse actions.
Our operations are subject, directly or indirectly, to other federal, state and foreign laws and regulations that are complex and their application to our specific
products, services and relationships may not be clear and may be applied to our business in ways that we do not anticipate. Compliance with laws and
regulations will require us to expend considerable resources implementing internal policies and procedures for compliance and ongoing monitoring, and will
require significant attention of our management team. This will be challenging as an early-stage company with limited financial resources and human capital.
These laws include, for example:
·
·
·
·
Title XI of the Social Security Act, commonly referred to as the federal Anti-Kickback Statute, which prohibits the knowing and willful offer, payment,
solicitation or receipt of remuneration, directly or indirectly, in cash or in kind, in return for or to reward the referral of patients or arranging for the referral
of patients, or in return for the recommendation, arrangement, purchase, lease or order of items or services that are covered, in whole or in part, by a
federal healthcare program such as Medicare or Medicaid;
The civil False Claims Act, that forbids the knowing submission or “causing the submission” of false or fraudulent information or the failure to disclose
information in connection with the submission and payment of claims for reimbursement to Medicare, Medicaid, federal healthcare programs or private
health plans;
The federal Physician Self-referral Law, commonly known as the Stark Law, which prohibits physicians from referring Medicare or Medicaid patients to
providers of “designated health services” with whom the physician or a member of the physician’s immediate family has an ownership interest or
compensation arrangement, unless a statutory or regulatory exception applies, and similar state equivalents that may apply regardless of payor; and
The U.S. Foreign Corrupt Practices Act of 1977, as amended, or FCPA, the U.S. domestic bribery statute contained in 18 U.S.C. § 201, the U.S. Travel
Act, and the USA PATRIOT Act, which among other things, prohibit companies and their employees, agents, third-party intermediaries, joint venture
partners and collaborators from authorizing, promising, offering, or providing, directly or indirectly, improper payments or benefits to recipients in the
public or private sector.
Many states and foreign governments have adopted similar laws and regulations. Violations of law could subject us to civil or criminal penalties, monetary
fines, disgorgement, individual imprisonment, contractual damages, reputational harm, diminished profits and future earnings and curtailment of our operations.
We could also be required to change or terminate some portions of operations or business or could be disqualified from providing services to healthcare
providers doing business with government programs.
New legislation and regulations could be passed that affect our operations and result in additional risks and/or costs to our business.
From time to time, legislation is drafted, introduced and passed in Congress that could significantly change the statutory provisions governing the testing,
approval, manufacturing and marketing of products that are or will be regulated by the FDA or CMS. In addition to new legislation, CMS and FDA regulations and
policies are often revised or interpreted by the agencies in ways that may significantly affect our business and our products. It is impossible to predict whether
further legislative changes will be enacted or FDA or CMS regulations, guidance, policies or interpretations will be changed, or what the impact of such changes,
if any, may be. The 2016 presidential election and change in administration make it even more difficult to predict if and how federal regulations may change
and/or federal agencies might alter their positions. Changes in laws and the development of new regulations could affect our business operations and/or the cost
of compliance.
39
EDGAR Stream is a copyright of Issuer Direct Corporation, all rights reserved.
Risks Related to Intellectual Property
If we are unable to obtain and maintain intellectual property protection for our technology, or if the scope of the intellectual property protection
obtained is not sufficiently broad, our competitors could develop and commercialize technology and diagnostic tests similar or identical to ours, and
our ability to successfully commercialize our technology and diagnostic tests may be impaired.
Our ability to compete successfully will depend in part on our ability to obtain and enforce patent protection for our products, preserve our trade secrets and
operate without infringing the proprietary rights of third parties. We have applied for patents that protect our technology. Our patent portfolio includes one U.S.
patent, five pending U.S. patent applications, one pending international PCT patent application, and numerous corresponding non-U.S. patent applications. Each
patent and patent application covers methods of use. However, we cannot assure you that our intellectual property position will not be challenged or that all
patents for which we have applied will be granted. The validity and breadth of claims in patents involve complex legal and factual questions and, therefore, may
be highly uncertain. Uncertainties and risks that we face include the following:
·
·
·
·
·
our pending or future patent applications may not result in the issuance of patents;
the scope of any existing or future patent protection may not exclude competitors or provide competitive advantages to us;
our patents may not be held valid if subsequently challenged;
other parties may claim that our products and designs infringe the proprietary rights of others—even if we are successful in defending our patents and
proprietary rights, the cost of such litigation may adversely affect our business; and
other parties may develop similar products, duplicate our products, or design around our patents.
The patent prosecution process is expensive and time-consuming, and we may not be able to file, prosecute, maintain, enforce or license all necessary or
desirable patent applications at a reasonable cost or in a timely manner, or in all jurisdictions. We may choose not to seek patent protection for certain
innovations and may choose not to pursue patent protection in certain jurisdictions, and under the laws of certain jurisdictions, patents or other intellectual
property rights may be unavailable or limited in scope. It is also possible that we will fail to identify patentable aspects of our discovery and nonclinical
development output before it is too late to obtain patent protection.
The patent position of companies like ours is highly uncertain, involves complex legal and factual questions and has in recent years been the subject of much
litigation. The U.S. Patent and Trademark Office, or U.S. PTO, has not established a consistent policy regarding the breadth of claims that it will allow in medical
technology patents. In addition, the laws of foreign jurisdictions may not protect our rights to the same extent as the laws of the United States. For example, India
and China do not allow patents for methods of treating the human body. Publications of discoveries in the scientific literature often lag behind the actual
discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18 months after filing, or in some cases not at all.
Therefore, we cannot know with certainty whether we were the first to make the inventions claimed in our owned or licensed patents or pending patent
applications, or that we were the first to file for patent protection of such inventions. As a result, the issuance, scope, validity, enforceability and commercial value
of our patent rights are highly uncertain. Our pending and future patent applications may not result in patents being issued that protect our technology or CELx
tests, in whole or in part, or which effectively prevent others from commercializing competitive technologies and diagnostic tests. Changes in either the patent
laws or interpretation of the patent laws in the United States and other countries may diminish the value of our patents or narrow the scope of our patent
protection.
Moreover, we may be subject to a third-party pre-issuance submission of prior art to the U.S. PTO or patent offices in foreign jurisdictions, or become
involved in opposition, derivation, reexamination, inter parties review, post-grant review or interference proceedings challenging our patent rights or the patent
rights of others. An adverse determination in any such submission, proceeding or litigation could reduce the scope of, or invalidate, our patent rights, allow third
parties to commercialize our technology and compete directly with us, without payment to us, or result in our inability to commercialize CELx platform without
infringing third-party patent rights. In addition, if the breadth or strength of protection provided by our patents and patent applications is threatened, it could
dissuade companies from collaborating with us to develop or commercialize current or future CELx tests.
Even if our owned patent applications issue as patents, they may not issue in a form that will provide us with any meaningful protection, prevent competitors
from competing with us or otherwise provide us with any competitive advantage. Our competitors may be able to circumvent our owned patents by developing
similar or alternative technologies or products in a non-infringing manner.
40
EDGAR Stream is a copyright of Issuer Direct Corporation, all rights reserved.
The issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, and our owned patents may be challenged in the courts or
patent offices in the United States and abroad. Such challenges may result in loss of exclusivity or freedom to operate or in patent claims being narrowed,
invalidated or held unenforceable, in whole or in part, which could limit our ability to stop others from using or commercializing similar or identical technology
and product candidates, or limit the duration of the patent protection of our technology and potential diagnostic tests. Given the amount of time required for the
development, testing and regulatory review of new diagnostic tests, patents protecting such tests might expire before or shortly after such candidates are
commercialized. As a result, our owned patent portfolio may not provide us with sufficient rights to exclude others from commercializing diagnostic tests similar
or identical to ours.
Patent reform legislation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or
defense of our issued patents.
On September 16, 2011, the Leahy-Smith America Invents Act, or the Leahy-Smith Act, was signed into law. The Leahy-Smith Act includes a number of
significant changes to U.S. patent law. These include provisions that affect the way patent applications are prosecuted and may also affect patent litigation. The
U.S. PTO recently developed new regulations and procedures to govern administration of the Leahy-Smith Act, and many of the substantive changes to patent
law associated with the Leahy-Smith Act, and in particular, the first to file provisions, only became effective on March 16, 2013. Accordingly, it is not clear what,
if any, impact the Leahy-Smith Act will have on the operation of our business. However, the Leahy-Smith Act and its implementation could increase the
uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could have a
material adverse effect on our business and financial condition. Depending on future actions by the U.S. Congress, the federal courts, and the U.S. PTO, the
laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce our existing
patents and patents that we might obtain in the future. In addition, there may be patent law reforms in foreign jurisdictions that could increase the uncertainties
and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents in those foreign jurisdictions.
Third parties may initiate legal proceedings alleging that we are infringing their intellectual property rights, the outcome of which would be uncertain
and could have a material adverse effect on the success of our business.
Our commercial success depends upon our ability, and the ability of our collaborators, to develop, manufacture, market and sell our CELx tests and use our
proprietary technologies without infringing the proprietary rights of third parties. There is considerable intellectual property litigation in the medical technology,
biotechnology and pharmaceutical industries. We may become party to, or threatened with, future adversarial proceedings or litigation regarding intellectual
property rights with respect to our CELx platform, including interference or derivation proceedings before the U.S. PTO and similar bodies in other jurisdictions.
Third parties may assert infringement claims against us based on existing patents or patents that may be granted in the future.
If we are found to infringe a third party’s intellectual property rights, we could be required to obtain a license from such third party to continue developing and
marketing our CELx platform and CELx tests. However, we may not be able to obtain any required license on commercially reasonable terms or at all. Even if
we were able to obtain a license, it could be non-exclusive, thereby giving our competitors access to the same technologies licensed to us. We could be forced,
including by court order, to cease commercializing the infringing technology or product. In addition, we could be found liable for monetary damages, including
treble damages and attorneys’ fees if we are found to have willfully infringed a patent. A finding of infringement could prevent us from commercializing our CELx
platform or force us to cease some of our business operations, which could materially harm our business. Claims that we have misappropriated the confidential
information or trade secrets of third parties could have a similar negative impact on our business.
We may be subject to claims by third parties asserting that our employees or we have misappropriated their intellectual property, or claiming
ownership of what we regard as our own intellectual property.
Our current and future employees may have been previously employed at universities or other biotechnology, diagnostic technology or pharmaceutical
companies, including our competitors or potential competitors and strategic partners. Although we try to ensure that our employees do not use the proprietary
information or know-how of others in their work for us, we may be subject to claims that these employees or we have used or disclosed intellectual property,
including trade secrets or other proprietary information, of any such employee’s former employer. Litigation may be necessary to defend against these claims.
41
EDGAR Stream is a copyright of Issuer Direct Corporation, all rights reserved.
In addition, while it is our policy to require our employees and contractors who may be involved in the development of intellectual property to execute
agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who in fact develops intellectual
property that we regard as our own. Our and their assignment agreements may not be self-executing or may be breached, and we may be forced to bring claims
against third parties, or defend claims they may bring against us, to determine the ownership of what we regard as our intellectual property.
If we fail in prosecuting or defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or
personnel. Even if we are successful in prosecuting or defending against such claims, litigation could result in substantial costs and be a distraction to
management.
Any lawsuits relating to infringement of intellectual property rights necessary to defend ourselves or enforce our rights will be costly and time
consuming, and could be unsuccessful.
Because competition in our industry is intense, competitors may infringe or otherwise violate our issued patents, patents of our licensors or other intellectual
property. To counter infringement or unauthorized use, we may be required to file infringement claims, which can be expensive and time consuming, and could
distract our technical and management personnel from their normal responsibilities. Any claims we assert against perceived infringers could provoke these
parties to assert counterclaims against us alleging that we infringe their patents. In addition, in a patent infringement proceeding, a court may decide that a patent
of ours is invalid or unenforceable, in whole or in part, construe the patent’s claims narrowly or refuse to stop the other party from using the technology at issue
on the grounds that our patents do not cover the technology in question. An adverse result in any litigation proceeding could put one or more of our patents at
risk of being invalidated or interpreted narrowly. We may also elect to enter into license agreements in order to settle patent infringement claims or to resolve
disputes prior to litigation, and any such license agreements may require us to pay royalties and other fees that could be significant. Furthermore, because of the
substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be
compromised by disclosure.
If we are not able to prevent disclosure of our trade secrets and other proprietary information, the value of our CELx platform could be significantly
diminished.
We rely on trade secret protection to protect our interests in proprietary know-how and in processes for which patents are difficult to obtain or enforce. We
may not be able to protect our trade secrets adequately. We have a policy of requiring our consultants, advisors and strategic partners to enter into confidentiality
agreements and our employees to enter into invention, non-disclosure and non-compete agreements. However, no assurance can be given that we have
entered into appropriate agreements with all parties that have had access to our trade secrets, know-how or other proprietary information. There is also no
assurance that such agreements will provide meaningful protection of our trade secrets, know-how or other proprietary information in the event of any
unauthorized use or disclosure of information. Furthermore, we cannot provide assurance that any of our employees, consultants, contract personnel, or
strategic partners, either accidentally or through willful misconduct, will not cause serious damage to our programs and/or our strategy, for example by disclosing
important trade secrets, know-how or proprietary information to our competitors. It is also possible that our trade secrets, know-how or other proprietary
information could be obtained by third parties as a result of breaches of our physical or electronic security systems. Any disclosure of confidential data into the
public domain or to third parties could allow our competitors to learn our trade secrets and use the information in competition against us. In addition, others may
independently discover our trade secrets and proprietary information. Any action to enforce our rights is likely to be time consuming and expensive, and may
ultimately be unsuccessful, or may result in a remedy that is not commercially valuable. These risks are accentuated in foreign countries where laws or law
enforcement practices may not protect proprietary rights as fully as in the United States. Any unauthorized disclosure of our trade secrets or proprietary
information could harm our competitive position.
42
EDGAR Stream is a copyright of Issuer Direct Corporation, all rights reserved.
Risks Relating to Our Common Stock
Our executive officers, directors and principal stockholders, if they choose to act together, have the ability to control all matters submitted to
stockholders for approval.
Our executive officers and directors, combined with our stockholders who each own more than 5% of our outstanding common stock, in the aggregate, own
approximately 50% of our outstanding capital stock. As a result, if these stockholders were to choose to act together, they would be able to control all matters
submitted to our stockholders for approval, as well as our management and affairs. For example, these persons, if they choose to act together, would control the
election of directors and approval of any merger, consolidation or sale of all or substantially all of our assets. This concentration of ownership control may:
·
delay, defer or prevent a change in control;
· make changes to our management and the board of directors challenging for other stockholders; or
·
impede a merger, consolidation, takeover or other business combination involving us that other stockholders may desire or may result in you obtaining a
premium for your shares.
Our internal control over financial reporting does not currently meet the standards required by Section 404 of the Sarbanes-Oxley Act, and failure to
achieve and maintain effective internal control over financial reporting in accordance with Section 404 of the Sarbanes-Oxley Act could have a
material adverse effect on our business and stock price.
We previously have not been required to maintain internal control over financial reporting in a manner that meets the standards of publicly traded companies
required by Sections 404(a) or 404(b) of the Sarbanes-Oxley Act. Internal control over financial reporting is a process designed to provide reasonable assurance
regarding the reliability of financial reporting and the preparation of financial statements in accordance with GAAP. We are not currently in compliance with, and
we cannot be certain when we will be able to implement the requirements of Section 404(a). We may encounter problems or delays in implementing any
changes necessary to make a favorable assessment of our internal control over financial reporting. If we cannot favorably assess the effectiveness of our internal
control over financial reporting, investors could lose confidence in our financial information and the price of our common stock could decline.
Additionally, the existence of any material weakness or significant deficiency would require management to devote significant time and incur significant
expense to remediate any such material weaknesses or significant deficiencies and management may not be able to remediate any such material weaknesses
or significant deficiencies in a timely manner. The existence of any material weakness in our internal control over financial reporting could also result in errors in
our financial statements that could require us to restate our financial statements causing us to fail to meet our reporting obligations and cause stockholders to
lose confidence in our reported financial information, all of which could materially and adversely affect us.
Provisions in our corporate charter documents and under Delaware law could make an acquisition of our company, which may be beneficial to our
stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current management.
Provisions in our certificate of incorporation and our bylaws may discourage, delay or prevent a merger, acquisition or other change in control of our
company that stockholders may consider favorable, including transactions in which you might otherwise receive a premium for your shares. These provisions
could also limit the price that investors might be willing to pay in the future for shares of our common stock, thereby depressing the market price of our common
stock. In addition, because our board of directors will be responsible for appointing the members of our management team, these provisions may frustrate or
prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our
board of directors. Among other things, these provisions:
·
·
·
·
·
·
allow the authorized number of our directors to be changed only by resolution of our board of directors;
limit the manner in which stockholders can remove directors from our board of directors;
establish advance notice requirements for stockholder proposals that can be acted on at stockholder meetings and nominations to our board of directors;
require that stockholder actions must be effected at a duly called stockholder meeting and prohibit actions by our stockholders by written consent;
limit who may call stockholder meetings;
authorize our board of directors to issue preferred stock without stockholder approval, which could be used to institute a “poison pill” that would work to
dilute the stock ownership of a potential hostile acquirer, effectively preventing acquisitions that have not been approved by our board of directors; and
43
EDGAR Stream is a copyright of Issuer Direct Corporation, all rights reserved.
·
require the approval of the holders of at least two-thirds of the votes that all our stockholders would be entitled to cast to amend or repeal specified
provisions of our certificate of incorporation or bylaws.
Moreover, we are governed by the provisions of Section 203 of the Delaware General Corporation Law, which prohibits a person who owns in excess of 15%
of our outstanding voting stock from merging or combining with us for a period of three years after the date of the transaction in which the person acquired in
excess of 15% of our outstanding voting stock, unless the merger or combination is approved in a prescribed manner.
Any of these provisions of our charter documents or Delaware law could, under certain circumstances, depress the market price of our common stock.
The price of our common stock may be volatile and fluctuate substantially, which could result in substantial losses for purchasers of our common
stock.
Our stock price may be extremely volatile. The stock market in general and the market for smaller medical technology companies in particular have
experienced extreme volatility that has often been unrelated to the operating performance of particular companies. As a result of this volatility, you may not be
able to sell your common stock at or above the initial public offering price. The market price for our common stock may be influenced by many factors, including:
·
·
·
·
·
·
·
·
·
·
the success of competitive products or technologies;
results of planned clinical trials of our CELx HSF Test or other CELx tests may develop in the future;
regulatory or legal developments in the United States and other countries;
developments or disputes concerning patent applications, issued patents or other proprietary rights;
the recruitment or departure of key personnel;
the level of expenses related to any of our CELx tests or clinical development programs;
actual or anticipated changes in estimates as to financial results, development timelines or recommendations by securities analysts;
operating results that fail to meet expectations of securities analysts that cover our company;
variations in our financial results or those of companies that are perceived to be similar to us;
changes in the structure of healthcare payment systems;
· market conditions in the pharmaceutical, biotechnology and medical technology sectors;
·
·
·
sales of our stock by us, our insiders and our other stockholders;
general economic and market conditions; and
the other factors described in this “Risk Factors” section.
We may be subject to securities litigation, which is expensive and could divert management attention.
Smaller medical technology companies like us often experience volatile stock prices, and companies that have experienced volatility in the market price of
their stock have been subject to an increased incidence of securities class action litigation. We may be the target of this type of litigation in the future. Securities
litigation against us could result in substantial costs and divert our management’s attention from other business concerns, which could seriously harm our
business.
If securities or industry analysts do not publish research or reports about our business, or publish negative reports about our business, our stock
price and trading volume could decline.
The trading market for our common stock depends in part on the research and reports that securities or industry analysts publish about us or our business.
We do not have any control over these analysts. There can be no assurance that analysts will cover us or provide favorable coverage. If one or more of the
analysts who cover us downgrade our stock or change their opinion of our stock, our stock price would likely decline. If one or more of these analysts cease
coverage of our company or fail to regularly publish reports on us, we could lose visibility in the financial markets, which could cause our stock price or trading
volume to decline.
44
EDGAR Stream is a copyright of Issuer Direct Corporation, all rights reserved.
We are an “emerging growth company,” and the reduced disclosure requirements applicable to emerging growth companies may make our common
stock less attractive to investors.
We are an “emerging growth company,” as defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act, and may remain an emerging
growth company for up to five years. For so long as we remain an emerging growth company, we are permitted and intend to rely on exemptions from certain
disclosure requirements that are applicable to other public companies that are not emerging growth companies. These exemptions include:
·
·
·
·
·
being permitted to provide only two years of audited financial statements, in addition to any required unaudited interim financial statements, with
correspondingly reduced “Management’s Discussion and Analysis of Financial Condition and Results of Operations” disclosure;
not being required to comply with the auditor attestation requirements in the assessment of our internal control over financial reporting of Section 404(b)
of the Sarbanes-Oxley Act;
not being required to comply with any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit
firm rotation or a supplement to the auditor’s report providing additional information about the audit and the financial statements;
reduced disclosure obligations regarding executive compensation; and
exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute
payments not previously approved.
We have taken advantage of reduced reporting burdens in this report. We cannot predict whether investors will find our common stock less attractive if we
rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock
and our stock price may be more volatile.
We incur increased costs as a result of operating as a public company, and our management will be required to devote substantial time to new
compliance initiatives and corporate governance practices.
As a public company, and particularly after we are no longer an emerging growth company, we will incur significant legal, accounting and other expenses
that we did not incur as a private company. The Sarbanes-Oxley Act, the Dodd-Frank Wall Street Reform and Consumer Protection Act, the listing requirements
of The Nasdaq Capital Market and other applicable securities rules and regulations impose various requirements on public companies, including establishment
and maintenance of effective disclosure and financial controls and corporate governance practices. Our management and other personnel will need to devote a
substantial amount of time to these compliance initiatives. Moreover, these rules and regulations have increased our ongoing legal and financial compliance
costs and will make some activities more time-consuming and costly.
Pursuant to Section 404 of the Sarbanes-Oxley Act, or Section 404, we will first be required to furnish a report by our management on our internal control
over financial reporting for the year ending December 31, 2018. As discussed above, if we cease to be an emerging growth company, we will be required to
include an attestation report on internal control over financial reporting issued by our independent registered public accounting firm as required by Section 404(b).
To achieve compliance with Section 404 within the prescribed period, we will be engaged in a process to document and evaluate our internal control over
financial reporting, which is both costly and challenging. In this regard, we will need to continue to dedicate internal resources, potentially engage outside
consultants and adopt a detailed work plan to assess and document the adequacy of internal control over financial reporting, continue steps to improve control
processes as appropriate, validate through testing that controls are functioning as documented and implement a continuous reporting and improvement process
for internal control over financial reporting. Despite our efforts, there is a risk that we will not be able to conclude, within the prescribed timeframe or at all, that
our internal control over financial reporting is effective as required by Section 404. If we identify one or more material weaknesses, it could result in an adverse
reaction in the financial markets due to a loss of confidence in the reliability of our financial statements.
Since we do not anticipate paying any cash dividends on our capital stock in the foreseeable future, stock price appreciation, if any, will be your sole
source of gain.
We currently intend to retain all of our future earnings, if any, to finance the growth and development of our business. In addition, the terms of any future debt
agreements may preclude us from paying dividends. As a result, appreciation, if any, in the market price of our common stock will be your sole source of gain for
the foreseeable future.
45
EDGAR Stream is a copyright of Issuer Direct Corporation, all rights reserved.
ITEM 1B. Unresolved Staff Comments
Not applicable
ITEM 2. Properties
Facilities
We currently lease and occupy approximately 5,000 square feet in Minneapolis, Minnesota, which includes our clinical laboratory and offices. This lease
expires in May 2018 and is renewable annually. In September 2017, the Company entered into an operating lease agreement for approximately 16,000 square
feet in Minneapolis, Minnesota to accommodate expansion in research and development and general corporate office needs. The new lease commences and
the Company will be moving to the facility in May 2018, in conjunction with the termination of the existing lease. The lease agreement extends through April
2021, with the right to extend the term for two periods of one year each and provides for monthly rent, real estate taxes and operating expenses. We believe that
the new leased space is adequate to meet current and anticipated future requirements and that additional or substitute space will be available as needed to
accommodate any expansions that our operations require.
ITEM 3. Legal Proceedings
From time to time we may be involved in disputes or litigation relating to claims arising out of our operations. We are not currently a party to any legal
proceedings that could reasonably be expected to have a material adverse effect on our business, financial condition and results of operations.
ITEM 4. Mine Safety Disclosures
Not applicable.
ITEM 5. Market For Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.
Market Price Information
PART II
Our common stock has been listed on The Nasdaq Capital Market under the symbol “CELC” since September 20, 2017. Prior to that date, there was no
public trading market for our common stock. Our common stock priced at $9.50 per share in our initial public offering on September 19, 2017. The following table
sets forth for the periods indicated the high and low intra-day sale prices per share of our common stock as reported on The Nasdaq Capital Market:
Year Ended December 31, 2017
Third quarter from and after September 20, 2017
Fourth quarter
High
Low
$
$
15.55 $
21.98 $
11.10
11.68
Holders
As of February 28, 2018, there were approximately 117 holders of record of our common stock. The actual number of holders of common stock is greater
than this number of record holders and includes stockholders who are beneficial owners, but whose shares are held in street name by brokers and nominees.
The number of holders of record also does not include stockholders whose shares may be held in trust by other entities.
46
EDGAR Stream is a copyright of Issuer Direct Corporation, all rights reserved.
Dividends
We have never declared or paid any cash dividends on our common stock. We currently intend to retain our future earnings, if any, to finance the operation
and expansion of our business. We do not expect to pay cash dividends on our common stock in the foreseeable future. Payment of future cash dividends, if
any, will be at the discretion of our board of directors after taking into account various factors, including our financial condition, operating results, current and
anticipated cash needs, outstanding indebtedness and plans for expansion and restrictions imposed by lenders, if any.
Recent Sales of Unregistered Securities
In September 2017, upon the closing of our initial public offering, our then-outstanding convertible notes were automatically converted into an aggregate of
881,911 shares of common stock. These shares of common stock were issued pursuant to an exemption from the registration requirements of the Securities Act
provided by Section 3(a)(9) or Section 4(a)(2) of the Securities Act.
Issuer Purchases of Equity Securities
None.
Equity Compensation Plan Information
The information required by this Item concerning equity compensation plans is incorporated herein by reference from Part III, Item 11 of this report.
Use of Proceeds from Registered Securities
On September 22, 2017, we issued and sold 2,760,000 shares of our common stock in the initial public offering at a public offering price of $9.50 per share,
for aggregate gross proceeds of $26.2 million. All of the shares issued and sold in the initial public offering were registered under the Securities Act pursuant to
a Registration Statement on Form S-1 (File No. 333-220128), which was declared effective by the SEC on September 19, 2017. Craig-Hallum Capital Group
LLC acted as the sole manager for the offering. The offering terminated on September 22, 2017.
The net offering proceeds to us, after deducting underwriting discounts of approximately $1.8 million and offering expenses paid by us totaling approximately
$1.1 million, were approximately $23.3 million. No offering expenses were paid directly or indirectly to any of our directors or officers (or their associates) or
persons owning 10.0% or more of any class of our equity securities or to any other affiliates.
At December 31, 2017, the net proceeds from our initial public offering were held in a diversified portfolio of bank deposits, government money market funds,
government securities (U.S. Treasury and U.S. government agency securities), and certificates of deposit. All investments are highly liquid, with liquidity and
capital preservation being the primary investment objectives. There has been no material change in our planned uses of the net proceeds from those described
in the Prospectus dated September 19, 2017.
ITEM 6. Selected Financial Data
The following tables present, as of the dates and for the years indicated, our selected historical financial data, as indicated therein. The statement of
operations data for the years ended December 31, 2017 and 2016 and the balance sheet data as of December 31, 2017 and 2016 are derived from our audited
financial statements that are included elsewhere in this report. Our historical results are not indicative of the results to be expected in the future.
You should read this information together with our financial statements and the related notes, as well as the section entitled “Management’s Discussion and
Analysis of Financial Condition and Results of Operations” included elsewhere in this report.
47
EDGAR Stream is a copyright of Issuer Direct Corporation, all rights reserved.
Statements of Operations Data:
Operating expenses:
Research and development
General and administrative
Total operating expenses
Loss from operations
Other income (expense)
Interest expense
Interest income
Other income (expense), net
Net loss before income taxes
Income tax benefits
Net loss
Net loss per share attributable to common stockholders, basic
and diluted
Weighted average common shares outstanding used to compute
net loss per share attributable to common stock, basic and
diluted
Years Ended
December 31,
2017
2016
$
$
$
4,980,427 $
972,518
5,952,945
(5,952,945)
(451,664)
152,879
(298,785)
(6,251,730)
-
(6,251,730) $
3,064,762
263,664
3,328,426
(3,328,426)
-
18,018
18,018
(3,310,408)
-
(3,310,408)
(0.84) $
(0.52)
7,460,640
6,313,089
As of December 31,
2017
2016
Balance Sheet Data:
Total assets
Total current liabilities
Total stockholders’ equity
$
31,969,510 $
578,053
31,391,457
6,056,977
445,359
5,611,618
48
EDGAR Stream is a copyright of Issuer Direct Corporation, all rights reserved.
ITEM 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations
You should read the following discussion and analysis of our financial condition and results of operations together in conjunction with our financial statements
and the related notes included elsewhere in this report. Some of the information contained in this discussion and analysis or set forth elsewhere in this report,
including information with respect to our plans and strategy for our business and expected financial results, includes forward-looking statements that involve risks
and uncertainties. You should review the “Risk Factors” discussed in section 1A of Part I of this Form 10-K.
OVERVIEW
We are a cellular analysis company that is discovering new cancer sub-types and commercializing diagnostic tests designed to significantly improve the
clinical outcomes of cancer patients treated with targeted therapies. Our proprietary CELx diagnostic platform is the only commercially ready technology we are
aware of that uses a patient’s living tumor cells to identify the specific abnormal cellular process driving a patient’s cancer and the targeted therapy that best
treats it. We believe our CELx platform provides two important improvements over traditional molecular diagnostics. First, molecular diagnostics can only provide
a snapshot of the genetic mutations present in a patient’s tumor because they analyze dead cells. Using dead cells prevents molecular diagnostics from
analyzing in real-time the dynamic cellular activities, known as cell signaling, that regulate cell proliferation or survival. Cancer can develop when certain cell
signaling activity becomes abnormal. Since genetic mutations are often only weakly correlated to the cell signaling activity driving a patient’s cancer, a molecular
diagnostic is prone to providing an incomplete diagnosis. CELx tests overcome this limitation by measuring real-time cell signaling activity in a patient’s living
tumor cells. When a CELx test detects abnormal signaling activity, a more accurate diagnosis of the patient’s cancer driver is obtained. Second, molecular
diagnostics can only estimate the probability of a patient’s potential drug response based on a statistical analysis of the drug’s clinical trial results. Instead of this
indirect estimate of drug response, CELx tests directly measure the effectiveness of a targeted therapy in a patient’s living tumor cells. This enables physicians
to confirm that the therapeutic matching the patient’s cancer driver is functional in the patient’s tumor cells before prescribing it, which significantly increases the
likelihood of a positive clinical outcome.
Our first analytically validated and commercially ready test using our CELx platform, the CELx HSF Test, diagnoses two new sub-types of HER2-negative
breast cancer that traditional molecular diagnostics cannot detect. Our internal studies show that approximately 20% of HER2-negative breast cancer patients
have abnormal HER2 signaling activity similar to levels found in HER2+ breast cancer cells. As a result, these HER2-negative patients have undiagnosed HER2-
driven breast cancer and would be likely to respond to the same anti-HER2 targeted therapies only HER2+ patients receive today. Our CELx HSF Test is
targeting HER2-negative breast cancer patients receiving drug treatment. We are fielding a prospective clinical trial in collaboration with Genentech and the
NSABP to evaluate the efficacy of Genentech’s HER2 targeted therapies in patients with these newly identified cancer sub-types. We expect interim results from
this trial in late 2018 and final results six to nine months later.
In addition to our CELx tests for HER2-negative breast cancer, we are developing CELx tests to diagnose 14 new potential cancer sub-types we have
discovered in breast, lung, colon, ovarian, kidney, bladder and hematological cancers. Approved or investigational drugs are currently available to treat these new
potential cancer sub-types. We expect to launch these additional tests on a staggered basis over the next few years while continuing our research to identify
additional new cancer sub-types.
On September 22, 2017, we completed our underwritten initial public offering, or IPO, of 2,760,000 shares of our common stock at a price to the public of
$9.50 per share. The aggregate net proceeds received by the company from the offering were approximately $23.3 million, net of underwriting discounts and
commissions and offering expenses. Shares of our common stock began trading on September 20, 2017 on The Nasdaq Capital Market under the symbol
“CELC”.
49
EDGAR Stream is a copyright of Issuer Direct Corporation, all rights reserved.
Following the IPO, we entered into a lease agreement for building space to accommodate expansion in research and development and general corporate
office needs. The new lease commences and we will be moving to the space in May 2018, in conjunction with the termination of our existing lease. The lease
agreement extends through April 2021 and provides for monthly rent, real estate taxes and operating expenses.
We have not generated any revenue from sales to date, and we continue to incur significant research and development and other expenses related to our
ongoing operations. As a result, we are not and have never been profitable and have incurred losses in each period since we began operations in 2012. For the
year ended December 31, 2017 and 2016, we reported a net loss of approximately $6.3 million and $3.3 million, respectively. As of December 31, 2017, we had
a combined accumulated deficit of approximately $12.6 million under Celcuity LLC and $2.0 million under Celcuity Inc. As of December 31, 2017, we had cash,
cash equivalents, and investments of approximately $31.4 million.
RESULTS OF OPERATIONS
Components of Operating Results
Revenue
To date, we have not generated any revenue. Initially, our ability to generate revenue will depend primarily upon our ability to obtain partnership agreements
with pharmaceutical companies to provide companion diagnostics for such pharmaceutical partners’ existing or investigational targeted therapies. We expect
these partnerships to generate significant revenue from the sale of tests to identify patients eligible for clinical trials, from milestone payments, and, potentially,
from royalties on the incremental drug revenues our tests enable. Once a new drug indication is received that requires use of our companion diagnostic to
identify eligible patients, we expect to generate revenues from sales of tests to treating physicians.
Research and Development
Since our inception, we have primarily focused on research and development of our CELx platform, development and validation of our CELx HSF Test, and
research related to the discovery of new cancer sub-types. Research and development expenses primarily include:
·
·
·
·
·
·
employee-related expenses related to our research and development activities, including salaries, benefits, travel and stock-based compensation
expenses;
laboratory supplies;
consulting fees paid to third parties;
clinical trial costs;
facilities expenses; and
legal costs associated with patent applications.
Internal and external research and development costs are expensed as they are incurred. As we initiate clinical trials to evaluate efficacy of targeted
therapies in cancer patients selected with one of our CELx tests, the proportion of research and development expenses allocated to external spending will grow
at a faster rate than expenses allocated to internal expenses.
General and Administrative
General and administrative expenses consist primarily of salaries and related benefits, including stock-based compensation expense related to our
executive, finance and support functions. Other general and administrative expenses include professional fees for auditing, tax, and legal services, insurance and
travel expenses. We may incur additional fees for legal, accounting, insurance and other professional service fees associated with being a public company,
which may increase further when we are no longer able to rely on the “emerging growth company” exemption we were afforded under the JOBS Act.
50
EDGAR Stream is a copyright of Issuer Direct Corporation, all rights reserved.
Sales and Marketing
Selling and marketing expenses consist primarily of professional and consulting fees related to these functions. To date, we have incurred immaterial sales
and marketing expenses as we continue to focus primarily on the development of our CELx platform and corresponding CELx tests. We expect to begin to incur
increased selling and marketing expenses in anticipation of the commercialization of our CELx HSF Test. These increased expenses are expected to include
payroll-related costs as we add employees in the commercial departments, costs related to the initiation and operation of our sales and distribution network and
marketing related costs.
Interest Expense
Interest expense primarily consists of the amortization of debt discount and debt financing costs related to the issuance of our unsecured convertible
promissory notes that were converted to common stock upon our IPO.
Interest Income
Interest income consists of interest income earned on our cash, cash equivalents, and investment balances.
Results of Operations
Comparison of the Years Ended December 31, 2017 and 2016
Statements of Operations Data:
Operating expenses:
Research and development
General and administrative
Total operating expenses
Loss from operations
Other income (expense)
Interest expense
Interest income
Other income (expense), net
Net loss before income taxes
Income tax benefits
Net loss
Research and Development
Years Ended
December 31,
Increase
(Decrease)
2017
2016
$
%
$
4,980,427 $
972,518
5,952,945
(5,952,945)
3,064,762 $
263,664
3,328,426
(3,328,426)
1,915,665
708,854
2,624,519
(2,624,519)
(451,664)
152,879
-
18,018
(451,664)
134,861
(298,785)
(6,251,730)
-
(6,251,730) $
18,018
(3,310,408)
-
(3,310,408) $
(316,803)
(2,941,322)
-
(2,941,322)
$
63%
269
79
79%
n/a
748
(1,758)
89
-
89%
For the year ended December 31, 2017, our total research and development expenses increased $1.9 million, or 63%, to $4.98 million from $3.07 million for
the prior year. The increase primarily resulted from a $1.32 million increase in compensation related expenses, including approximately $0.4 million of non-cash
stock-based compensation, to support development of our CELx platform and validation studies of our CELx HSF Test. In addition, other research and
development expenses increased $0.58 million due to legal expenses related to patent costs, start-up clinical trial costs, and business development activities.
51
EDGAR Stream is a copyright of Issuer Direct Corporation, all rights reserved.
Conducting a significant amount of research and development is central to our business model. We plan to increase our research and development
expenses for the foreseeable future as we seek to discover new cancer sub-types and to develop and validate additional CELx tests to diagnose such sub-types.
We also expect to incur increased expenses to support companion diagnostic business development activities with pharmaceutical companies as we develop
additional CELx tests.
General and Administrative
For the year ended December 31, 2017, our total general and administrative expenses increased $0.7 million or 269% to $1.0 million from $0.3 million for
the prior year. The increase primarily resulted from increases in compensation related expenses, including approximately $0.3 million of non-cash stock-based
compensation, and other expenses associated with being a public company such as professional accounting and legal fees, and director and officer insurance.
We anticipate that our general and administrative expenses will increase in future periods, reflecting both increased costs in connection with the potential
future commercialization of CELx tests, an expanding infrastructure, and increased professional fees associated with being a public reporting company.
To date, we have incurred immaterial sales and marketing expenses as we continue to focus primarily on the development of our CELx platform and
corresponding CELx tests. We expect to begin to incur increased selling and marketing expenses in anticipation of the commercialization of our CELx HSF Test.
These increased expenses are expected to include payroll-related costs as we add employees in the commercial departments, costs related to the initiation and
operation of our sales and distribution network and marketing related costs.
Interest Expense
For the year ended December 31, 2017, interest expense increased $0.5 million, from zero for the prior year. The increase consisted of non-cash
amortization of debt discount and debt financing costs and accrued interest related to the issuance of our unsecured convertible promissory notes.
Interest Income
For the year ended December 31, 2017, interest income increased by approximately $0.13 million, or 748% to $0.15 million from $0.02 million for the prior
year. The increases resulted from interest earned on our cash, cash equivalents, and investments.
LIQUIDITY AND CAPITAL RESOURCES
Since our inception, we have incurred losses and cumulative negative cash flows from operations. Through December 31, 2017, we have raised capital of
approximately $13.7 million and $7.5 million through private placements of common equity and unsecured convertible notes, respectively. On September 22,
2017, we also closed on the initial public offering of our common stock, which generated approximately $23.3 million of additional cash after taking into account
underwriting discounts and commissions and offering expenses. Cash from these capital raising activities has been our primary source of funds for our
operations since inception. As of December 31, 2017, our cash, cash equivalents, and investments were approximately $31.4 million, and we had a combined
accumulated deficit of approximately $12.6 million under Celcuity LLC and $2.0 million under Celcuity Inc.
We expect that our research and development and general and administrative expenses will increase as we continue to develop our CELx platform and
additional CELx tests, conduct research related to the discovery of new cancer sub-types, conduct clinical trials, and pursue other business development
activities. We will also start to incur sales and marketing expenses as we commercialize our CELx HSF Test. We expect to use cash on hand to fund our
research and development expenses, capital expenditures, working capital, sales and marketing expenses, and general corporate expenses, as well as for the
increased costs associated with being a public company.
Based on our current business plan, we believe that our current cash on hand will provide sufficient cash to finance operations and pay obligations when due
during at least the next 24 months.
52
EDGAR Stream is a copyright of Issuer Direct Corporation, all rights reserved.
We may seek to raise additional capital beyond the currently anticipated amount to expand our business, pursue strategic investments, and take advantage
of financing or other opportunities that we believe to be in the best interests of the Company and our stockholders. Additional capital may be raised through the
sale of common or preferred equity or convertible debt securities, entry into debt facilities or other third-party funding arrangements. The sale of equity and
convertible debt securities may result in dilution to our stockholders and those securities may have rights senior to those of our common shares. Agreements
entered into in connection with such capital raising activities could contain covenants that would restrict our operations or require us to relinquish certain rights.
Additional capital may not be available on reasonable terms, or at all.
Cash Flows
The following table sets forth the primary sources and uses of cash for the years ending December 31.
Net cash provided by (used in):
Operating activities
Investing activities
Financing activities
Net increase (decrease) in cash and cash equivalents
2017
2016
$
$
(4,947,982) $
(28,976,983)
30,708,406
(3,216,559) $
(2,888,288)
(40,903)
3,718,299
789,108
Operating Activities
Net cash used in operating activities was approximately $4.9 million for the year ended December 31, 2017 and consisted primarily of a net loss of
approximately $6.3 million and approximately $0.1 million in working capital changes, adjusted for non-cash items of approximately $1.5 million. The
approximately $0.1 million of working capital change was primarily due to approximately $0.2 million increase in prepaid insurance and deposits, offset by
approximately $0.1 million increase in accounts payable and accrued expenses. Non-cash expense items of approximately $1.5 million consisted of depreciation
of approximately $0.1 million, stock-based compensation expense of approximately $0.9 million and interest expense of approximately $0.5 million primarily
related to amortization of debt discount and debt financing costs. The net cash used in operating activities was approximately $2.9 million for the year ended
December 31, 2016 and consisted primarily of a net loss of approximately $3.3 million, adjusted for approximately $0.3 million of non-cash items, including
depreciation of approximately $0.07 million and stock-based compensation expense of approximately $0.2 million.
Investing Activities
Net cash used in investing activities for the year ended December 31, 2017 was approximately $29.0 million and consisted of approximately $28.75 million
of investments in certificates of deposit, government securities (U.S. Treasury Notes and U.S. government agency securities) and approximately $0.25 million in
purchases of property and equipment. Net cash used in investing activities for the year ended December 31, 2016 was approximately $0.04 million and
consisted of purchases of property and equipment.
53
EDGAR Stream is a copyright of Issuer Direct Corporation, all rights reserved.
Financing Activities
Net cash provided by financing activities for the year ended December 31, 2017 was approximately $30.7 million and reflects the net proceeds of
approximately $7.5 million from the sale of unsecured convertible promissory notes and warrants to certain investors through a private placement, as well as the
net proceeds of approximately $23.3 million from the sale of common stock in our initial public offering. Net cash provided by financing activities for the year
ended December 31, 2016 was approximately $3.7 million and reflects the net proceeds from the sale of membership units of Celcuity LLC to certain investors.
OFF-BALANCE SHEET ARRANGEMENTS
We do not currently have any off-balance sheet arrangements as defined in Item 303(a)(4) of Regulation S-K.
RECENT ACCOUNTING PRONOUNCEMENTS
From time to time new accounting pronouncements are issued by the Financial Accounting Standards Board, or FASB, or other standard setting bodies and
adopted by us as of the specified effective date. Unless otherwise discussed in Note 2 to our financial statements included elsewhere in this report, we believe
that the impact of recently issued standards that are not yet effective will not have a material impact on our financial position or results of operations upon
adoption.
CRITICAL ACCOUNTING POLICIES AND USE OF ESTIMATES
Our management’s discussion and analysis of financial condition and results of operations is based on our financial statements, which have been prepared in
accordance with accounting principles generally accepted in the United States, or Generally Accepted Accounted Principles (“U.S. GAAP”). The preparation of
these financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of
contingent assets and liabilities at the date of the financial statements, as well as the reported expenses during the reporting periods. These items are monitored
and analyzed by us for changes in facts and circumstances, and material changes in these estimates could occur in the future. We base our estimates on
historical experience and on various other factors that we believe are reasonable under the circumstances; the results of which form the basis for making
judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Changes in estimates are reflected in reported
results for the period in which they become known. Actual results may differ materially from these estimates.
Our significant accounting policies are more fully described in Note 2 to our financial statements included in this report. Of our significant accounting policies,
we believe that the following is the most critical:
Stock-Based Compensation
The Company recognizes compensation expense for employees based on an estimated grant date fair value using the Black-Scholes option-pricing
method. The Company has elected to account for forfeitures as they occur.
The fair value of options granted to nonemployees is determined using the fair value of the service provided or the fair value of the option granted,
whichever is more reliable. The fair value is measured at the value of the Company’s common shares at the earlier of the date that the commitment for
performance by the counterparty has been reached or the counterparty’s performance is complete. Awards granted to nonemployees are remeasured to fair
value at each period end date until vested and expensed on a straight-line basis over the vesting period.
The inputs for the Black-Scholes valuation model require management’s significant assumptions. Prior to the Company’s IPO, the common share price was
determined by the Company’s board based on recent prices of common shares sold in private offerings prior to the IPO. Subsequent to the IPO, the common
share price was determined by using the quoted price on the grant date. The risk-free interest rates were based on the rate for U.S. Treasury securities at the
date of grant with maturity dates approximately equal to the expected life at the grant date. The expected life was based on the simplified method in accordance
with the SEC Staff Accounting Bulletin Nos. 107 and 110. The expected volatility was estimated based on historical volatility information of peer companies that
are publicly available.
54
EDGAR Stream is a copyright of Issuer Direct Corporation, all rights reserved.
All assumptions used to calculate the grant date fair value of nonemployee options are generally consistent with the assumptions used for options granted to
employees, except the expected life is equal to the contractual term.
For grants of restricted stock, we record compensation expense based on the quoted fair value of the shares on the grant date over the requisite service
period. Compensation expense for ESPP rights is recorded in line with each respective offering period.
ITEM 7A. Quantitative and Qualitative Disclosures About Market Risk
As a smaller reporting company, we are not required to provide disclosure pursuant to this item.
55
EDGAR Stream is a copyright of Issuer Direct Corporation, all rights reserved.
ITEM 8. Financial Statements and Supplementary Data
REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
To the Board of Directors and
Stockholders of Celcuity Inc.
Opinion on the Financial Statements
We have audited the accompanying balance sheets of Celcuity Inc. (the Company) as of December 31, 2017 and 2016, and the related statements of
operations, changes in stockholders’ equity, and cash flows for each of the years in the two-year period ended December 31, 2017, and the related notes
(collectively referred to as the financial statements). In our opinion, the financial statements present fairly, in all material respects, the financial position of the
Company as of December 31, 2017 and 2016, and the results of its operations and its cash flows for each of the years in the two-year period ended December
31, 2017, in conformity with accounting principles generally accepted in the United States of America.
Basis for Opinion
These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s financial
statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and
are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the
Securities and Exchange Commission and the PCAOB.
We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable
assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor
were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal
control over financial reporting, but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting.
Accordingly, we express no such opinion.
Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing
procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial
statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall
presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.
/s/ Boulay PLLP
We have served as the Company’s auditor since 2017.
Minneapolis, Minnesota
March 15, 2018
56
EDGAR Stream is a copyright of Issuer Direct Corporation, all rights reserved.
Celcuity Inc.
Balance Sheets
December 31,
2017
December 31,
2016
$
2,639,789 $
21,556,857
50,000
27,726
209,708
24,484,080
5,856,348
-
50,000
5,717
-
5,912,065
280,056
144,912
7,205,374
-
$
31,969,510 $
6,056,977
$
71,913 $
506,140
578,053
331,534
113,825
445,359
578,053
445,359
Assets
Current Assets:
Cash and cash equivalents
Investments
Restricted cash
Deposits
Prepaid assets
Total current assets
Property and equipment, net
Long term investments
Total Assets
Liabilities and Stockholders’ Equity:
Current Liabilities:
Accounts payable
Accrued expenses
Total current liabilities
Total Liabilities
Commitments and contingencies
Stockholders’ Equity:
Members’ equity contributions: 0 and 6,440,139 shares issued and outstanding as of December 31, 2017 and
December 31, 2016, respectively
-
13,349,654
Preferred stock, $0.001 par value: 5,000,000 and 0 shares authorized as of December 31, 2017 and December 31,
2016, respectively; 0 shares issued and outstanding as of December 31, 2017 and December 31, 2016
-
-
Common stock, $0.001 par value: 45,000,000 and 0 shares authorized as of December 31, 2017 and December 31,
2016, respectively; 10,087,516 and 0 shares issued and outstanding as of December 31, 2017 and December 31,
2016, respectively
Additional paid-in capital
Accumulated deficit
Total Stockholders’ Equity
Total Liabilities and Stockholders’ Equity
10,087
33,388,597
(2,007,227)
31,391,457
31,969,510 $
-
593,365
(8,331,401)
5,611,618
6,056,977
$
See accompanying notes to the financial statements
57
EDGAR Stream is a copyright of Issuer Direct Corporation, all rights reserved.
Celcuity Inc.
Statements of Operations
Operating expenses:
Research and development
General and administrative
Total operating expenses
Loss from operations
Other income (expense)
Interest expense
Interest income
Other income (expense), net
Net loss before income taxes
Income tax benefits
Net loss
Net loss per unit, basic and diluted
Weighted average common shares outstanding, basic and diluted
See accompanying notes to the financial statements
58
Years Ended
December 31,
2017
2016
$
$
$
4,980,427 $
972,518
5,952,945
(5,952,945)
3,064,762
263,664
3,328,426
(3,328,426)
(451,664)
152,879
(298,785)
(6,251,730)
-
(6,251,730) $
-
18,018
18,018
(3,310,408)
-
(3,310,408)
(0.84) $
(0.52)
7,460,640
6,313,089
EDGAR Stream is a copyright of Issuer Direct Corporation, all rights reserved.
Balance at December 31, 2015
Member shares issued, net
Stock-based compensation
Non-employee stock-based
compensation
Net loss
Balance at December 31, 2016
Warrants issued - unsecured convertible promissory
note holders
Warrants issued - placement agent
Corporate conversion from Celcuity LLC to Celcuity
Inc.
Corporate conversion to common stock
Common stock issued in initial public offering, net of
underwriter commission of $1,835,400, initial public
offering costs of $1,133,553 and underwriter
warrant of $784,111
Warrant issued - underwriter
Conversion of unsecured convertible promissory note
to common stock
Exercise of common stock warrants
Stock-based compensation
Non-employee stock-based compensation
Net loss
Balance at December 31, 2017
Celcuity Inc.
Statements of Changes in Stockholders’ Equity
Member Contributions
Common Stock
Additional
Accumulated
Shares
Amount
Shares
Amount
Paid-In Capital
Deficit
Total
$
5,891,181
548,958
-
9,961,962
3,387,692
-
-
-
6,440,139
-
-
13,349,654
-
-
-
(6,440,139)
-
-
-
(13,349,654)
$
-
-
-
-
-
-
-
$
-
-
-
-
-
-
-
75,452
330,607
141,408
45,898
-
593,365
776,717
286,999
$
(5,020,993) $
-
-
-
(3,310,408)
(8,331,401)
5,016,421
3,718,299
141,408
45,898
(3,310,408)
5,611,618
-
-
776,717
286,999
-
6,440,139
-
6,440
(12,575,904)
13,343,214
12,575,904
-
-
-
-
-
-
-
-
-
-
$
-
-
-
-
-
-
-
2,760,000
-
881,911
216
5,250
-
-
10,087,516
$
2,760
-
882
-
5
-
-
10,087
$
22,464,226
784,111
6,839,436
2,052
677,366
197,015
-
33,388,597
-
-
-
-
-
(6,251,730)
(2,007,227) $
$
22,466,986
784,111
6,840,318
2,052
677,371
197,015
(6,251,730)
31,391,457
See accompanying notes to the financial statements
59
EDGAR Stream is a copyright of Issuer Direct Corporation, all rights reserved.
Celcuity Inc.
Statements of Cash Flows
Cash flows from operating activities:
Net loss
Adjustments to reconcile net loss to net cash used by operations:
Depreciation
Stock-based compensation
Non-cash interest expense
Non-cash interest income
Changes in operating assets and liabilities:
Prepaid assets and deposits
Accounts payable
Accrued expenses
Net cash used by operating activities
Cash flows from investing activities:
Purchases of investments
Purchases of property and equipment
Net cash used by investing activities
Cash flows from financing activities:
Proceeds from sale of member shares, net of issuance costs
Proceeds from sale of convertible promissory notes
Proceeds from initial public offering of common stock
Proceeds from exercise of common stock warrants
Payments for debt issuance costs
Payments for initial public offering costs
Net cash provided by financing activities
Net change in cash and cash equivalents
Cash and cash equivalents:
Beginning of period
End of period
Non-cash financing activities:
Debt issuance costs netted against proceeds from sale of convertible promissory notes
Debt discount related to investor and agent warrants (Note 11)
Initial public offering costs included in accounts payable
Underwriter’s reimbursable offering costs netted against initial public offering proceeds
See accompanying notes to the financial statements
60
Years Ended
December 31,
2017
2016
$
(6,251,730) $
(3,310,408)
104,704
874,386
451,664
(25,097)
73,059
187,306
-
-
(231,717)
(262,507)
392,315
(4,947,982)
-
69,779
91,976
(2,888,288)
(28,737,135)
(239,848)
(28,976,983)
-
(40,903)
(40,903)
-
7,493,330
24,109,650
2,052
(40,961)
(855,665)
30,708,406
(3,216,559)
3,718,299
-
-
-
-
-
3,718,299
789,108
$
$
5,856,348
2,639,789 $
5,067,240
5,856,348
844,170 $
1,063,715
2,889
275,000
-
-
-
-
EDGAR Stream is a copyright of Issuer Direct Corporation, all rights reserved.
CELCUITY INC.
NOTES TO FINANCIAL STATEMENTS
1.
ORGANIZATION
Nature of Business
Celcuity Inc., a Delaware corporation (the “Company”), is a cellular analysis company that is discovering new cancer sub-types and commercializing diagnostic
tests designed to significantly improve the response rates of cancer patients treated with targeted therapies. The Company’s proprietary CELx diagnostic
platform is currently the only commercially ready technology the Company is aware of that uses a patient’s living tumor cells to evaluate the functional status of
the cell signaling pathways associated with cancer. The CELx platform identifies the abnormal signaling activity driving a patient’s cancer and quantifies how
effectively a targeted therapy can treat it. This enables physicians to select the therapeutic that precisely matches and inhibits a patient’s cellular dysfunction,
which significantly increases the likelihood of a positive clinical outcome. The Company’s first analytically validated and commercially ready CELx test diagnoses
two new sub-types of HER2-negative breast cancer. The Company is currently fielding a prospective clinical trial to evaluate the efficacy of HER2 targeted
therapies in patients with these newly identified cancer sub-types. In addition to the CELx tests for HER2-negative breast cancer, the Company is developing
CELx tests to diagnose 14 new potential cancer sub-types in breast, lung, colon, ovarian, kidney, bladder and hematological cancers. The Company expects to
launch these additional tests on a staggered basis over the next few years. The Company was cofounded in 2012 by Brian Sullivan and Lance Laing and is
based in Minnesota. The Company has not generated any revenues to date.
2.
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Basis of Presentation
The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) and
pursuant to the rules and regulations of the SEC. Operating results for the year ended December 31, 2017 are not necessarily indicative of results to be
expected for any future year.
On September 15, 2017, in relation to preparing for its initial public offering (“IPO”), Celcuity LLC filed a certificate of conversion, whereby Celcuity LLC effected a
corporate conversion from a Minnesota limited liability company to a Delaware corporation and changed its name to Celcuity Inc. Pursuant to the corporate
conversion, units of membership interest in the limited liability company were converted into shares of common stock of the corporation at a conversion ratio of
40 units for one share of common stock. As a result of the corporate conversion, accumulated deficit was reduced to zero on the date of the corporate
conversion, and the corresponding amount was credited to additional paid-in capital. The corporate conversion was approved by members holding a majority of
our outstanding units, and in connection with such conversion, the Company filed a certificate of incorporation and adopted bylaws. Pursuant to the Company’s
certificate of incorporation, the Company is authorized to issue up to 45,000,000 shares of common stock $0.001 par value per share and 5,000,000 shares of
preferred stock $0.001 par value per share. The Company determined that the corporate conversion is equivalent to a change in the Company’s capital
structure. As such, all references in the audited financial statements to the number of shares and per-share amounts of member units are now presented as
common stock and have been retroactively restated to reflect this conversion.
On September 22, 2017, the Company completed its IPO whereby it sold 2,760,000 shares of common stock at a public offering price of $9.50 per share. The
aggregate net proceeds received by the Company from the offering were approximately $23.3 million, net of underwriting discounts and commissions of
approximately $1.8 million and offering expenses of approximately $1.1 million. Upon the closing of the IPO, 10,082,050 shares of common stock were
outstanding, which includes 881,911 shares of common stock as a result of the conversion of the Company’s Unsecured Convertible Promissory Notes (See
Note 11). The shares began trading on September 20, 2017 on The Nasdaq Capital Market under the symbol “CELC”.
Accounting Estimates
Management uses estimates and assumptions in preparing these financial statements in accordance with U.S. GAAP. Those estimates and assumptions affect
the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities, and the reported revenues and expenses. Actual results could
differ from those estimates. Significant items subject to such estimates and assumptions include the valuation of stock-based compensation and warrants issued
to investors, a placement agent and an underwriter, and prepaid or accrued clinical trial costs.
61
EDGAR Stream is a copyright of Issuer Direct Corporation, all rights reserved.
Cash and Cash Equivalents
The Company maintains its accounts primarily at one financial institution. At times throughout the year, the Company’s cash balances may exceed amounts
insured by the Federal Deposit Insurance Corporation. At December 31, 2017 and December 31, 2016, the Company had $2,612,104 and $5,842,193,
respectively, in money market funds and U.S. Treasury Bills that are considered cash equivalents.
Investments
The Company maintains its investments in certificates of deposit, U.S. governmental agency securities and U.S. treasury notes and has classified them as held-
to-maturity at the time of purchase. Held-to-maturity securities are those securities in which the Company has the ability and intent to hold until maturity. Held-to
maturity securities are recorded at amortized cost, adjusted for the amortization or accretion of premiums and discounts. Premiums and discounts are amortized
or accreted over the life of the related held-to-maturity security using a straight-line method. At December 31, 2017 and 2016, the Company had $28,762,231
and $0, respectively, of investments.
Property and Equipment
Property and equipment are stated at cost. Depreciation is provided over estimated useful lives using the straight-line method. Maintenance and repairs are
expensed as incurred; major improvements and betterments are capitalized.
Estimated useful lives of property and equipment are as follows for the major classes of assets:
Asset Description
Furniture and Equipment
Leasehold Improvements
Long-Lived Assets
Estimated
Lives
4
2-3
Long-lived assets, such as property and equipment, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount
of an asset may not be recoverable. If circumstances require a long-lived asset or asset group be tested for possible impairment, the Company first compares
undiscounted cash flows expected to be generated by that asset or asset group to its carrying value. If the carrying value of the long-lived asset or asset group is
not recoverable on an undiscounted cash flow basis, an impairment is recognized to the extent that the carrying value exceeds its fair value. Fair value is
determined through various valuation techniques including discounted cash flow models, quoted market values, and third party independent appraisals, as
considered necessary.
Comprehensive Loss
Comprehensive loss includes net loss as well as other changes in stockholders’ equity that result from transactions and economic events other than those with
stockholders. For all periods presented, there was no difference between net loss and comprehensive loss.
Risks and Uncertainties
The Company is subject to risks common to companies in the development stage including, but not limited to, dependency on the clinical and commercial
success of its diagnostic tests, ability to obtain regulatory approval of its diagnostic tests, the need for substantial additional financing to achieve its goals,
uncertainty of broad adoption of its approved products, if any, by physicians and consumers, and significant competition.
Fair Value of Financial Instruments
The Company’s accounting for fair value measurements of assets and liabilities that are recognized or disclosed at fair value in the financial statements on a
recurring or nonrecurring basis adheres to the Financial Accounting Standards Board (“FASB”) fair value hierarchy that prioritizes the inputs to valuation
techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities
(Level 1 measurements) and the lowest priority to measurements involving significant unobservable inputs (Level 3 measurements). The three levels of the fair
value hierarchy are as follows:
·
·
Level 1 Inputs: Unadjusted quoted prices in active markets for identical assets or liabilities accessible to the Company at the measurement date.
Level 2 Inputs: Other than quoted prices included in Level 1 inputs that are observable for the asset or liability, either directly or indirectly, for
substantially the full term of the asset or liability.
62
EDGAR Stream is a copyright of Issuer Direct Corporation, all rights reserved.
·
Level 3 Inputs: Unobservable inputs for the asset or liability used to measure fair value to the extent that observable inputs are not available, thereby
allowing for situations in which there is little, if any, market activity for the asset or liability at measurement date.
The level in the fair value hierarchy within which a fair measurement in its entirety falls is based on the lowest level input that is significant to the fair value
measurement in its entirety.
The carrying values of cash equivalents, restricted cash, accounts payable, accrued expenses and other financial working capital items approximate fair value at
December 31, 2017 and December 31, 2016, due to the short maturity nature of these items.
Income Taxes
The Company accounts for income taxes using the asset and liability method, as required by the accounting standard for income taxes. Under this method,
deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of
existing assets and liabilities and their respective tax bases, as well as net operating loss and tax credit carryforwards. Deferred taxes are measured using
enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on
deferred taxes of a change in tax rates is recognized in results of operations in the period that includes the enactment date. The effects of any future changes in
tax laws or rates have not been considered. The Company regularly reviews deferred tax assets to assess their potential realization and establish a valuation
allowance for portions of such assets to reduce the carrying value if the Company does not consider it to be more likely than not that the deferred tax assets will
be realized.
The Company recognizes the impact of an uncertain tax position in its financial statements if, in management’s judgment, the position is more-likely-than-not
sustainable upon audit based on the position’s technical merits. This involves the identification of potential uncertain tax positions, the evaluation of applicable
tax laws and an assessment of whether a liability for an uncertain tax position is necessary.
Stock-Based Compensation
The Company’s stock-based compensation consists of common stock options and restricted stock issued to certain employees and nonemployees of the
Company and the Company’s Employee Stock Purchase Plan. The Company recognizes compensation expense for employees based on an estimated grant
date fair value using the Black-Scholes option-pricing method. The Company has elected to account for forfeitures as they occur.
The fair value of options granted to nonemployees is determined using the fair value of the service provided or the fair value of the option granted, whichever is
more reliable. The fair value is measured at the value of the Company’s common shares at the earlier of the date that the commitment for performance by the
counterparty has been reached or the counterparty’s performance is complete. Awards granted to nonemployees are remeasured to fair value at each period
end date until vested and expensed on a straight-line basis over the vesting period.
Research and Development
Research and development costs are expensed as incurred. Research and development costs amounted to $4,980,427 in 2017 and $3,064,762 in 2016.
Clinical Trial Costs
The Company records prepaid assets or accrued expenses for prepaid or estimated clinical trial costs conducted by third-party service providers, which include
the conduct of preclinical studies and clinical trials. These costs are a significant component of the Company’s research and development expenses. The
Company accrues for these costs based on factors such as estimates of the work completed and in accordance with agreements established with its third-party
service providers under the service agreements. The Company makes significant judgments and estimates in determining the accrued liabilities balance in each
reporting period. As actual costs become known, the Company adjusts its prepaid assets or accrued expenses. The Company has not experienced any
material differences between accrued costs and actual costs incurred. However, the status and timing of actual services performed, number of patients enrolled
and the rate of patient enrollments may vary from the Company’s estimates, resulting in an adjustment to expense in future periods. Changes in these
estimates that result in material changes to the Company’s prepaid assets or accrued expenses could materially affect the Company’s results of operations.
Segment Data
The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.
63
EDGAR Stream is a copyright of Issuer Direct Corporation, all rights reserved.
Application of New or Revised Accounting Standards
Pursuant to the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”), a company constituting an “emerging growth company” is, among other things,
entitled to rely upon certain reduced reporting requirements. The Company is an emerging growth company, but has irrevocably elected not to take advantage of
the extended transition period afforded by the JOBS Act for the implementation of new or revised accounting standards. As a result, the Company will comply
with new or revised accounting standards on the relevant dates on which adoption of such standards is required for public companies that are not emerging
growth companies.
Recently Issued Accounting Pronouncements
In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842), which provides guidance for accounting for leases. The new guidance requires
companies to recognize the assets and liabilities for the rights and obligations created by leased assets, initially measured at the present value of the lease
payments. The accounting guidance for lessors is largely unchanged. The ASU is effective for annual and interim periods beginning after December 15, 2018
with early adoption permitted. It is to be adopted using a modified retrospective approach. The Company is currently evaluating the impact that the adoption of
this guidance will have on the Company’s financial statements.
3.
NET LOSS PER COMMON SHARE
Basic and diluted net loss per common share is determined by dividing net loss attributable to common stockholders by the weighted-average common shares
outstanding during the period. For all periods presented, the common shares underlying the options and warrants have been excluded from the calculation
because their effect would be anti-dilutive. Therefore, the weighted-average shares outstanding used to calculate both basic and diluted loss per common shares
are the same.
For the years ended December 31, 2017 and 2016, 64,410 and 55,283 options and 55,055 and 0 warrants, and 414 and 0 restricted stock share equivalents,
respectively, have been excluded from the computations of diluted weighted-average shares outstanding.
4.
INVESTMENTS
The following table summarizes the Company’s held-to-maturity investment securities at amortized cost as of December 31, 2017:
Short-term investments:
Certificates of Deposit
Governmental Agency Securities
U.S. Treasury Notes
Total
Long-term investments:
Certificates of Deposit
Governmental Agency Securities
Total
Gross
Unrealized
Holding
Gains
Gross
Unrealized
Holding
Gains
Amortized Cost,
as Adjusted
$
$
14,001,237 $
5,945,314
1,610,306
21,556,857 $
Amortized Cost,
as Adjusted
$
$
4,165,000 $
3,040,374
7,205,374 $
Gross
Unrealized
Holding Losses
Estimated Fair
Value
- $
-
-
- $
20,146 $
18,101
633
38,880 $
13,981,091
5,927,213
1,609,673
21,517,977
Gross
Unrealized
Holding Losses
Estimated Fair
Value
- $
-
- $
21,481 $
14,907
36,388 $
4,143,519
3,025,467
7,168,986
The Company had no investments as of December 31, 2016. The Company’s held-to-maturity investments of $21,556,857 and $7,205,374 will mature in 2018
and 2019, respectively.
64
EDGAR Stream is a copyright of Issuer Direct Corporation, all rights reserved.
5.
PREPAID ASSETS
Prepaid assets consisted of the following at December 31:
Directors & Officers insurance
Prepaid rent
Other
Total
6.
PROPERTY AND EQUIPMENT
Property and equipment consisted of the following at December 31:
Leasehold improvements
Furniture and equipment
Less: Accumulated depreciation
Total
2017
2016
$
$
162,914 $
21,673
25,121
209,708 $
-
-
-
-
2017
2016
22,307 $
517,868
540,175
22,307
278,020
300,327
(260,119)
280,056 $
(155,415)
144,912
$
$
Depreciation expense was $104,704 and $73,059 for the years ending December 31, 2017 and 2016, respectively.
7.
ACCRUED EXPENSES
Accrued expenses consisted of the following at December 31:
Accrued bonuses
Accrued payroll
Other
Total
8.
COMMITMENTS
Lease Obligation
2017
2016
389,802 $
61,829
54,509
506,140 $
72,917
40,341
567
113,825
$
$
The Company leases its corporate space in Minneapolis, Minnesota. At December 31, 2017, the Company had the following minimum commitments for
payment of rentals which at inception had a non-cancellable term of more than one year:
2018
2019
2020
2021
Total
Operating
Lease
141,456
188,850
193,338
64,940
588,584
$
$
Annual rent expense for operating leases was $51,455 and $49,632 for 2017 and 2016, respectively. In connection with the corporate lease, the Company is
required to maintain a $50,000 standby letter of credit. The standby letter of credit expires on July 31, 2018.
65
EDGAR Stream is a copyright of Issuer Direct Corporation, all rights reserved.
In September 2017, the Company entered into a non-cancelable operating lease agreement for building space to accommodate expansion in research and
development and general corporate office needs. The new lease commences and the Company will be moving to the facility in May 2018, in conjunction with
the termination of the existing lease. The new lease agreement extends through April 2021 and provides for monthly rent, real estate taxes and operating
expenses.
Clinical Research Study
In May 2017, the Company entered into an agreement with a clinical research organization to conduct a clinical research study. The Company made a payment
of $300,000 in June 2017 and $50,000 in November 2017 and is obligated to make payments of $200,000 and $50,000 in 2018 and 2019, respectively.
Additional payments will be due as patients are enrolled in the study. The maximum amount of these additional payments is estimated to be approximately
$2,040,000 over the course of the agreement.
9.
STOCKHOLDERS’ EQUITY
On September 15, 2017, in connection with its IPO, Celcuity LLC filed a certificate of conversion, whereby Celcuity LLC effected a corporate conversion from a
Minnesota limited liability company to a Delaware corporation and changed its name to Celcuity Inc. Pursuant to the conversion, units of membership interest in
the limited liability company were converted into shares of common stock of the corporation at a conversion ratio of 40 units for one share of common stock. The
Company had 257,604,208 member units issued and outstanding as of September 15, 2017. After giving effect to the corporate conversion, the number of
common shares outstanding as of such date is 6,440,139. As a result of the corporate conversion, accumulated deficit was reduced to zero on the date of the
corporate conversion, and the corresponding amount was credited to additional paid-in capital. The corporate conversion was approved by members holding a
majority of our outstanding units, and in connection with such conversion, the Company filed a certificate of incorporation and adopted bylaws. Pursuant to the
Company’s certificate of incorporation, the Company is authorized to issue up to 45,000,000 shares of common stock $0.001 par value per share and 5,000,000
shares of preferred stock $0.001 par value per share. All references in the audited financial statements to the number of shares and per-share amounts of
common stock have been retroactively restated to reflect this conversion.
On September 22, 2017, the Company completed its IPO whereby it sold 2,760,000 shares of common stock at a public offering price of $9.50 per share. The
aggregate net proceeds received by the Company from the offering were approximately $23.3 million, net of underwriting commissions of approximately $1.8
million and offering expenses of approximately $1.1 million. Upon the closing of the IPO, 10,082,050 shares of common stock were outstanding, which includes
881,911 shares of common stock issued as a result of the conversion of the Company’s Convertible Notes (See Note 11). The shares began trading on
September 20, 2017 on The Nasdaq Capital Market under the symbol “CELC”.
At December 31, 2017 and 2016, the Company had common stock shares and member shares outstanding of 10,087,516 and 6,440,139, respectively.
Warrants
In connection with the 2016 private placement unit offering, the Company issued ten-year warrants to the placement agent of the private placement. The
warrants allow the agent to purchase up to 55,249 common shares at $7.56 per share. The warrants are immediately exercisable and expire on January 14,
2026 and May 2, 2026. These warrants are equity classified and the fair value of $330,607 is reflected as additional paid-in capital.
In connection with the private offering of convertible notes (Note 11), the Company issued ten-year warrants to purchase 48,615 common shares at a price of
$8.42 per share to the placement agent. In addition, the Company granted the convertible notes investors the right to receive a seven-year warrant to purchase
131,675 common shares at an exercise price that is equal to the conversion price of the notes (Note 11). With the completion of the IPO on September 22, 2017,
these warrants were issued.
In connection with the IPO, the Company issued a five-year warrant to the underwriter. The warrant allows the underwriter to purchase up to 138,000 common
shares at $10.45 per share. This warrant is immediately exercisable and expires on September 19, 2022. This warrant is equity classified and the fair value was
$784,111 at the IPO offering date.
At December 31, 2017 and 2016, the Company had warrants to purchase 373,323 and 55,249 common shares outstanding, respectively, at a weighted average
exercise price of $9.42 and $7.56, respectively. A total of 216 and 0 warrants were exercised in the years ending December 31, 2017 and 2016, respectively.
66
EDGAR Stream is a copyright of Issuer Direct Corporation, all rights reserved.
10.
STOCK-BASED COMPENSATION
2012 Equity Incentive Plan
The 2012 Equity Incentive Plan, as amended, was adopted by the Company’s board and approved by the members of the Company on August 10, 2012. The
Company reserved a maximum of 625,000 common shares available for issuance under the 2012 Equity Incentive Plan. The 2012 Equity Incentive Plan
provides for share options, restricted share awards, performance share awards or share bonuses. The exercise price of each share option granted under the
2012 Equity Incentive Plan is not less than one hundred percent (100%) of the fair market value of one share on the date of grant. The maximum permitted term
of options granted under the 2012 Equity Incentive Plan is ten years. The Company’s board has administered the plan and determined the provisions of
incentive awards, including eligible recipients, number of shares subject to an incentive award, exercise price, vesting schedule, duration of an incentive award
and other restrictions an incentive award may be subject to. The 2012 Equity Incentive Plan was fixed on September 6, 2017 and any new awards will be issued
under the terms of the 2017 Stock Incentive Plan.
2017 Stock Incentive Plan
The 2017 Stock Incentive Plan, or the 2017 Plan, was adopted by the Company’s board on September 6, 2017 and became effective following the corporate
conversion which took place on September 15, 2017. The Company reserved a maximum of 750,000 common shares available for issuance under the 2017
Plan. The number of shares reserved for issuance under the 2017 Plan will increase automatically on January 1, 2019 and each subsequent anniversary through
January 1, 2027 by the number of shares equal to 1.0% of the aggregate number of outstanding shares of the Company’s common stock as of the immediately
preceding December 31. However, the Company’s board may reduce the amount of the increase in any particular year. The maximum permitted term of options
granted under the 2017 Plan is ten years. The 2017 Plan provides for share options, restricted stock awards, stock appreciation rights, restricted stock units,
performance awards and stock bonuses. The exercise price of each share option granted under the 2017 Plan is not less than one hundred percent (100%) of
the fair market. The 2017 Plan will generally be administered by the compensation committee of the Company’s board of directors and has the authority to
interpret the plan, grant awards and make all other determinations necessary for the administration of the plan.
The Black-Scholes option-pricing model was used to estimate the fair value of equity-based awards with the following weighted-average assumptions at
December 31:
Risk-free interest rate
Expected volatility
Expected life (years)
Expected dividend yield
2017
1.89 - 2.40%
75.0%
5.5 to 10.00
0%
2016
2.00%
75.0%
6.25 to 10.00
0%
The inputs for the Black-Scholes valuation model require management’s significant assumptions. Prior to the Company’s IPO, the common share price was
determined by the Company’s board based on recent prices of common shares sold in private offerings prior to the IPO. Subsequent to the IPO, the common
share price was determined by using the price on the grant date. The risk-free interest rates were based on the rate for U.S. Treasury securities at the date of
grant with maturity dates approximately equal to the expected life at the grant date. The expected life was based on the simplified method in accordance with
the SEC Staff Accounting Bulletin Nos. 107 and 110. The expected volatility was estimated based on historical volatility information of peer companies that are
publicly available.
All assumptions used to calculate the grant date fair value of nonemployee options are generally consistent with the assumptions used for options granted to
employees, except the expected life is equal to the contractual term. In the event the Company terminates any of its consulting agreements, the unvested
options underlying the agreements would also be cancelled. Unvested nonemployee options are marked-to-market at each reporting period by using the price on
the last trading date of the reporting period.
67
EDGAR Stream is a copyright of Issuer Direct Corporation, all rights reserved.
The following table summarizes the activity for all stock options outstanding at December 31 under the Plan:
2017
2016
Options outstanding at beginning of year
Granted
Forfeited
Balance at December 31
302,088 $
233,630
(34,115)
501,603 $
5.91
9.78
7.87
7.58
114,525 $
190,063
(2,500)
302,088 $
Weighted
Average
Shares
Exercise Price
Shares
Weighted
Average
Exercise Price
3.07
7.60
3.60
5.91
Options exercisable at December 31:
201,705 $
5.80
71,463 $
2.91
Weighted Average Grant Date Fair Value for Options Granted
During the year:
$
6.35
$
5.22
The following table summarizes additional information about stock options outstanding and exercisable at December 31, 2017 under the Plan:
Options Outstanding
Options Exercisable
Weighted
Average
Remaining
Contractual
Life
Weighted
Average
Exercise
Price
Options
Outstanding
Aggregate
Intrinsic
Value
Options
Exercisable
Weighted
Average
Exercise
Price
Aggregate
Intrinsic
Value
501,603
8.56 $
7.58 $
5,702,716
201,705 $
5.80 $
2,652,723
The Company recognized stock based compensation expense for stock options of $818,098 and $187,306 for the years ending December 31, 2017 and 2016,
respectively.
A restricted stock award of 5,250 shares was granted to a member of the board of directors in 2017. The Company has 5,250 and 0 shares outstanding as of
December 31, 2017 and 2016, respectively and 0 shares vested as of December 31, 2017 and 2016, respectively. The Company recognized stock based
compensation expense for the restricted stock of $28,193 and $0 for the years ending December 31, 2017 and 2016, respectively.
The total remaining shares available for grant under the 2017 plan is 688,020.
Total unrecognized compensation cost related to stock options and restricted stock is estimated to be recognized as follows:
2018
2019
2020
2021
Total estimated compensation cost to be recognized
2017 Employee Stock Purchase Plan
$
$
829,895
412,803
299,706
116,950
1,659,354
The Company’s employee stock purchase plan, or ESPP, was adopted by the Company’s board on September 6, 2017, subject to stockholder approval at the
next meeting of stockholders. If stockholders do not approve the ESPP, it will be terminated and all contributions returned to the participants without the
purchase of any shares. The Company has reserved a total of 100,000 shares for issuance. The number of shares authorized and reserved for issuance under
the ESPP will be automatically increased on the first day of each of the Company’s fiscal years beginning in 2019 by the number of shares equal to 0.5% of the
total outstanding number of shares of common stock. However, the Company’s board may reduce the amount of the increase in any particular year. The ESPP
provides participating employees with an opportunity to purchase shares of the Company’s common stock at a discount through payroll deductions. The plan is
available to all employees unless they are employed for less than 20 hours per week or own 5% or more of the total combined voting power or value of the
Company’s common stock. The plan is administered using overlapping 24 month offering periods, referred to as an Offering Period. Each Offering Period has
four six-month purchase periods. A new Offering Period and purchase period begin every six months on May 1 and November 1 of each year. Participating
employees may purchase common stock, on a voluntary after tax-basis, at a price equal to 85% of the fair market value of a share of common stock on either the
offering date or the purchase date, whichever is lower. If the purchase date has a lower price, the employee will automatically be placed in the Offering Period
beginning immediately after the purchase date. The Company recognized stock based compensation expense of $28,095 and $0 for the years ending
December 31, 2017 and 2016, respectively.
68
EDGAR Stream is a copyright of Issuer Direct Corporation, all rights reserved.
The Company recognized total stock-based compensation, as follows for the years ended December 31:
Stock-based compensation expense in operating expenses:
Research and development
General and administrative
Total
2017
2016
$
$
608,456 $
265,930
874,386 $
187,306
-
187,306
11.
UNSECURED CONVERTIBLE PROMISSORY NOTES
In April and May of 2017, the Company issued to certain accredited investors convertible notes in the original principal amount of $5,750,000 and $2,587,500,
respectively, for total principal of $8,337,500 (the “Convertible Notes”).
The Convertible Notes accrued interest at a rate of 1.25% per annum from date of issuance until December 31, 2018 on a non-compounding basis. All principal
and interest was due on December 31, 2018. The IPO was considered a qualified financing, therefore the outstanding principal balance and all accrued interest
under the Convertible Notes automatically converted into 881,911 shares of common stock pursuant to the terms of such notes. The conversion price of the
Convertible Notes was equal to the price at which the equity securities were sold in the IPO, which was $9.50 per share.
In connection with the issuance of the Convertible Notes, the Company granted those investors the right to receive a seven-year warrant to purchase 131,675
common shares at an exercise price that is equal to the conversion price of the Convertible Notes. The gross proceeds of $8,337,500 was allocated $7,560,783
and $776,717 to the Convertible Notes and warrants, respectively, based on their relative fair value. The relative fair value of the warrants of $776,717 was
recorded as debt discount and credited to additional paid-in capital. The resulting debt discount was amortized to interest expense using the effective interest
method over the term of the Convertible Notes.
Cedar Point Capital, LLC (“Cedar”) served as the Company’s placement agent in connection with the placement of the Convertible Notes and earned a
commission of approximately 10% of the original principal balance of such notes. Debt financing costs in the aggregate of $885,131 (not including the agent
warrant discussed below), comprised primarily of the commission earned by Cedar, were amortized to interest expense using the effective interest method over
the term of the Convertible Notes until converted. In addition to the commission earned by Cedar, the Company issued an agent’s ten-year warrant to purchase
48,615 common shares. The exercise price was $8.42 per share. The fair value of the agent’s warrant was $286,999 and is considered additional debt discount
and was credited to additional paid-in capital. During the period beginning on January 1, 2017 and ending on September 22, 2017 (the date of the IPO closing),
the Company amortized $411,375 of debt discount and financing costs to interest expense for these Convertible Notes.
12.
Income Taxes
Following the conversion of Celcuity LLC to Celcuity Inc. on September 15, 2017, Celcuity Inc. will begin filing federal and state returns where required. No
income tax benefit was recorded for the period September 16, 2017 through December 31, 2017, due to net losses and recognition of a valuation allowance.
The following table presents a reconciliation of the tax expense computed at the statutory federal rate and the Company’s tax expense for the years ending
December 31:
Tax benefit at statutory federal rate
State income tax benefit, net of federal tax effect
Change in valuation allowance on deferred tax assets
Other permanent items
Revaluation of deferred taxes due to U.S. Tax Reform
Change in tax status
Income tax benefits
69
2017
2016
$
$
(682,000) $
(130,000)
897,000
3,000
366,000
(454,000)
- $
-
-
-
-
-
-
-
EDGAR Stream is a copyright of Issuer Direct Corporation, all rights reserved.
Deferred income taxes reflect the net effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and
the amounts used for income tax purposes. The Company’s deferred tax assets relate primarily to its net operating loss carryforwards and other balance sheet
basis differences. In accordance with ASC 740, “Income Taxes,” the Company recorded a valuation allowance to fully offset the net deferred tax asset, because
it is more likely than not that the Company will not realize future benefits associated with these deferred tax assets at December 31, 2017. The tax effects of
temporary differences and carryforwards that give rise to significant portions of the deferred tax assets are as follows:
Deferred tax assets (liabilities):
Accrued expenses
Share-based compensation
Property and equipment
Net operating losses
Valuation allowance
Net deferred tax assets (liabilities)
2017
2016
$
$
112,000 $
325,000
68,000
392,000
(897,000)
- $
-
-
-
-
-
-
On December 22, 2017, the Tax Cuts and Jobs Act (the Act) was signed into United States tax law. As a result, certain provisions in this Act effect the deferred
tax assets and liabilities and the deferred tax provision of the Company as of and for the year ended December 31, 2017. Among other provisions included in the
Act, the US federal corporate tax rate is reduced from a graduated rate up to 35% to a flat rate of 21%. The Company has adjusted its deferred tax assets and
liabilities at December 31, 2017 to reflect the Act’s reduction of corporate tax rates which are expected to be in effect in future years as the deferred tax assets
and liabilities are realized. The effect of this adjustment has been recognized as an increase in the deferred provision for income taxes of $366,000.
At December 31, 2017, the Company had federal and state net operating loss carryforwards of approximately $1.36 million each. The net operating loss
carryforwards will expire in the year ending December 31, 2037.
Under the provisions of Section 382 of the Internal Revenue Code of 1986, certain substantial changes in the Company’s ownership, including a sale of the
Company, or significant changes in ownership due to sales of equity, may limit in the future the amount of net operating loss carryforwards available to offset
future taxable income.
The Company recognizes uncertain tax positions in accordance with ASC 740 on the basis of evaluating whether it is more likely than not that the tax positions
will be sustained upon examination by tax authorities. For those tax positions that meet the more-likely-than not recognition threshold, we recognize the largest
amount of tax benefit that is more than 50 percent likely to be realized upon ultimate settlement. As of December 31, 2017 and 2016, the Company has no
unrecognized tax benefits. There are no unrecognized tax benefits included on the balance sheet that would, if recognized, impact the effective tax rate. The
Company does not anticipate there will be a significant change in unrecognized tax benefits within the next 12 months.
Prior to the conversion, Celcuity was a limited liability company and therefore was a disregarded legal entity for income tax purposes. Accordingly, no benefit for
income taxes was recorded prior to the conversion.
For years before 2013, the Company is no longer subject to U.S. federal or state income tax examinations. The Company’s policy is to recognize interest and
penalties related to uncertain tax positions as a component of general and administrative expenses. As of September 30, 2017, and December 31, 2016, the
Company did not have any significant uncertain tax positions.
70
EDGAR Stream is a copyright of Issuer Direct Corporation, all rights reserved.
ITEM 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure.
None
ITEM 9A. Controls and Procedures.
Evaluation of Disclosure Controls and Procedures
Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controls and
procedures as of December 31, 2017. The term “disclosure controls and procedures,” as defined in Rules 13a-15(e) and 15d-15(e) under the Securities
Exchange Act of 1934, as amended (the “Exchange Act”), means controls and other procedures of a company that are designed to ensure that information
required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the
time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure
that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the
company’s management, including its principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure.
Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their
objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on the
evaluation of our disclosure controls and procedures as of December 31, 2017, our Chief Executive Officer and Chief Financial Officer concluded that, as of such
date, our disclosure controls and procedures were effective.
Changes in Internal Control over Financial Reporting
There were no material changes in our internal control over financial reporting during the quarter ended December 31, 2017 that have materially affected, or
are reasonably likely to materially affect, our internal control over financial reporting.
Management Report on Internal Control over Financial Reporting
This annual report does not include a report of management’s assessment regarding internal control over financial reporting or an attestation report of our
registered independent public accounting firm due to a transition period established by rules of the SEC for newly public companies.
ITEM 9B. Other Information.
None.
ITEM 10. Directors, Executive Officers and Corporate Governance.
Directors
PART III
Brian F. Sullivan, age 56, is our co-Founder and has served as Chairman of the Board and Chief Executive Officer since we commenced operations in 2012.
Mr. Sullivan has over 25 years of experience founding and building successful, high growth technology companies. He was Chairman and CEO of SterilMed, a
medical device reprocessing company, from 2003, when he led an investment group to acquire a majority interest, until its sale to Ethicon Endo-Surgery Inc., a
Johnson & Johnson company, for $330 million in 2011. Previously, he was co-founder and Chief Executive Officer of Recovery Engineering, a filtration
company, which he took public and subsequently sold to Procter & Gamble for $265 million in 1999. Since 2003, Mr. Sullivan has served on the board of
directors of Entegris, Inc., a publicly-held company. Mr. Sullivan has received four U.S. patents and has several pending. He graduated magna cum laude with
distinction from Harvard College with an A.B. in economics. Among other attributes, skills, and qualifications, the board of directors believes Mr. Sullivan is
uniquely qualified to serve as a director based on his extensive operational and business development experience, and his knowledge in building stockholder
value, growing a company from inception and navigating significant corporate transactions and the public company process.
Lance G. Laing, Ph.D., age 56, is our co-Founder and has served as Chief Science Officer, Vice President, Secretary and Director since we commenced
operations in 2012. Dr. Laing’s career spans more than 15 years in drug discovery research and technology development. He received his doctorate in
biophysics and biochemistry from The Johns Hopkins University and completed a National Institutes of Health post-doctoral fellowship at Washington University
Medical School. He has received 17 U.S. patents and has an additional 24 U.S. patents pending. His drug discovery research career began at Scriptgen/Anadys
Pharmaceuticals (purchased by Novartis), where he worked under Professor Peter Kim, who became President of Merck Research. He also was Director of
Chemistry and Bioapplications and Director of Detection Product Development for two companies that each developed instruments similar to those Celcuity uses
to perform the CELx tests. His work at these two instrument companies gave him unique expertise and experience in developing a variety of patented
applications for these instruments. Most recently, he served as an executive director for an international drug discovery and development company. Among other
attributes, skills, and qualifications, the board of directors believes Dr. Laing is uniquely qualified to serve as a director based on his significant research, medical
and scientific expertise.
71
EDGAR Stream is a copyright of Issuer Direct Corporation, all rights reserved.
Maureen Cronin, Ph.D., age 65, recently retired as Executive Director of Research Informatics at Celgene Corporation, where she served beginning 2012.
Dr. Cronin’s career spans more than 25 years in biotechnology research and development and drug discovery research. She has served at seven biotechnology
or molecular diagnostics startups, including service as a senior research executive at two leading oncology precision medicine diagnostics companies. From
2001 to 2010, she was Vice President of Research at Genomic Health, Inc. and from 2010 to 2012, she was Vice President of Research and Development at
Foundation Medicine, Inc. Her technology research and development career began at Affymetrix (purchased by Thermo Fisher). She currently serves as a
director of a privately-held company. She received her doctorate in physiology and pharmacology from University of California, San Diego as a Regents’ Fellow
and completed a UCSD post-doctoral fellowship at the San Diego VA Hospital. She has been named an inventor on 17 U.S. and 11 European patents and has
authored or coauthored more than 40 peer reviewed publications. Her work at diagnostics and drug development companies gives her unique expertise and
experience in developing and delivering precision medicine tests. Among other attributes, skills, and qualifications, the board of directors believes Ms. Cronin is
uniquely qualified to serve as a director based on her significant diagnostics research and applied scientific expertise.
David F. Dalvey , age 59, has served as a member of Celcuity’s board of directors since February 2014. He was designated to serve as a board member by
certain institutional investors of Celcuity pursuant to an agreement entered into in connection with such investors’ purchase of equity units of the company.
Mr. Dalvey has more than 30 years of experience in the fields of corporate finance and venture capital, working primarily with growth-oriented technology and
life-science businesses. He has over 10 years of corporate finance advisory experience with two national investment banks, completing over 150 individual
transactions. He has been the General Partner of Brightstone Venture Capital, a venture capital management company, since September 2000. Brightstone is a
25-year old venture capital management company that has raised and managed ten venture partnerships. Previously, he held management positions with R.J.
Steichen and Company, an investment bank, from 1995 to 2000, The Food Fund LP, a venture capital firm, from 1992 to 1995 and Wessels, Arnold &
Henderson, an investment bank, from 1987 to 1992. Mr. Dalvey served on the board of directors for Navarre Corporation (now Speed Commerce, Inc.) from
2009 until November 2012, on the board of managers for Blue Rock Market Neutral Fund, a mutual fund registered under the Investment Company Act of 1940
from 2000 to 2014 and on the board of directors for Digitiliti, Inc. from July 2011 until October 2012. Mr. Dalvey has significant operational exposure as a board
director or advisor to many other public and privately held growth businesses and has served on these companies’ audit, strategic or governance committees,
including companies such as HomeSpotter, Definity Health, AppTec Laboratories, CHF Solutions, BiteSquad, Agiliti, and Nature Vision. Mr. Dalvey received a
B.S. in Business/Management Economics from University of Minnesota. Among other attributes, skills, and qualifications, the board of directors believes Mr.
Dalvey is uniquely qualified to serve as a director based on his leadership experience in operating both public and private companies and his experience working
in the investment community and with investment firms enable him to bring valuable insight and knowledge to our board of directors.
Richard J. Nigon, age 70, is currently Senior Vice President of Cedar Point Capital, LLC., a private company that raises capital for early stage companies,
where he has served since 2007. Mr. Nigon has also been a board member for Tactile Systems Technology since September 2012 and Northern Technologies
International Corp. since February 2010, including its non-executive Chairman of the board of directors since November 2012. Mr. Nigon also serves as a
director of several private companies. Mr. Nigon previously served as a board member for Vascular Solutions, Inc. from November 2000 to February 2017, when
it was acquired by Teleflex, Incorporated and as a board member for Virtual Radiologic Corporation from May 2007 until it was acquired in July 2010. From
February 2001 until December 2006, Mr. Nigon was a Director of Equity Corporate Finance for Miller Johnson Steichen Kinnard, a privately held investment firm,
which was acquired in December 2006 by Stifel Nicolaus, a brokerage and investment banking firm. After that acquisition, Mr. Nigon became a Managing
Director of Private Placements of Stifel Nicolaus until May 2007. From February 2000 to February 2001, Mr. Nigon served as the Chief Financial Officer of
Dantis, Inc., a web hosting company. Prior to joining Dantis, Mr. Nigon was employed by Ernst & Young LLP from 1970 to 2000, where he served as a partner
from 1981 to 2000. While at Ernst & Young, Mr. Nigon served as the Director of Ernst & Young’s Twin Cities Entrepreneurial Services Group and was the
coordinating partner on several publicly-traded companies in the consumer retailing and manufacturing sectors. We believe Mr. Nigon is qualified to serve on our
board of directors because of his extensive public accounting and auditing experience, including particular experience with emerging growth companies. We
also feel that he will bring to the board of directors a strong background in financial controls and reporting, financial management, financial analysis, SEC
reporting requirements and mergers and acquisitions. His strategic planning expertise gained through his management and leadership roles at private investment
firms also makes him well-suited to serve as a member of our board of directors.
72
EDGAR Stream is a copyright of Issuer Direct Corporation, all rights reserved.
Executive Officers
Information regarding our Chief Executive Officer, Brian F. Sullivan, and our Chief Science Officer, Lance G. Laing, PhD., is included above under the
heading “Directors”.
Vicky Hahne, age 51, joined as our Chief Financial Officer in July 2017. She has more than 20 years of financial leadership experience, including the most
recent 10 years in the healthcare industry. Prior to joining Celcuity, Ms. Hahne served as Controller of Respiratory Technologies Inc., a medical device
manufacturer, from 2015 to 2017. While at Respiratory Technologies, she played a key role in the due diligence process to sell the company to Koninklijke
Philips. In 2014, she served as Controller for Ability Network Inc., a healthcare information technology company. From 2007 to 2012, Ms. Hahne served as
Controller of Sterilmed Inc., a medical device reprocessing company, where she was significantly involved in the sale of the company to Johnson & Johnson.
Prior to these roles, Ms. Hahne held several senior financial positions at SimonDelivers Inc., including Chief Financial Officer. Ms. Hahne has extensive
experience in early stage, high growth companies with responsibilities including financial controls and stewardship, financial analysis, mergers and acquisitions,
building infrastructure and systems. She received a B.S. degree in Finance and Accounting from Northern State University and received her CPA certificate in
1990.
Other Senior Management
Laura Beggrow, age 55, joined as our Chief Commercial Officer in June 2016. She has more than 20 years of sales and marketing leadership experience in
the pharmaceutical and molecular diagnostic industry, including service as a Chief Commercial Officer, VP Sales and Marketing and President. Between 2004
and 2013, Ms. Beggrow served in various sales and marketing leadership positions at one of the leading molecular diagnostic companies in the U.S., Genomic
Health, Inc. During her tenure, her roles included V.P. U.S. Sales and Marketing and V.P. U.S. Sales, and she led successful launches of several key products.
From 2013 to 2014, she served as President of Strand Diagnostics, Inc., where she provided commercial and operational leadership. From 2014 to 2015, she
was Chief Commercial Officer of NantHealth, an early stage company developing a suite of molecular diagnostic products. Ms. Beggrow has a proven track
record of successfully launching products, developing strategic product portfolio plans, and building market leading sales organizations. Prior to these roles, Ms.
Beggrow served in various sales and sales management positions at Rhone-Poulenc Rorer, Genentech, Cell Therapeutics and Abbott Laboratories. She
received a B.S. in Nursing from The Ohio State University.
Corporate Governance
Our board of directors has adopted a Code of Business Conduct and Ethics that applies to our directors, officers and employees. This code is available on
the corporate governance section of our website (which is a subsection of the investor relations section of our website) at the following address:
www.celcuity.com. We intend to disclose on our website any amendments or waivers to the Code that are required to be disclosed by SEC rules.
Additional information required by this Item 10 will be contained in our definitive proxy statement for our 2018 Annual Meeting of Stockholders (the “Definitive
Proxy Statement”) and is incorporated herein by reference.
ITEM 11. Executive Compensation.
The information required by this Item 11 will be contained in the Definitive Proxy Statement and is incorporated herein by reference.
ITEM 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.
The information required by this Item 12 will be contained in the Definitive Proxy Statement and is incorporated herein by reference.
ITEM 13. Certain Relationships and Related Transactions, and Director Independence.
The information required by this Item 13 will be contained in the Definitive Proxy Statement and is incorporated herein by reference.
ITEM 14. Principal Accounting Fees and Services.
The information required by this Item 14 will be contained in the Definitive Proxy Statement and is incorporated herein by reference.
73
EDGAR Stream is a copyright of Issuer Direct Corporation, all rights reserved.
PART IV
ITEM 15. Exhibits, Financial Statement Schedules.
FINANCIAL STATEMENTS
Item
Report of Independent Registered Public Accounting Firm
Balance Sheets – December 31, 2017 and 2016
Statements of Operations – Years ended December 31, 2017 and 2016
Statements of Stockholders’ Equity – Years ended December 31, 2017 and 2016
Statements of Cash Flows – Years ended December 31, 2017 and 2016
Notes to Consolidated Financial Statements
ITEM 16. Form 10-K Summary
None.
FINANCIAL STATEMENT SCHEDULES
None.
EXHIBITS
See Exhibit Index to Form 10-K immediately following the signature page hereto, which is incorporated herein by reference.
74
Page
56
57
58
59
60
61
EDGAR Stream is a copyright of Issuer Direct Corporation, all rights reserved.
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
Dated: March 15, 2018
CELCUITY INC.
SIGNATURES
By
By
/s/ Brian F. Sullivan
Brian F. Sullivan
Chairman and Chief Executive Officer
(Principal Executive Officer)
/s/ Vicky Hahne
Vicky Hahne
Chief Financial Officer
(Principal Financial and Accounting Officer)
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and
in the capacities and on the dates indicated.
Each person whose signature appears below constitutes and appoints Brian F. Sullivan and Vicky Hahne as the undersigned’s true and lawful attorneys-in fact
and agents, each acting alone, with full power of substitution and resubstitution, for the undersigned and in the undersigned’s name, place and stead, in any and
all amendments to this Annual Report on Form 10-K and to file the same, with all exhibits thereto, and other documents in connection therewith, with the
Securities and Exchange Commission, granted unto said attorneys-in-fact and agents, each acting alone, full power and authority to do and perform each and
every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as the undersigned might or could do in
person, hereby ratifying and confirming all said attorneys-in-fact and agents, each acting alone, or his substitute or substitutes, may lawfully do or cause to be
done by virtue thereof.
Signature
Title
/s/ Brian F. Sullivan
Brian F. Sullivan
/s/ Lance G. Laing
Lance G. Laing
/s/ Maureen Cronin
Maureen Cronin
/s/ Dave F. Dalvey
Dave F. Dalvey
/s/ Richard J. Nigon
Richard J. Nigon
Chief Executive Officer and Chief Financial Officer
(Principal Executive Officer and Principal Accounting Officer)
and Director (Chairman)
Chief Science Officer, Vice President and Secretary, and
Director
Director
Director
Director
75
Date
March 15, 2018
March 15, 2018
March 15, 2018
March 15, 2018
March 15, 2018
EDGAR Stream is a copyright of Issuer Direct Corporation, all rights reserved.
EXHIBIT INDEX
CELCUITY INC.
FORM 10-K
Description
Form of Plan of Conversion (incorporated by reference to Exhibit 2.1 to the Company’s Registration Statement on Form S-1/A filed with the
SEC on September 12, 2017).
Certificate of Incorporation of the Company (incorporated by reference to Exhibit 3.1 to the Company’s Quarterly Report on Form 10-Q filed
with the SEC on November 13, 2017).
Bylaws of the Company (incorporated by reference to Exhibit 3.2 to the Company’s Quarterly Report on Form 10-Q filed with the SEC on
November 13, 2017).
Specimen Certificate representing shares of common stock of Celcuity Inc. (incorporated by reference to Exhibit 4.1 to the Company’s
Registration Statement on Form S-1/A filed with the SEC on September 12, 2017).
Exhibit
No.
2.1
3.1
3.2
4.1
10.1+
Celcuity Inc. 2017 Employee Stock Purchase Plan (incorporated by reference to Exhibit 10.1 to the Company’s Registration Statement on
Form S-1/A filed with the SEC on September 12, 2017).
10.2+
Celcuity Inc. 2017 Stock Incentive Plan (incorporated by reference to Exhibit 10.2 to the Company’s Registration Statement on Form S-1/A
filed with the SEC on September 12, 2017).
10.3+
Form of Stock Option Agreement pursuant to Celcuity Inc. 2017 Stock Incentive Plan (incorporated by reference to Exhibit 10.3 to the
Company’s Registration Statement on Form S-1/A filed with the SEC on September 12, 2017).
10.4+
Form of Restricted Stock Agreement pursuant to Celcuity Inc. 2017 Stock Incentive Plan (incorporated by reference to Exhibit 10.4 to the
Company’s Registration Statement on Form S-1/A filed with the SEC on September 12, 2017).
10.5+
Form of Restricted Stock Unit Agreement pursuant to Celcuity Inc. 2017 Stock Incentive Plan (incorporated by reference to Exhibit 10.5 to the
Company’s Registration Statement on Form S-1/A filed with the SEC on September 12, 2017).
10.6+
Form of Stock Appreciation Rights Agreement pursuant to Celcuity Inc. 2017 Stock Incentive Plan (incorporated by reference to Exhibit 10.6 to
the Company’s Registration Statement on Form S-1/A filed with the SEC on September 12, 2017).
10.7+
Celcuity LLC 2012 Equity Incentive Plan, adopted August 10, 2012, as amended by First Amendment to the Celcuity LLC 2012 Equity
Incentive Plan, adopted November 12, 2015 (incorporated by reference to Exhibit 10.7 to the Company’s Registration Statement on Form S-1
filed with the SEC on August 23, 2017).
10.8+
Form of Incentive Plan Unit Option Agreement pursuant to the Celcuity LLC 2012 Equity Incentive Plan (incorporated by reference to Exhibit
10.8 to the Company’s Registration Statement on Form S-1 filed with the SEC on August 23, 2017).
10.9+
Form of Warrant to Purchase Units of Membership Interest issued by Celcuity LLC to Cedar Point Capital, LLC, as placement agent of
membership units and unsecured convertible promissory notes of Celcuity LLC (incorporated by reference to Exhibit 10.9 to the Company’s
Registration Statement on Form S-1 filed with the SEC on August 23, 2017).
10.10
Form of 1.25% Unsecured Convertible Promissory Note issued by Celcuity LLC (incorporated by reference to Exhibit 10.10 to the Company’s
Registration Statement on Form S-1 filed with the SEC on August 23, 2017).
76
EDGAR Stream is a copyright of Issuer Direct Corporation, all rights reserved.
10.11
Form of Warrant to Purchase Shares of Common Stock issued by Celcuity Inc. in connection with the conversion of 1.25% Unsecured
Convertible Promissory Notes (incorporated by reference to Exhibit 10.2 to the Company’s Current Report on Form 8-K filed with the SEC on
September 25, 2017).
10.12
Commercial Lease, dated March 11, 2014, as amended by First Amendment to Commercial Lease, dated March 20, 2014, as amended by
Second Amendment to Commercial Lease, dated August 31, 2016, by and between West Glen Development, LLC and Celcuity LLC
(incorporated by reference to Exhibit 10.12 to the Company’s Registration Statement on Form S-1 filed with the SEC on August 23, 2017).
10.13
Commercial Lease, dated September 28, 2017, between West Glen Development I, LLC and Celcuity, LLC (incorporated by reference to
Exhibit 10.11 to the Company’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (“SEC”) on November 13,
2017).
10.14
Clinical Trial Agreement, dated May 8, 2017, between NSABP Foundation, Inc. and Celcuity LLC (incorporated by reference to Exhibit 10.13 to
the Company’s Registration Statement on Form S-1 filed with the SEC on August 23, 2017).
10.15+
Confidentiality, Assignment of Inventions and Non-Competition Agreement, dated November 15, 2011, between Celcuity LLC and Brian F.
Sullivan (incorporated by reference to Exhibit 10.14 to the Company’s Registration Statement on Form S-1 filed with the SEC on August 23,
2017).
10.16+
Confidentiality, Assignment of Inventions and Non-Competition Agreement, dated November 15, 2011, between Celcuity LLC and Lance G.
Laing (incorporated by reference to Exhibit 10.15 to the Company’s Registration Statement on Form S-1 filed with the SEC on August 23,
2017).
10.17+
Confidentiality, Non-Compete and Proprietary Rights Agreement, dated May 17, 2017, between Celcuity LLC and Vicky Hahne (incorporated
by reference to Exhibit 10.16 to the Company’s Registration Statement on Form S-1 filed with the SEC on August 23, 2017).
10.18
Form of Indemnification Agreement between Celcuity Inc. and each of its officers and directors (incorporated by reference to Exhibit 10.17 to
the Company’s Registration Statement on Form S-1/A filed with the SEC on September 12, 2017).
10.19
Representative’s Warrant to Purchase Common Stock (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-
K filed with the SEC on September 25, 2017).
23.1*
Consent of Boulay PLLP.
24.1*
Power of Attorney (included on the signature page).
31.1*
Certification of principal executive officer required by Rule 13a-14(a).
31.2*
Certification of principal financial officer required by Rule 13a-14(a).
32.1**
Section 1350 Certification of principal executive officer.
32.2**
Section 1350 Certification of principal financial officer.
101
Financial statements from the Annual Report on Form 10-K of the Company for the year ended December 31, 2017, formatted, in Extensible
Business Reporting Language (XBRL): (i) the Balance Sheets, (ii) the Statements of Operations, (iii) the Statements of Changes in
Stockholders’ Equity, (iv) the Statements of Cash Flows, and (v) the Notes to Financial Statements.
*
Filed herewith.
** Furnished herewith.
+ Management contract or compensatory plan.
77
EDGAR Stream is a copyright of Issuer Direct Corporation, all rights reserved.
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We have issued our report dated March 15, 2018, with respect to the financial statements included in the Annual Report of Celcuity Inc. on the Form 10-K for
the year ended December 31, 2017. We hereby consent to the incorporation by reference in the Registration Statement of Celcuity Inc. on Form S-8 (File No.
333-221117).
Exhibit 23.1
/s/ Boulay PLLP
Minneapolis, Minnesota
March 15, 2018
EDGAR Stream is a copyright of Issuer Direct Corporation, all rights reserved.
CERTIFICATION UNDER SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
I, Brian F. Sullivan, certify that:
Exhibit 31.1
1.
2.
3.
4.
I have reviewed this annual report on Form 10-K of Celcuity Inc.;
Based on my knowledge, this report does not contain any untrue statement of material fact or omit to state a material fact necessary to make the
statement made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by
this report;
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the
financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in
Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-
15(f)) for the registrant and have:
(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our
supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by
others within those entities, particularly during the period in which this report is being prepared;
(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our
supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for
external purposes in accordance with generally accepted accounting principles;
(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the
effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most
recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely
to materially affect, the registrant's internal control over financial reporting; and
5.
The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to
the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are
reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal
control over financial reporting.
Date: March 15, 2018
By
/s/ Brian F. Sullivan
Brian F. Sullivan
Chairman and Chief Executive Officer
EDGAR Stream is a copyright of Issuer Direct Corporation, all rights reserved.
CERTIFICATION UNDER SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
I, Vicky Hahne, certify that:
Exhibit 31.2
1.
2.
3.
4.
I have reviewed this annual report on Form 10-K of Celcuity Inc.;
Based on my knowledge, this report does not contain any untrue statement of material fact or omit to state a material fact necessary to make the
statement made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by
this report;
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the
financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in
Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-
15(f)) for the registrant and have:
(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our
supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by
others within those entities, particularly during the period in which this report is being prepared;
(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our
supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for
external purposes in accordance with generally accepted accounting principles;
(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the
effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most
recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely
to materially affect, the registrant's internal control over financial reporting; and
5.
The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to
the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are
reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal
control over financial reporting.
Date: March 15, 2018
By
/s/ Vicky Hahne
Vicky Hahne
Chief Financial Officer
EDGAR Stream is a copyright of Issuer Direct Corporation, all rights reserved.
CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED
PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
Exhibit 32.1
I, Brian F. Sullivan, certify that:
1.
I have reviewed this annual report on Form 10-K of Celcuity Inc.; and
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the
statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this
report.
Date: March 15, 2018
/s/ Brian F. Sullivan
Brian F. Sullivan,
Chief Executive Officer and President
EDGAR Stream is a copyright of Issuer Direct Corporation, all rights reserved.
CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED
PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
Exhibit 32.2
I, Vicky Hahne, certify that:
1.
I have reviewed this annual report on Form 10-K of Celcuity Inc.; and
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the
statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this
report.
Date: March 15, 2018
/s/ Vicky Hahne
Vicky Hahne,
Chief Financial Officer
EDGAR Stream is a copyright of Issuer Direct Corporation, all rights reserved.